var title_f35_41_36496="Strangulated hernia";
var content_f35_41_36496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strangulated hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAO0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5yGlIttayS5PnxeYMHtuI/pRHpsDMMh/purcupI7jQdA2ZLR2rRONuORK569+DUFunzDj8qbNIxTI7bRLKbBKyKPZ+la9v4U02Rc4mznr5n/1qmsIs5UHPHIxxW9artwH4A6VDOiMI9jIi8GaSeSlxz/01/8ArVci8C6K55FwPbzelb0aZVM5PP0q9bIMZwPXHXNTqzqhRg90c/D8PdCfrHcH/tqav2nw28PS43QXJ9vPNdHCQpO8HGMkGtGCVYwhPTsw7UNnXDD0+sTmovhb4YdlzDdY74uDzV+P4SeFPkH2a8diccXLfzxW9HeJCrHZuJOc7e3SpzqTvKyCJlCgYIbAz14pNsr6vT/lRhH4R+D45DvtrzZjOPtJHfH41Yb4O+EQfltrwpxg/aietaMeqXAkeS4EbJ/Cuc47/SiXxRHExd42lgzggtkgZ7fSjXuQ6NKOvKjJf4T+DotQS3eyvimNpcXLfePQfzq1H8HfBszukVtdCQAEKLs9CMiugtfEy3Y85bC42ITztOAP60tjq8E1xKsQjiOPvHg9uP8ACizEqVN7RRzUPwh8Hebsks7vaePlumJGKlk+D3gzGY7S9PXnz254rrFlupUjVJtqo5Ylerdadvk2fNI/y8nHb1qG33Nlh4fyo4CX4T+E0kKGzvQRn5hO2Aazrn4X+GYy22G446ZmYfpXozsJdxk3EyDOT3P0qhLhwxCvgjIPOR+NUncPYU/5Uebz/Drw2hObW6HX/ls1VJfAOgIR+6uBn1mau8uo3Ytku2OST3qk6svGPqeTVK5nPD0/5UcZ/wAIJ4fLY8i4U9/35psngHQ+NsFwMjj98TmuxZBnkc9M0mAF2gk54wB9eRTRzyoQXQ4tvAeiL1iuCenExOKrnwPo+5h5c+B2Mp4ruHQbXyucd+9UpEILEcrxTu0YulDscrF4I0XzF3JcFc8/vjXe/BP4aeEdc8Ra5pWu2ctxLb4ltiLhk/d57gYyeR+VY6hiV4IOM12HgLUrbQvE1vrV1KERY/JZc4MhPGB2zj17Cqh72hjVppR0PTT8BfAGONLnB9RdSf40v/ChvAGP+QTKR/19Sf416hG2+NW45APFVNb1KHSNIvNRus+RbRNK2OpwOg9zSscabPk344+BfCeg69ZaV4dsJIrkxh5z57Pyxwq4PT1/EV3mkfs/eCpNIs3vba+e6MY80i5IG7HOBiuI8Kyz+MviWl9qTb3eY3Mg7AL0A9B0FfTlngQAFe/avOxdVxajF2PRVPkpptas+IddsVg+HvgW5U5a4tLgHjptuHrAtk+ZSM/lXR6jfx3vw08FWqq6S2aXSOWXAYNKWBB79/yrJsUHykdAa9OWjOSCukaVgMDIOea1rYDDcDrxWbCu0D+6PwrWswNvofas2dUUXbfAUA5+prRtlOBgjn0qrbHGMdfrWhAm3k4BNI7KaL8AIjBIOW9OamCZIwgbBGQeBTLV8dQB6dqvI64DNwB/FQ0dcVYikj3KADJtPJXA5p7CPbmPjHGGFOZsruBYkAtgDr6VeFgWij+8rHG7jnFI0dlqYk9xuUjYg9AR0Fc9rErRRu1rGpbIId1xn1/+tXcz6c6oQFYgtgN09cfjWJqugzfZwROZWJIKMmSqADv0yTmqSucmIvy6GPod3qbw+ZLd3ZKpvYI20D2x0rZubq3TUUilbzo3TzEm4DIfesaO4W0bZIrq7YEi4yCPSrDsly5aFQ27HB4H0FaWuckZyVktza0vVftErKu8BO54DD1/St2CQuo3Hdn+EHFYNvYPEsQhVEyCWbI6f1roLW2YDcpBKtj3xWMoq56cJtq0guBtj3IuW4BA7A1GzIUASQgAY5FXZ4g7ghWCjB+UjDc9frUFxlGLhOGPyk/xe1JKwNmPdYHB4wueneqM8W3Jwdp7g81qP+8lV0DAHhg3Y/5zUUkYQ+W4JBXI5/X61pFXIk7GP9nfOcErjjPIpQgGQSATyRjj6VeiIG5SpI6Zz39aryg4Ksp9ePSqsYTZUkUKBtGRge9UZQQcY+XrmtCRWO0Fm2444ziqMygk7n56ZpMxaISinHPI4Aqlq5I0reCoMDh8npjof51bZTs4JqvcIZLK4jwGDowx6nFTexm1c+sPh7qP9reCdFvSCGktkDA+oGD/ACrzb9o/xP8AZ9Nt/D1rJ+9uCJrja3RAflU/U8/hVj9njxDD/wAKzvDeSlYdLmk3FzyqY3f4149rM15428aTTCP/AEi+mAVB/CvQD8BinOVlc58Lh3Oo+yO3+Bvh110+91qVcbyIofcDqa9rtTvt05PFQaHpEOkaJbafEoVIoguB3OOtWLAqIiD2NeHUqe1k5HVUqKSstkfGVzZo3wm8HXkT7xuuYJB/cfzC238QQax7BMHauMA81B4cvpbjwe2nuzGK3n85Fzx83BIFaWlxjAJ5zXut3OSMUrWL8UeCDgH2Her1shIztxzimW6YXdgcdBVy1UAYHfrUG8UW7ZASOc4HQ1qQRk4cYyQDyapW6EemQeAelalqATgDH8qZ200WYADkswz9MiplAYrnhc5II6mmwLkuArHbweOKuRLuVGK4CnOfeg6ehJ5eJIizqvTd271v2FowjV3ZWH3mweWHNZ62olaJQzhtpYqBlu2MntWzZROsRaRFwM5wfX2pMhu5YjtRcSEKD5eFOelQyaUXdyEBjPGM9P8A9dbcFmixCAEYHzEdO/ApbmMQN+5AJCEspPBOcZotYzcjgJ/DMSSM3lNvbODnqByM1F/Y3lIJI1QA9mIH6+tdrEBc/MHzEV+8e1RQ6ajTcopGM424GfUCqTFoYsWksI4S+1T1PGRmrdjE3klWPz8kFcketdKdNikURsx2AbmXPWka3tyqhCAwOF2d+4H5VLRSmc3d23lhnKNx2DZyPp/WskuXkI3MctjavQg8/nXUXnmpueMq0ecMD1B/nWNPAPJ3KSB0Qqcg0rF81zHuDGp4wNx+6O5qpPknGSWUc5/StC8txNtlxtJ/hPUY71UQB1WQnPU4PoK0ihPUzydswLEEHvmkc5UbT35PrmnzQgtuj5X0B/WoD5ibgcg5xkfyqjNq5XlGD1J56CqU6j5l/iHUVelJ+XPPHeqEpO444x0zUsykrFWVjt/nVIttJwcg9KuO3DIRis6fCsCMdc5rNuxlsavhme+tPCd1psUzx208iPNEBwccgE16h8DvDcRvZtZuFVnUFIR6eprhLQ+ba3GzaF/duAOoytevfBgY0dwc/eNceLm1Tdj2cXh44fCXp9j0KVazV/dPIhwAGrXYZBrMuUzOx9a8uHZnztGXRnx1YeGXT4b+GtatYvlnjmguGH/XRirH8RisqwHzbeCRxXu/wx0qLUPgHpkEq7laCY/QiRiDXhMZ23XB5Jr3aNXn5l2Zc0kotG5bJ+75birsICjGB61UtWDoPY4PFaKgZIwc+lao0pluDkqccngAVqwYDKTknoeKy4c7yOMjHJrVtWUqrAbjnOB3waaOumX7NF2lTuLAlQv9a1LS1PEhCtEvzFVOBVSBlBDcLjgv6Zq7Bu2rsXeBng/Lkf8A1qbVjS5biQCQqvIfjdjgjnj+ta9jOS0EflgoDgA44wODisq3BiUuXBZT0B4/xq79oMSoAjsN2M8D/IqbAbdpcMkrMyIobGWJPXoAParDTO0kj4Kqp24A7Y9+vOazLed5BHIsTJgEBG4I7c1ell86BtjM4dcbTx365oM2htvFHDulSQxxswbAOckds46d6lj+eTy33AknDg4z3qjIzQrDGP3JY4cnGH/z+dOto/JdGdXmJ3KxPbGMH/PpVCZpoI4ZUiZS2QSCT+ef0pt3LBFALkvwTwepzjt9Kie7aNE2EOWzxjsOvNNWbeQpUJGBgD3GOc+9JgkQF0Jkf7O3PTLct71ialbKjgAAcEbcc4rSu3USyToW27SoVefrWdeSFwqpFK0g6kgAED1NJlxMa6Z4tyL1H3Tj29fWqcqiMs5+bOcoo6GtG7YF0G0EDk8YNUZXBZwHGEbj+8M//rpospTpsIC4G4Z49Kpz8ffUZ9avSBg+STkDsOtULs7Rgcn0zmrJaKMpYAjPGMAZ5rPmO3OTgAg49KvSEgEj1rKvJPkYDAOai5hUZDcSE5IPJ6/Ss9i/PHHrVhY2JZiSRjpSOu1MEj2qTB3Ok8KfPa3WQC4CjJ68Z4r1j4P3qBJ7cEZVjxXi3h+78i6CnG1l2k/5966vwFrB0/xWqs22OY7eT3FceJg5wdj3oyWJwXs3utP8j6Sqtcxb2BHpUttIJoUcdxTyM146dtT5VNxZ458LJltf2fbG5wMRWdy3/jz186quZywzwa9q0jUvsH7LOnnIWS4Q26j1zM2f0Brx2xXeQe3evbwqs5vzN97I0rB/LYKQcHvWtbSAkjJxVKK3OQccDoanhYxttIHHOSOldSZrFW3NGLhiRyprXs38vgYPoG7Gsm1ddvf1xWpCQHCg5zyM1SOuBqWsgL7XTGenoa0IZvLwEwCHKkgZwD3qjaFVyZNpKjpVuIlGZgqhFGcnqWPY+1DNGXRKVOUKqijDsOufWrcUpEkfmBmBGQBxjvzVED95GnJBJOD3+tXFRprwjcypgg8cliOP0pEvYvWk4kTbk7ZFAG04x14zU7z7UWUFwsWA0Z5yOn50trAoURBMSJgnngY9KbHAsc7lnLKWLKztgE56KPbmgTFmiWULlc7W+TJyfY89OtK90beEO/mgLlen3u1PmdlSPgsXyN6/mPfpQ3mPeNCY1MYHDs3Q4B6f1piJrVkEvnKRGzr3O4Y/wptzdSIQTKoV/wCHbjjPao7m3QxwG33Nt4yBgKf88Uy4bdCyeSwc9Ax4JHXr2pMRDeOlxCTBNuDHAK5wPc1SMq+ZFAGYZB9xx1ANXFZIB+4hcAj53XkA+4qhNAsc6SRGMR7x68A56/jRYq5Hdots/mOc7Vyo7gntWPdxF44mICndk45JHf8Az7VsahsEiYUPvOxh/X2qtMFSJY2QFl5U9cf5FBaMqbCA5UjrkjnI9ayrknBH8IPcVrXBaVnLZAAwp6DHqKybrjI6Y5J9aLlJXKN0wVSo79QKxLk7jtP41pXhIwSfwrLOfM7c1NzkqrWxNFGduB261Wu0ABHQ+nrWnCvyE468VTv0O4ruXOeccipbRUqdo3KFpKVk4JAFalxK8Esd0mRgh1x1yKylhPmHbuHfBPWtVEFxZvBnEgGU9SfShpF4aq4St3PpP4c67HrOhQSKwLFRn2NdbXzR8GPE507WTps74jkOU9j3FfSkMgliV05BFeJiKPs5uPQ48dS5Z+0js/zPkXU9Vx8EPAemoxHmfaJ3A9BIyj+ZrndMTGCeM8Vj6fqL33hvRIG+7ZQNCmPQyM39a3LGIuikA5B/SvbhFwTXr+ZnHWzRvWqlwAc9vpU8ttlflGO+fX3p+nIHIXBPbHqa2/s6siLgt7+lUj0o07xMKDdGwyBj0PetVByowRjrtqpcQEM3BKjueKltn+Uknj2OKdxwVtDbs8lwAAD6nnFadqcxFVGQxIzjmsm2JCDaQA2MNnFdBayERAINxUcjGADQzRomggXennE+YRgAn06VftWR1m3K5Ut9/HXHHPpz6VnwSoxBP+sDAgAnr3xTb6RonEaJM0rsdm0ZBJ6k/wCe9CaMnFs1Yh57utqhXO1Sx4xj/wDXU91JDPdQoigMEJG8DnHWsiza4lZEgkaPLMjGQBiQOuQenNaU8QjlEkjf6o9MfNkDtTIdyaRXlVVVRlQMhT34OSafeGVJUkQgKiMNvqeOfrWck89w6sLgpGmVdeAdx9PXvVmRhIg5UEE5AbLYPBoB6Ekj3O4yRS+ZG2d6qOg6596eZdsRYkOmd2GOCAe4BquEdyZElKxxg5VRtzxxn6Yqsl1K0jwztGZCxAbyyd4xkHn60wsV4HvbjzGDYhIDIQ27f2JPof8ACq0wCASu5OCAZAM5HUdOtWdR1GOxt1jWEYcqgUNgkn19uKy7pxHulXDqw2sG4C+gx/hQOKJyqS7wzyElsgHgj0OKg6u4znByDnOcdR7VU1OfywHjUFj0XPNMExadEwMEgtk88j+VI1SJpArAuxBHTaOOcZrGuxjlug9emTWtcbRK7Myldxxg8/lWZfEiLJPB5HvSZcTn7rBXgnIOKpwRh3wOT0zVm7wSR3657Va0u1ZzkKSM8Y61mY8nPUsWYoUWIdC2Ky7yIbuASfeukltgkYHTHPWsm7jAY7STmkdVSF42MIw9iffFCymKZSucDoausnOQOp4zUFzHjn0FUefKFtUZ+rM+n6jb6jaHZuYPkdnHUV9N/D7xRFq3hyC4DDOAGGeh7183JGL21lsJcBpBmIn+F+3+fem+EvGF14dguLTLAbx8p7HnNc2Ioe2jbqjRclRcs9E/wf8AwTi/B0Rm0m2JycFu+O9dva2wRFYA46HnFcx4EQf8I/A23LZbn8TXZwRYQjrgcV2Pc4aEdLl/TCysODsJyGFdhZQfulJU7CuTubg+1c3pSY2KQQCOM9jXc6RCpiUKPkXGB/8ArqXoerHSJjahZAREqoB6gD+tc/NBtfCdelegvaF4sDZkkggnqPr+Nc7f2YBbPyt6Hp+BovcFuVrSNRneVI25APGa10FuqAgSLuI2KvUt6VnRARvskJXcegXkVs2wBdSYQ6jABJ6e4phK62B2aKPEkrJIxHykZI5wKsXI2ESB5FCLjey7sZ7iq2oLI00SQymONQGkbgMSOmM9+lWtNu0urcxZuJmVtpDx4K896djHm6D7eJJJJUEwnjbGWPLEgY2n8cc1JBasLJ1gYPbqhYKfmG/0J64qvNDDaTB8MA+AcvwBnvVpdQhkBtwVLbiDtJAOO4P+elP0E2Stk2ivEjOVTJyuOevHvTEeD7FJe3TB0jG8JDjcD3AHc1FJdxHCtC8m1S2VYYXr1rL0W1khgLTGQxPP56xkBtoK4Kg+nf1qkiHI35tQgW0eSKCRmxuIbIZT3yfxrL1S8js41laVma4AkCkk9ucH8Kd4gmvjpFw+kRtFk7ZJMbyFAxwvc5wKwLJbweRLeQPJIRsTMhBQ9eQe3b8KaiJVNbImM83263dYVlMmWO9u3bHvVK51Bjcgx7ZwrkeXsOB2zn1/lUGuz6huWOyijVYmC/M43K3YnGOvNZD3lw8xLRtFs6ADpgcjj9aTQ4y1sazXbzboruGOPyyM7T19gR1HfNSzXYhQCLyg7cbRzn3xWEqT3Mrld5KoGbnCn2+tMjunNy7nClQFUs2Mn2FSzZS1sdAkjA7pCApGcnAJPpzVG7uUMRyQWUnpyc0YaS1VjGJJskgyZFZZiXJMZBlIyzds1FzV6DBGZ5Q2MgHpXUaPYKFzxnrjNUdCsmmYYQOAM5rvdOsvkHA28Y4qHoVBKOpz+oW4CBSD83PFcxfJ+8KscAZzXcazbMVdm4x0HQGuNvY8K5IzjqKC73RkyRqflJ49R3qrNGuzBJBHXB/WrpXc3BOKhuI8qSmMjjincwnC6MSYPE6sAcjnNZXihAl3HdRpuS5TccDo44b/AB/Gt65QhTkHPvTNPuYY42juYopQDlfMGcZ6/wBKfmjkSV3GXUxvh/geGrPpnL/j81ddAM8g4JNcp4BRf+EYsx3+c+5+Y12NpCCFwcN1ANXfUmjG8Uael7mkUkEg4wfoa9B09DII4/LxxjIPQ854riNKt3MiqBtzxuPT6V6Fo1uFVM9D6c81MjsbsX/syGNEUAKo4GP85rn7+2X7Q6uiEA7s9PriuqzHt3EAkcrjqvFc7qLhciQBRjdk9T7ClbsSpanPSRokjEMSB/Cx7exqWxQ+SWDupBGN3QA+nrVCR0uEZ98eRkKWGAP/AK9XoLloIAdhdBj7xyGHpj8Krl0Lc0a0mnTXYWEhXChW+RuAQeufpV2MPBw0axbjl9oOSRVC11KJreOQAqrfMNvG1s96tajcqYYnMjq+4BZVHzeuPrzVK5g9dSa4W1aMHJZXUu25CQR3Fcdfaqb3U5LCy+Xyo9/ygcJ3/HFdpo95aWzP50gy6fOx5bYOeR7ZqhrcINhMbP7HayOTsfysyZOTgn0ORVIzlJ20MvTb5rRStw8bwo4BkRd2WPt755rftbeWdri6geYqxwqoAAox1rG0WabTTbx30jXQ3eZuVTk4zk5Hb2NdpFKjWQcbIkK5QLJhiOhIPtg1aRlKaOcksk3yebf3bZIDISRn8v8APFc/NMgBs7f7TNPGFZmd8lQcgHjkDjrXWz3EHkTJdSsmOVCj1BwM+uOa86vLmHSZJNRGmST2q7g00TYwByMjPP8AnimDkkatrIsU8lzdxBJpF2beGzjvj6etc5q9xGLsx29rLFgEuzsOp/8ArUtn4is9UK3G91LDcE2gH5T0yPY1l69rxtrnybK1WdQpYuCeAPU+oFQ0aOcVG9zcmMKKXiRo1RQHJ7jtmsW4jjEss8ZknfooONoJFcrcTGS8MFwHkgm+YeXLgkZ7noc5rRjuJBYO0CncudoCkk88/WoYvbqXQ2oJWW3iSV+E+UKxPPv/AFqIzL56xhgWcgKMdayrTUPNklIGMlSqlemeuT6Vq2OmyS3HnTpuYOREEYFmGM556DilY0VRzS5T0fwlZ7cKo5IDFhyCK7oW+LcDA+UduK4vTDdafJZrDaj5wCzBs5GO+OmPWu9tU326mQfN04qZI1cupy+qwhiepReMEd/WuK1qHaSRwoPOB3r1PVLY+Vxtz1Ge9efeIY3MTOAnPHHT0qEtTeE01ocYCXbGcc4470+aJSMgfKBgnuKnSMoep54wB1q35QERYRncx6kYqmi15nMXcRC5ZW575rBusrJxkZ5rrruJWyAMHHPpWDcQZfg8UI4cRT1KHw3QP4asicD7wB/4Ea7i0jVZMnC4BOfSuO+Gkf8AxS1ie2GJ/wC+jXfxYWM5ONx4wOat7lYeP7tG5oMCF08w56EY6H0/z7131nCUjAA24XB9q4Lw1OeF2EEHAUnGeef6V6FbOWt2jB3SKoYjPJBpPUc7opXwaCIiOQ/L8oBABP1Ncj4i1eOGMg7Wm+6SgzjHNdbd3Jhtm+2oIzxuz0Pp9a8s8Y39u+qrFFOqIwOFY9WzncPaiKE5WRSlvw0flxvht3mEjoPYj+tQxahJLJNAsjAO21+MbRngZ6Z/KsY3IS3u1aQu4VgVQ8gE9z/WotPvYLSSUu0hSVdzKg37QCOOD71qjklV11OzfVI4gALdcqVWMSMcIuPvH1JOBVjStZn1CWVpY5RBGSGV+Ap+vfrXn1xfSXlzIttJK/nAfZ0X5SuOPmznPAzgV1E9le2qqY5ADAEJAGd7N1P4cCtErmaq31JPEWo3A1KCO0t4GZAAw42uM55/maybDxNcPfTxvZztIONgbCsc/oMd617Wzi+yrMIgJYyFeRSSWJznAxgZ6VS1exkvfNn064it5Yseci4JdSew6ce9DiEnLdM7bwp4gtr+CCWdPKnOE2udwAA6e5rZ1PVLeK3jeZtrKxiWQ4xg9ABXjulahqmlhrrU4VW0XczT9SMAdAPWtKUQ+JYIriG7kREUbVDZBHT7p/GiwlNNeZqa3c2Go7i8syRROUaQZAY+uR/L2qKa2k03TLmOC6FzZTv5kbNjaAB796wIZLVWeHVElVoUVIlbhBjjcMdcCs7xDrEFzHODJst1x5axnGcADcO3vz3oJc0veZm65Ix1RjprutwwWNlwSMewHTjPbvS6Hdfa45ILwkyjLeWTtXnH/wBakvlhtLbKGWSeYgpM56ngjkdOOKq/bwkE7XVrgqNkbq3JPc+/fmoITtK5bv5xImxZosAYyvByeMMamtbrZZJEr4kzt3OcjHrn/H1rlgrSpI9ucQlh8oYg7lGRx7Y6+taegQS395MztOzITNkHAYn1/Q0nEITbdkbVvcTbxDDC5VsKp4JJ75I4x1r0nwlBCbNFumCsoIYgcsSeme+a43QtE8iFg5AkZ9wUsMscdgT7da76wm05AotpUEiIrMxctgk4A496ho9ChBpXZ2ul26SoEZypGS6Z+Yd+38q3HS4iUCGFWU4H3tu0fSuI8CxHTbKe9vbeRbi4uGhiiCkscEnc/XB5/KvQYyxhh3sTKRuJA6GoZo3syO7jZbbYzFw3948gVwuuWu6Q7AU3Y4HRRXe3ku5SDgEjgYrk9RjMxYK25eDzxgjtSRVK9jgGt/3kYXrnBzVkxjAAORnv1H1rWmsQGO9MDng1VkgA53YzgEnsfaqOhSOf1KLAwpDKRxXNXbCOTgjnrxXX6gB5BBB3HnNcxOq7/mHPWixhXelyp8LFx4U049AA+T/wI16FBbFotrAAEnkHP+c1xHwnTf4P01flGd2TjkfMa9LtoB5YMahmUYyelN7hSf7uPoGi2gjkXc3GewznHHH5dK7O3tllZGidoZDjc6dWAPSsbS7UiZthjClt55PP4V0rTmJTuUbtvC+p7UrindnN+L5TbsJS0caEEF2OUPbp614pr1lLJritHMzWqvkozZ+ZQMcD1Jr1nxLomq643nQ3jKsZHm2pxtbHqPX+dcR4g0t9M0uUPHAL4sXyD83P/wBYdPwq4mNSLkrHG6uySTtaI4w43TiPAJXuPY1HHFbLDPEcyCRQNkfGwHov05HNYOoXhWGcMzRyQvlz1Zsnr7irtq5gtXgizFNEdq5OcN94cjg8VWqOHmTOwg0lILBpY4zKkAzFIp+6DgnPr9as+DLye9fUJ4ZsR52CCQZA+p7en4VTttbksNPVbhxEpAVnQAjjr8vv/SrXho6fYwXVyt35l2zNuCnapGSQSuQO/wDOtExtLSxN4n1m/stMj0+GBU+1YDzJlkhGc8AdD61xej6lfaekt188UJwGUjhj7Z6465Ndp4V8TaRJfvY20ZQyBjMSSQOe4PrjtVvxBosOqQHfPFHaTS4+6VLMBxgDoRVMT11TMyC+F94feeUW8zbRIUZRgtjg57ZxWRDYNLZpLDb/AGK4Llw0Z+U4OcnHY5wB7UyLQEtre7sY7yVkbcJUY/MeRyCPrjHvRpmqWUenNYWZuUEb+UZ35XJOck54zz7UmJO7XMZOuvqWp6hLAzpF5S7R538RCg7jjofaqVhotii+Vefa1mkVCsqENHnIOfpk4rp76NpWilt2ivVAwQCcgehI7mqV/PLZWE5luWS2Yt5UajJVh1qWJxV7mDqf2pc2a7ZYoAXWViSVwepx06/kKy4ibtpZJDLKY1wFU42ZPUY9/wBK1GRbuJori5zGqKSQMHdz3xzn3HasyLzYfltwvkMjZK8AnnJJ6kg9O1Ize5c0yGZHc29zbRCQ7CSOen3cHpjB5rsPDFgbG4HkRwzSljI86tgqB/MVj6NbRnRwIljeYu2GcAnBzgE+uK6HT9PMMkMX2lYgAEIXIz9ffms5M7aEGrMval/Z1/cKmkTTve7C0p64XOTkd+eK6bTtANxp+mzRJPb3NzL5cnHzEj+HC8Kv16Ve8IaRbaVa+bboQ8hO/KZOM5zn9c13dhpyIbua4VRFcMGX5znaBxn0NQ5HYodXuXdMt4LWzisUM2Il5Zjkn8amubllaJYUJRQS3t/iaa6CK1LqoRidx2+vr71BpdxcXCO90ojV8EDPAOKzC3UszncVYsevBPArJuYvMkYhmznJHb6VpXDbkIVOvTdVNgFHy8Z5JxzmmXFWRhahCiTnaDjqc+tYt2mAd4X3NdPeKd21QoxwOvWsLUV8pXLD5e4x19cU4vUtaHOaiwGQBwBjHoa5m6XMhy+z046102pHKkcEkZBrmbojfgitTOo9BfhCpbwlpgHOQ/T/AHjXq1vGy7GQDYvQ9eK8v+EK/wDFGaW6gblVh/48a9Vs13IEZMxs2CCelKRNN3gvQ17FAG3KFHqRxtrRMO8Znk24wwKioIMCLcAcnjAHHpmluxI1sVU8AHOB2/Gs73KaEmjMMLm0cCZwcNjr9a4Hxz4Zl1Ky3iWJJtwJIOVOB6V27XBSyKKHYg43MMZ6c1gardyWYW1W2WSJiWX5juXd94ehHXvRETV1qfMXiGyntdUvLe4AZIXBZwMAn0AH1GfpVCIybGiEwBLACIHnLcdvz/GvQvH3hu5ie51FQZYXlzsK9ie4HfjPpXFW99DAUcJE0cgYFCpXn6j+ddEXoeRVpuE2th18LuGNJLpZV2qgUREkq3QDPc45/GvQvCmlxizELWxMpJeUzjBdscE47D0FYGkQxXT2r7WSNBkIjk49q6WK7Gjw3FyX3rMCyxbxvUdM56Yz0q49wgrast6Z4HsYr5Wl+1qVO9vKwODnkk9M9PpXSXWmxPZtCriOMsXgDtlkPpkdfT0qj4c1iGS0lt4zK+Gy7MDwTxtA7/8A66m1MyyrG+nylEU4aIrzz6n+naquaxit0cGNJk0jXn8l0mjvFG+FnBKjOeT26/jTPEOmwRTP5iPbqi/vGjGVIx0I/E9Oma3L61t5JriVleMldpdGI2kH88YrNe/M1lJaIn2hgGXeTsAHoM9eOKlkSjZWZDoumQW0U8lpdu0bNvBJ7Y4GPy5rF+z6wIz5ka3DNLiKMEMdoJ56DHUc96BJcqiWMCo5L5DKMGLIJAI75wBn1q7Pez29hIlpNvuPuAFc88HgdSAKNzO/QoGMarbxRxOlrJCu6eMDDbgTnHfuee1czemWMi2QY2Jj5Tu3MOT/AE/KtzMOm2U16WH9sSEK0ZAAVD34469q54tI4SZ4iC+4jnHXrjv60rEt9ep0Wl6tO9jFb20R/dgkELjj1z65rtPC6XF2PPkYMyKyszcBuevT0rhdFVJp45LCV45IjlkcHA74+mc1678NYHnDTzQNEithPMO4Z/vYrKSO3Cyu1c7XRVks44omWQxhPkiClnfjJyT0x71de81C9DQR2zx7ogxZ+SD3H5dMUaZo8dndG8e4lnAZnAZjsDMOTjvUN1qM017JHZXQyrEsoGdygdCexzUW1O/mudBCix2cUUj75EAzgcD2qi1vcXLLIk5TbJkqXJVgM/r0qje3V59gK28EwuJDkqG27fcVq2vnJDFHIpcsBuLEZB98VFikTK7Y2Elznk8elRTZUblXgjn2qxuXftIG/gMVFMZASRknk0LcZRlUyBXIBI69q5/VYnlcp0XAyc10c6lGBGAQSMY4FYmoDLFSAGxuJwfp19auDsJnK6kkYiYEYJ9ulctd7o5OAOeea6zUE3FtpO1T+XFczdR5YcsM89PWtTKorqyJ/g6obwZpYx0DE57/ADGvVbEpuHl8cd68m+EJLeDtLA7q3/oRr1fTAW5OD2B9KiYUfhVzbtnYSYOPTrUsiGQsQxA4AGetNQgENgMccY609pCI2Yhs+9YmjRk6skTGOK4lljkdtqyKuQR6H/69RSTQQxyvdsCiKeGOePXj8qv6jbNcWTiN2jmPO5Rkj3+tclCbP7RPBIFEseI3lL5Lnscf55qlqGxmeJNR0/U9JnW1kTbAxQxsCrnjnGev0r5+McaXgiKQtGWJiKjB3A9Dn0A78GvoC38Nxp5c1yXuxkiRZeQM++OorxPXbIad4puLeAf6NvaSMOegPUdOtbwR5+MbaTZpafqGm6ZIRMC0rjMpGdq5J6e3Wun07T0uWWXas08gGWlkG3B6kegx27VyY0yG5tFBlRLjcGlJOABjpjp3yR64rVs9Rews47cuZv3wQPCVB5Hf045z0rRHNF99jprSzFqZvs7CBB8yypyAM9iT05q7ezukBMK/u8cJ1Lk9ck96oaNMlzbxROx8pwH4Jwc9mPQf1rYiEF7FJdEiRYzsdgM7RnG7jr06U7o6Y7HH6fqGuC/NveRI9u7FmYn/AFf90bu64x+NXr21t4VQKQzjlSB69Sa2jCg1BI1QKWwEOcAZPGfxFZckckbvI/luqjapReuCOTnkc9fapJasV4lgaMl5Fa4AJVmYADAAPTmuQdV0u6LpGyTlisfmEFGDdc9SPatV7t7XUkhdI40cu4kI6H6j1znB/wAa5/WbNpJXdpjJJuaXcqYUjIxz6/yp3OabuZ0No0lyQ6yCJ5CDlAQox3PY8f1qpqojRrfaQ0WNqD+LpnkfXvW7EBdxT2t+Atw6bAu44yW4JxndgH26U5tEaVFyxmnC/wAa8ADgAfSkRYxfCyl9cgifcELYYsxC8Hof5V9L6RNbWot41heMrncsa525AIBHUDpXzBeJNY3h/eyLNGyOGU4UtnOa9u8K+Jri70e3uNPKG9kbY0j4J3A8g9unei1zehPlVjvL7XFtpnjkjYZVREAp5PPHPHaq0OuadbWrsqJFO8vl4wfnfPX6961rxFuI4458NdEEhAMFTjmsy8i8uSCNIIyrMNwZc4A/i+tRKJ3U53LTtdzXEX2fMYXHmEHLIP8ACthN32ghjI7bs9gKxIEurIvKz73cAKueC3/6q17C1EZNw7SrJJ8zRs2VB9awZ1o0ExHGcKADk4FRuSRuAwfU9afs4JGCD0pBhY+cEdOakZWmbdxx0yD1NZGonIBBKg1rKzbsNhs9OKzL51MbADapH41qiWctqPzuXKsoBx6Z7Z/SuauCxkLGMgHjHcV1+oL5in5wAG+Xsa5a9UtOzBiMnPXBrWLMpFX4N/N4O00A4OxsZ7/Ma9Y02SOFBtAb2968h+EZ2eDtMYdSH6j/AGjXrOnMXHPXuazmrDpfCjdsZ0nQHAz9Kkm+ZySeg6f4e9VrJFTGDgnk1ZlYgKTxg8+1ZNmnLqVmd7a2d4QzYBdgeawDAxInuoIvnw7jGCD9fqa6OQjHmEdsH0rmPEjX0oaGAoLVl3Z43Eg+/wDKnF9Acbaiz3qRWV2boNiI7RGq9c8AnHWvD/GEoi8Wh1HmQIACqruVOeQfT617XNAZLXEsrwlIwrugHTp+VeEeIUgHieaMvudcM7IWVSc8cH8K6IbHBir2NQeTc2paEKZJSQodcj3B7H6Vo6ZotujK6QFS7AoA/UAdR2x/hUOhx5t1tbg4J+aUA9D68d+orqLeFEihjtUj2ggpHyBjdjv19Pzq4q5jFJ6srXVvLeQgWgEUYJjaJu7DByBjp196hiL6dYkxxziJP3in+KQtgEnPH0rR8STLGilYfLlkdU3t8qFuSNvrkf5NaWnsLzwxcAKq3AhVYkyGLgk/PkflVWG5a3OWS6kv4kubqOTOWARhzuHHHqpOMGp5DEQkJAT7p+VvTBIOeD0/WrOqwxJKIyTHD5QXzFUlRhR8x9celYaWzQRrbSq32aU43SHll6c98f8A1qVrA7lrVRBptrNcosTTL1YgMDu4wRXLxxpftILi4ZUcABEAVWB4GB256k+lbuoRYihijBuBM+5gR8q8Y/Djtk9KpWf2OGGdYvKNx5nAIJ2jjBHc/j0qtzCW5JJo9vJaRpOyCTaBhD90D196jl0yGGczRSmEx8xbB0+vXNa1rAqZZgNrDJZhktjvSXKBIwCgwe5HI46dabXUaRxHixYp9NW3QeXMP3gKpncxOMZ/X8a0/gzeRQGaOV0BWRZDvHYeg/Cma3YpcqzRMUcKQADwfSuW0K//ALJ8TW91KzrHJJtYD07/AK1mnZi1jJH0xYNBe6k2sC8fZEPKVHG0Z9ffrVu/upFid4Ckm48HOB0/OsezlsZ7IDkxTc424GcDv+FWLSRILYW7TRyySZVCMdu31qZ7HbRdmbFqJL62t/OAjm27iufut2NX9PMwVlugdynCswALDHX+dYumLcos3mXRLPjandB6575ratnZo8ygA+/cVyyPQimWg+0bcHJOM9hQ5O1uAenFInCsSd2OKUqGbIxzSRTRCG2uNxGFHP8AhWZdZYliRknINaxUO4QjODnnvWbNFhnzklhgr2ArRGbRh3K7ieOpIyBXNajE/mhfuYHcjmutvogEZW+bjr2A9K5nUQ4uMY3EDnIzj2rWLMmc58IQT4N0scEYbt/tGvWNHQhCWwF6keteS/CEY8HaYckZ3AbfQseterWABJXJyBnFRNjor3F6HRKE2AqBjr9Kd1BJOSM1WhfJy2AP7tSNIYtzH7h5JzWDRvYdI+0EkBgRyKwtZ+y20YnnVclgF+bHPYGtSeTqUHBwefSsjUY47y3MdwSArZHbjHrRHQfLoc9qJ1CAyNAqi1ERwrjO5j6mvH9RjY6zeXU6yuihA3l8lyDnBr1XxNOn9muRceTHGhZHJ4yBwpHpXmmhxyzz+dIfNSVQc/3vUiuqGp52K3SR0fh1WYSTBlZGbG7jdnOOfX/63vW86JbxiGLeI1HmNITg59uPXmsi0Qi3jtoreNGi+dCDg5OSVIB5yK6q3VpbdYygcoh3I7gAgcnGOnsD6VsjmS6GPqmnPq6wjzvOijcMCpGVXGCvPT1BrbxFp9jDbPH5bwyrIrBgpbP3sY7Hj6VQmluYdKMdqixCNgyfIAUweSO5JyDzQY7qWaZkjyZX+7275I9jntUyZ00qd3dmfql7Fb2sKxKjMHKBAjF+CTgDv+NQS3cJltpp7aSKF3xvuB8u3HI2+np9K0LBhcaik8kYCbfmYghiwJwQPQYFWdQ0htTsHlbds/h3/LkZzjHYDFRc2lC6Zy8l5bve3S2KyvCj7xzwU9l6buM1zc9zBPqy3EShDKAsgY4JI54/SuvvbNdPsohPcxLCBj+4znJ79+vX2rjdbW2i/facuLfaWbOcqfY459601sedUTTNtZGVV2E+Z2OMlR2GKV/NOWZRk4Jy2SfxqO3A8oleWY5xzV0WcpRclRkfdxyBT3AyLlGDHAJyOuM1534njMd6xBCh/nUepHGc/SvTL2D7KA5xISDkqAMf41xHia3827swuxmlkCru6c8f1rNqzIktD0r4dayt94fg87MuwhPLA6MO9db/AKJ5sOdybmLKV6k5zzXlPgNn8P302k3zqoZyUbP3z9a9KtsyybZB5iuwwzcYFN6x0O3Du+p09nCouWlLSM23bjPDe9aaPKMKFwvqT1rKRxBD8gLkYABH61rWj74xvAUcEjHf0rle56UXoXlYeWoBAGB3qYAeX84HpmoIsSMTtACrjNPjiZZDu4izxUgTo/3Sq5ySBVK/3SZCYjO38SfQ1ejZQRx0yOPpVK4t23nAIB681SIe5jXcQORL8wxkAccmuc1RXS4xCGJ6tjn+ddfdAxyH724DAH19a5q9zHJghVPOOC2R2rWLM2jhfhKQfBumHbn5WHBxj5jXqunOUX+/uHUnpXl3wg2nwdpgYHLK2O4+8a9NsdqbY9yu4wfT9aiQ6K9xehv2o2xYxzkdepqbCkMpj3KRzxnNVpPMkgURLtYc5zSo7RQqjyZYDknjNYtmyVxkqtIMAgADoaqzrtjKy8r/AHh16d6sPvI4YlTzk9qrySkQbFOCvGe4oRbOD8ZxxR6XchpGDZDDb1GeP6Vx1vEzgGIHEYAVSf4u9dR8SoC8KNhdvmhcge2Rx+dYOm4hihBDEqm4YBJJPH8q66ex5eKd52NSxRt7ImyKR/kG9SxQdN2fXuMZroNOkE2nvLHIizwN5bF13ExjAPHck45Fc5aOkt8S28Mke1VyRhzg5Oe2ODW9Z3YTV7QSRt5au0UgAGeTnAPfkDn0rW+pko82wXsix3nlhxMiEbYxjPPJJHPH/wBem2mpJOheE7iM4ZTgfQVHrUhmluEdCVRtpeM4IB6ZGOak0qHy1LOyrbqNoVeox/KpauztpNxIbi7NrdWysjSXTqdqRJu3kn8uPXtVhry6EJS4kUuDtEcOcMe+c/XrShwsqzqIhIcx7uSV55ye9TsYZlfMRxE2fMPylj160WuNvU5vWrR7qUNIdsaRmNEZtxGTk57ZrnvEtsLa3kjhhh+ysmS6n7uccAV2N59njtnaTLbmwxc9c1zN+VYTJgspACkcbTkZx68fzqjkr01ujB8OX63FtGrnKx/K4OR0/oa24L6aSBpd0caNgB5Ryceg9Md+9YzWzQK6xANG2MoeO/T9aiju0kjNqZo3jIKb3JyATyD7j19qlOxybI0J9Qe6hISBpIwcpLyvnD2B6jjGa5y4t5bvxJo9rIu9nuwqqOmCf6V1MTIkEbGdIo1iKpJIARGg4JB/yfrWz8JPD/8Abvid9f2KdLsA9vavJz5rd5PcdefenLuOC5pJGX4z0ISxRwPG3mbsPIpw0TqOCBjOam8A+JBqNk1pcYW9szsIH8QFdN8TXWTVppogNxAVuepAxzXjGnXq6J48jkB2xSsN6npz/wDXqW9TqdqU0+59BaZdeeqsQRjjn1retmCoeAQOa5jTZFaPK5HAPPHNdDZSkAAjI9a55HqQV0a0T78YbrjIq6OcqWI5JzVG1BLEkAA8detXImyrYX86gJD1bDSBCAg56UT7DGGU/LjnjkZpkRbIZiFwcHjt2pzj5WkG5v4QM8U0ZMydRUvknczZ+nFc5dJ5cmCWB74at/VZBjbGhbPy4Q9+axmUXCqSx44GVBx7ZrVCZ518JVP/AAhenbSMjeRnpjca9P07aJnfMfzYKeorzH4TYXwZpa/xHc2M8/eNen2RbzFfAwRjD9qmQUv4cfQ2onJUANhmAOR2qUgeXsJUt15qsAERXiXkHnHP1qw5OF+Yjdzgjt6VizoRUZi2EyApyBVFojHcFjIW6nk/pVq6jkMf7kgtnIA7etUWLquZl5xyQPemhs5Lx/cGZbaMM3+sBOVwAdp71i6QzC4VIm2s4EZY8dRwT3rS8bEPbwPuyqXCg547VjacSfMjUssiEOjKwzkD3/E11Utjy66/em8kX2TYzQq0rxjIY8Nn+XReKSwcTaiImcuLVgwUqAXJH8qhN2rOkdz80vnpKhL/AHw45yPwqd/s4uttu5jLknODxxyf/wBdaX1HTjpcdqV5CZS0bhizZZgP46NOkO+WNyAgxzkDAxnB9azpgk9wJZVVjkYZhyR+FakMINvtiTMmSeeMjrgetDNoxJvIEYQsyiQyZ5BI3HuR34qjuMUMcQZxk7g3UPgnk9+1TahIVkDR5b+4d3Q/Q1lXVrJLcLKjlZypVucYXHIqkjKcrakF9Kl2skMcvCPhuP4u+M/hVSOGW3lBmk+0c4IYgY9hRNa+XfCaMqxwA3OBx3x64FWTEI1KmLMvDZJyfpj15p8pzqfPLUjkskaSNnJHnjGB61yvxB0sQobhdw8vlgByT2Bx+NdolvGZshmMgAYHPK+lVPFcEktjI0o3ExFgQOGxWbRpKCcHcyfDWk2muaQ1o6s0eTIyLIVBHXHH1r1zRdRit7ONI5DaxAbYSFBVR3AA9K8s8D3o07SRPgnZhcAcnPUCugbUktS5RDICwaNCeVY98dxTeyJwyja7K/jCdWlmdSzCTnLHJPoa8b1x1XxLbuo5V48KWzwDnmvS/FWotsWa8U28bRlnZurH0A7V5fpkTa14vhQAeW0w+6c4Re/6Vmk9WPFT5pxjE+h9GuVuLNXHAbkAjGRXRW0pHloq5OcMfQGuU00GJAqD5h0z3rpLKUq2XADY6EVjI9WKsbqzNtxHxtAOCP6VPbrcxtIZZBNG/K5AGKpQMHk8zncOMg4/CrqsqYO4KrdQeRUjZoRPudVIAIAOO1NLmQMoA+U4Yf4VEkzAnqMHG7HUZp0wI8zbklhggGmjJozNQSOEKcHdzjaemeKwrx2SXCmRv9lTjbwK279ArHb93ui8k46ZNcxqJuPO/coJP73sfSrRLRxfwojX/hC9OYKuTGxz3+8f/r16TpxL7fmDBhuBx94CvM/he0kXgjSHTGSCHB/iG89+1el6ayiTO0K2MkY6Dt9amSHR/hx9DaUmNV2DaGPzHHUUjOrMpQ5UdCT1oBcuMAHGFLHOKJYh5p4I29D2rOxqmRySqkgCAA4yexGapag52bTnHt1q3M643Bck8nnGaoXTnYVXaXA5xQlqVucR45VpdHm+bG0B1wMkYPX+dYXh6fdOsOBnICzElTxzXYagizRyCYKGKkMO2MdK85tXaz1AROxWWNgu4dCOzV0RdjgxMWpKR2Nwq/aWyjyRkhUyAjqV7/lUN3Ptt5RE0jSN94EYbrwPpVEMxRR55J+8wOTz6j0qGW5Rogqg/J985xxVvccGlAk+0O9oEUhnB5B4Ax7+uat2FzOdvmyRHk5CHofUHp2rKt40uWy8gDJhQwbg49fer8SR+UIovMbBJ4XCgetONjNOT1RcuLgkzEPmQjKluOnpjvVdbiSOOL7SwEhPMYOcMRjk9enPpVg2rNMkRKhDkgnt61IkzWxMcQUrKSrZQHA9RmtLilSb1ZnvbiaRUVgQTjcMYJHv9e9W7WCNYlEhxtOzCcnnp+NbMWkLcAvHPEUILFh0B69KlktHtI0VYlcupPI+7/tjHT/GqujKMeW5m2tuJbmXCFQ77dyDIAA4PvStBmymjm5/dsoUrzj/ADitmWX7DBCWQiMqinaDg5Gf/wBdYd3tmHlW+1XLFS27g5PT9DS3LcmlY5GwT7PpNw4BIE6IAPrzTZfFENtYJNeXI2RfIE2enQHHJq3aQwR6Q1zKz5WaRnHZsDA/U1494kbdqksatkRse/Ge9RY5HUcI6F3xH4iuteuREgcxbztTqzc8dP5V3PgLw1/ZKfa7sf6dKo46iNfT61R8EaPBbWUN28Ya5lG7cf4R6Cu0R+PQdKxnO+iO3CULv2k9zcs3bcGB3HqRXR2EgMalux+Y5rl7BlC84Az0zXRacmWaQPlWxgNWT2PVsblo+4k5OMYzir0THepYEr0AFYkc+12iVgGPatK3kLMNrc461Ami+XEbcDJ64ycUgukjRVIb5hwccEe1RREcsfzJpZGyVJAJwTnHAq0ZyRU1CR2iYIVBbgk8Z56ViXKOpURhfVsk9a1rl1kypxkLkjPT61ivCr4YmT05q0ScN8LCx8CadnLIFYbQcZ+Y16BZyMkRORsPKcdq87+FrofBukiQLjYwDE9t5Oa9BtSzCOPbuZUwW9efX0oaM6b9yJuxbjAAjfiTyfpVgAKpXzCWI53dSfaqe5n3hCN65BY8fjSkoLcsiKJVAGSep9jWbRsmK7DygQoGDjr6Vn3CuxwQFHXANWXOzOwE4HO7v7VUaQY3kAMcgk+lKxaMW9JabrlsZPvxXFeLrFtkV1F/rkYlgOAV7frXb3uDOGDABunqax79dysevGMH0rRGdaCnBo4yG/aCJWkK7v4gRxjFTy3AchUb5eo461TuLZknaMjAHK8DOP8APFV1ZkA3cbpNuQcZx3FWeVzte6zasFZ3RQq4z8rAYAPqa2rdRDO7GM9AWbqMHrXP6Vcyea6srBVYA5HbvXRi6ZYWdVVnYDHBJHPNNM76STjdD4oYZJvtJZtozxuAUDHb6/0ply9q8MrRT5uOgkx9314qvOwuBFui+4MJnkVmsWR2EiKjDOMnrnoeKbkVy8pZTVb2x5t53MYBG5gPmJHOBWponjE6csv2mL7SXTYmfkw38iPaub3zKTuO4Fup5xQJIVk2uCI15yx70lJnNOKep0T+LxIzKkDo6gYwdy+/BqO11ZMyTwhUc5ITqMknIHoa5+4eN2QHC5YAL3Oc/kKj1S9fTrN47VNkhBLF+Mr7egq1JowlLe5Wv9QMGiXCPja7b8E/wqf6mvJ7pzcXpOf9a/X6mtrWb64+yRK0mGD7gPr3qj4ZsH1HVYY1XKodzk9AKrpc4b80kkesaYnl20KD7oUAflWqMAnIyKpwxCMKuT0q0HO4le3OPWuRnv0FZampbqoxjIPqK2raWRNqxrg57elYllkojAnPcHua2LWQbsLkEUrnYajxZVZUBEyjcD/StGzaR/nYbccAZ61l58wBSffg4NXrSMLEoY52/MCe9Il6GnHKsI3SZUnpk/pUkmHQyMxZR8wGc+/SqIDMwQgMDyfpU5kVt6hdoAOSOMGmjORDfOjBRF1/2RyD6/pWFdTBZm3gbickyHr747Vdvrl2DkfM3IIHHGe3rWCZnKqQQxxhiR3rWKMzkvhmSvgvScZICvnGO7mvQtKLGMqZnc9Nw9PQ15v8ND/xR+nDceFZgCOBhjzXd2EyO+/zTkjptwD/AI0rmVP+HH0Oitt0qPv8lWZdvy8n6Zqy7qqE5O3AAXbuI96pWs2ABnGBhtvQDtTDKFdE2vn+HHAwahm0R5uBvIAO4nPPFUJ5jhWIBK9MjtVgz/OwLbN3fPpVW4RQDkkbumV60Iso3BTcMEjPIJ71mXRIUBtvoD6ircxcRqHILKSVJHUZrPvmdl4jI9FHBPv9KofQxb+NQQdo8wEYA9Kx0aJ5nkg+dkc5LD7p9K3bgZBG4EnocVkyhobguQDGzANkdD2NVGXRnm4qnZ8yIATNI0cTledwI4/A+tamlXLWocXTZIOV2HtWXKpjZjFjPXb606O5hZUO0bwMlGPND0YqFRb9TfvbhZFWSNgwxyBxsrFuTOro0OGzkAOcipWuElyhyhxx3wKYQgCAjLr27LS3N5y5iNxKEyHZC3JA65qn5xErRyAZADDJ4FWp3kErtguMAKD2pskZZIxFCDk8k+3f3qkrnNVetxYriFGMshPmYyshGQvrisjxNeMLdJpDiPgKpPJ+o9Pat02ESKk106eUTuUd2IHp021w/izU4mHlsisUO8IzZ3noCfXFaWaVmcU5nMatOJ7hmDMeeM+n+Ndb8OrdkjmucZDNt59vSuGGXkUDlmP55r1rQLdbPToLdOAgAJ9T3NTUfLGw8Mrzuby528fhmrMZ+UEDnoc1UjAGME4PepdzK425J69cCsGe3B21NS0fb8rOSuM5PFa1nMBICrYXpgjqaxIFR1LnIwOR6VtaegkCPvAwMgHnHpUnXFaGwgYouEBzjn0qa3nd8qpUoMcg4GKpwuowCGBGAPc1aghjDsUjwcZJB4P4UCkaDyF5AA2dxGFHGfoadeP5UbDIHGRnnr7VQZy7bhIqRoMEgY2n2pC+AwDFcdSGyWHqfSqSMWyu8nnFkDNxyGAGBWM7oJH3l2yc4yBitaWQhTsKlew6HH+FYd6jNJjaVA6bec+9aIi5xPw7kb/hFNNDsSgU456fMa7+wkG3OXKv0x1GOprz74dts8LaexXPytg54HzGu0tWUBASzg9+1IyoL93E31c+VHtJY43YZ8d8ZNW/M8ncR8zZI2BuB7ZrJgKyqPPC/nggDt71NP5kirtlI6kLjINDVzZaMmuJFUqSYyRyc+39Krz3bTFljVz23j+I8URxxRh0cEMqgOcZBHpUT7InCoCIhyP4RSVikNuyfLOcEqp49Ky7wOY12ofMbtnOK05gCpO7Pyg56k+1UJgHkDtkHbg+goGzHuCVUq3yj0PUVnS8lgwJyO9a19Gu8scge/esqQ53kDI460mc1RdDIWdoLnYWKqRw+cgn3HUVLly7SeUo/h3noT6DHSn3CJvyzNn+LbjOKopfmGJhKCR0aPkAHryfxrRO6PNkvZyNWHdJ95FRsfMFJ4qWKCNApwCT1PcGqCXyPJxtjcDGGXP61JkTKjSSbiDwRwD/AI0rG8aisPYNK2bh1VFIPAxuH9aWO5VDH8quTnA54H978OlV7luHOz93HkHIB/P2rF12/hWBkSQxKoBXaerex6kdOK0gc9Wd+pNrviGKAyhctMR97aMKPRR2rzu9lZ5nMh3SE84bgeoqXUb43kpdm7ZGDzknkt+tUQcso6npWhxSd2bHhixF1f8AmPnZHyMdzXptt8qhTnArjNAiFrAowM56j9a621IfAJI4rnqO53YZWRrQuFA3AcVMvyPnqp6ZqjEQowQeec1bVcjkHJI6Vk9j0actDRtHAGWXNbdpMob5I2xjnH86xLLgYfJzwfatm24C+XwAMnnFTc9GGxqK6L94/MenbJ/rUybn+8HAzuPHHsapQHzZOUJ28rznH4Vaed9rtkhQNrDOMD1pikOZZEkC9Ex8xQYOc0kLxh2RizMcn5h8pqE/KWbzGdX/AIScAHtzULKGBMu8Nt3Dack+9aoxaJLtlCM8Kn5hnKDOKw7h2L5UyD/dFXrmRkh+fcMHAGeOntVG5Lq+SoUn0frVIg4fwC5PhiwABOEYAA4/iNddA5tmVUYOqgHH9K4vwHGD4YsecYVj1/2jXWW7LsI2gITnk1PU5cPL3EahmYhZIQDjqM4z/nNbEbjaEVmAxyR1/OufhlYAbTyOSByB9K1UmVwpeRhnqvT8sUHVFXJ3aSWZchlQgqAB949iaWaSORgrSZYcflUcjlxuLNgYO0dqrvtdf3e4sBywI7mkaJD7i4Xc+7OQucYxj2rPkdlUlmJXjj0NWmYMxQEFioBY/wCetVboDyBuzsx2559zTB6Gfc5JOeSOh9qy5RnPp0I9a1HYAthiQR0PWsqZgkjZPBHGKlo5ajKXQEMNoHGPWs3U1d1yGPTgEcVoMxIKs3XoQaoXknVW5IFNbnDOz0MMX0tv/rZY0OSAH6/5NSHWLREmEsq78gsVPU+wqpqyxOCrk7/TFctcQhHAUY4x9a2iro45txeh1F9rm23RoIiY0UDKy/KM+3U/yzXM3t9NeSbpm3Mf89Pw601z+6I9BVYdc1olYxlJscGJPJpT6qRmm80AZODTJOy0mVWiic4yRg89a6S1uDsG3jnGa4nQJtwKN0Q547D6V1tsRtXAOMZ6Vzz3O2jLQ3YHDjIyG7itCFht4znrz2NZFo2dq9COAa0vvR4DBTjr3FYyO+mzUsydy5OM9D6VpxTsqE7QCeG54HvWJZuNibmOR3Hb8K1YwDgkrk8An/PNSenSleJpWrM7KzMuccf41bL9fMy7NyDnGD6VSgO+FcFSBwVwc0qsd4GfXjI61S1KkyVjGEAXpjhSO9V2mZvk3EAdVJ/lSkKzJ+8ZVz0PODUcyqHAbBC9n5/E4q0ZyEEpTcSvr9az53WR8gnH+31qabaA21s55x/d981nyu5clY1J6Hc1Xc55uxyHgbP/AAjNmPmyFYjHTG410yDC7kD7T+n4VyvgcZ8OWPODtbOP9411KHcqnkk9MHtUtHDQb5VYuWweRl4wPUHHH0rStm4CiUgjA24rNt2cKcM/B7elS7iJU8sH5iB93HNB3QlY03bYp3Z/2TnO6oneRGZU2gZPJ6j61HvaONQcEnt1yT70rn5myCCeOP60jfQZulVgCzMSPmPTJ9adKfnfJAB+Yhj1PrVWQy/aBvHB6AdabJv2BcAEfdPGfzpCbsitefIjFMnnkCsm5cAgH+I59TV27aRnITgYwe4qhMdmQoGMD+dNnDVdypMpIJQ4Ocj2FZ92Y8Hcewz7+9WrqcI4YYwRgE9z9azLpt6ozAqy54NNI457mRqmPvcn0+lc3dPmQDIJHoc10GqSqYNw6AVzMrbpc9Bmt4bHJVeo9z8jVWGQTjFTnJU5qAdTVmIUoODSUvcUAaOiS7b3afusuPxrs7SQ7Np7HFcXYWzGRXA+6Qc119q+5fmODwcVlUXU3oStobcUmeUXv0z0rVhk3Ln+L0NY1sQAhH3j+tX7SX58HO0nuOKwauehTkbNuVK4B57Y5rRSbGxThSMYzWRE4wpA68cVoW4DKp9+QTwazPSoy6GjDIp3Kw3MTztFTzuhUuojPIGTxjHrVNG/hA4ByCDz/wDWoZQckZKEHkHjNWjd6k0UhxwRtHYnH61ArtuYg4AyGA5NKWEcecqy4wCaovs5LKOe2SAfeqRlJktwwibazMSPmw1Zs0vz8j6ZbFSSzIepHAwMnH5VUlZmwy+WAfXvTOOpK+xyPhC9gi8O2ivcwxyLu+VnAP3j1rq7W9tT8gubdgegEgB/nRRQ9zzaFR7FqO7t1fd9pg/CUc/UVpQ39uW4nt2+so5NFFI9KnUa0Bry1dj/AKTEpPAXzRge9BuLZhtNzGqgf31yf1oooNFVbEkuoMNmeErt7OCTVea5jDZMsSuwBOGHX86KKRU5uxlzXMXmsPNjKkDaC46mqVxLE6fLPGGA2jDAmiig4qkjJv5k2YDowX7q7his64lHkfO6Z5PUUUVZytmJfzxtb4Vh93pWExBKkEc0UVvHY5Km5KWG0jIzVcdT9aKKogKmtI/NmCjr70UUID0HSNIUWy78ZIqO7iFndsi7cgZX2FFFXWS5BUW+exZs3BAYkYIzjPArTt5lLffU+2aKK4T04M0rZtz5DDLepq+bpYLeWUkKsas3TIOB0oorJnoUm0tCbTLiWWxjku1SG5kUM0YyQue31q6XRW8wOGyOQT/SiimdMZvlKvnbt+FG3+IdCar3UijK70K5456UUVaMakmUZpsIPcjjHT3qjNIAeSnrkGiimcUmf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scrotal swelling is seen in a patient with a strangulated indirect inguinal hernia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36496=[""].join("\n");
var outline_f35_41_36496=null;
var title_f35_41_36497="Lymphangitis of the hand and arm";
var content_f35_41_36497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangitis of the hand and arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangitis is an infection of the lymphatics characterized by a distal nidus and erythematous streaks that spread proximally up the arm. Note the red streak extending proximally from the ring finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36497=[""].join("\n");
var outline_f35_41_36497=null;
var title_f35_41_36498="Patient information: Vaccines for people with HIV (The Basics)";
var content_f35_41_36498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/35/31282\">",
"         Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/44/22210\">",
"         Patient information: Starting treatment for HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/29/7635\">",
"         Patient information: HIV and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/31/15861\">",
"         Patient information: Initial treatment of HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/39/44658\">",
"         Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines for people with HIV (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-for-people-with-hiv-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10259084\">",
"      <span class=\"h1\">",
"       Should people with HIV get vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Vaccines are especially important for people with HIV. That&rsquo;s because people with HIV are at higher risk of infections than other people, and vaccines help prevent infections. But only some vaccines are safe and appropriate for people with HIV.",
"     </p>",
"     <p>",
"      In general, people with HIV can get &ldquo;inactivated vaccines,&rdquo; which are vaccines that contain dead copies of a virus. People with HIV usually should NOT get &ldquo;live attenuated vaccines,&rdquo; which are vaccines that contain live but weakened copies of a virus. There are exceptions to this, though. For instance, some people with HIV should get the live attenuated vaccine to protect against chickenpox (called the",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/40/10881?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259099\">",
"      <span class=\"h1\">",
"       Which inactivated vaccines should I get?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have HIV, ask your doctor which vaccines you need.",
"     </p>",
"     <p>",
"      People with HIV usually need: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The flu vaccine &mdash; The flu can cause fever, chills, muscle aches, cough, or sore throat. The flu vaccine is also called the &ldquo;influenza vaccine,&rdquo; or the &ldquo;flu shot.&rdquo; People with HIV should get 1 dose of this vaccine every year.",
"       </li>",
"       <li>",
"        Pneumococcal vaccine &mdash; Pneumococcus is a germ that can cause an infection of the lungs, ears, blood, or tissues around the brain. The &ldquo;pneumococcal vaccine&rdquo; is sometimes called the pneumonia vaccine. People with HIV should get 1 to 2 doses of this vaccine between the ages of 19 and 64. Once they turn 65, they should get another dose if it's been more than 5 years since their last dose.",
"       </li>",
"       <li>",
"        Diphtheria, tetanus, and pertussis vaccines &mdash; Diphtheria can cause a thick covering in the back of the throat that can lead to breathing problems. Tetanus causes the muscles to work abnormally. Pertussis, also called &ldquo;whooping cough,&rdquo; is an infection that causes a severe cough. People with HIV should get vaccines against these 3 infections, which come in a single shot. After that, they should get vaccines against diphtheria and tetanus every 10 years, which also come in a single shot.",
"       </li>",
"       <li>",
"        Human papillomavirus (HPV) vaccine &mdash; HPV is a virus that can cause genital warts and some forms of cancer. People with HIV should get 3 doses of this vaccine. &nbsp;",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/38/10849?source=see_link\">",
"         Hepatitis B vaccine",
"        </a>",
"        &mdash; The hepatitis B virus causes a serious form of liver disease. People with HIV should get 3 doses of this vaccine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on their situation, some people with HIV might also need:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Meningococcus vaccine &mdash; Meningococcus is a germ that can cause a serious body-wide infection of the blood or an infection called meningitis, which affects the tissues around the brain. This vaccine might be appropriate for people who live in college dorms or who will be traveling to certain parts of Africa or the Middle East.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/58/11169?source=see_link\">",
"         Hepatitis A vaccine",
"        </a>",
"        &mdash; The hepatitis A virus can cause a serious form of liver disease. People can get it from eating or drinking unclean food or water. This vaccine might be appropriate for:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        People who use intravenous (IV) drugs",
"       </li>",
"       <li>",
"        Men who have sex with men",
"       </li>",
"       <li>",
"        People who already have other forms of liver disease",
"       </li>",
"       <li>",
"        People with a bleeding disorder called hemophilia",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Polio vaccine&ndash; The polio virus can cause muscle weakness and pain, and lead to long-term paralysis. Paralysis is when people are unable to move parts of their bodies. The polio vaccine is sometimes appropriate for people who will be traveling.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259114\">",
"      <span class=\"h1\">",
"       Which live vaccines should I get?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have HIV, there are certain live vaccines you should get. But you can only get them if your CD4+T cell counts are above 200. These vaccines include the: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/40/10881?source=see_link\">",
"         Varicella vaccine",
"        </a>",
"        (2 doses) &mdash; This vaccine protects against chickenpox, an infection that causes itchy, red bumps on the skin.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/51/4913?source=see_link\">",
"         Zoster vaccine",
"        </a>",
"        (1 dose) &mdash; This vaccine protects against shingles, a condition related to chickenpox that causes a painful, band-shaped skin rash.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259131\">",
"      <span class=\"h1\">",
"       What if I want to travel?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to travel, you will need to check with your doctor about which vaccines you might need based on where you are going. Some travel vaccines are safe for people with HIV, but others are not safe. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259146\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor before you start trying. There are certain vaccines that you will need to have before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259161\">",
"      <span class=\"h1\">",
"       Which side effects should I expect?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the vaccines mentioned here cause soreness in the arm that usually lasts about a day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10259176\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=see_link\">",
"       Patient information: Starting treatment for HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/35/31282?source=see_link\">",
"       Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/39/44658?source=see_link\">",
"       Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=see_link\">",
"       Patient information: Initial treatment of HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/29/7635?source=see_link\">",
"       Patient information: HIV and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/41/36498?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16829 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36498=[""].join("\n");
var outline_f35_41_36498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259084\">",
"      Should people with HIV get vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259099\">",
"      Which inactivated vaccines should I get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259114\">",
"      Which live vaccines should I get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259131\">",
"      What if I want to travel?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259146\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259161\">",
"      Which side effects should I expect?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10259176\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/39/44658?source=related_link\">",
"      Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36499="Patient information: Medicines for heart failure (The Basics)";
var content_f35_41_36499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16189\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"         Tips on taking medicines",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/40/13956\">",
"         Patient information: Diastolic heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/57/1939\">",
"         Patient information: Heart failure and atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/37/36435\">",
"         Patient information: Medicines after an ischemic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/36/17986\">",
"         Patient information: Medicines for atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/32/7684\">",
"         Patient information: Systolic heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for heart failure (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicines-for-heart-failure-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8479858\">",
"      <span class=\"h1\">",
"       What do heart failure medicines do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have heart failure, the medicines your doctor prescribes can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help you feel better and more able to do everyday tasks",
"       </li>",
"       <li>",
"        Reduce the symptoms of heart failure (such as swelling or trouble breathing)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a form of heart failure called &ldquo;systolic heart failure,&rdquo; medicines can also help you live longer and lower the chance you will need to go to the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8479873\">",
"      <span class=\"h1\">",
"       Which medicines might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Below is a list of the most common medicines used to treat heart failure. Very few people take all of the medicines listed. But if you have heart failure, the list probably includes at least some of the medicines you take.",
"     </p>",
"     <p>",
"      Many people with heart failure take 3 medicines or more. That may seem like a lot. But each of these medicines does something different. The medicines work together to keep you as healthy as possible.",
"     </p>",
"     <p>",
"      Keep in mind that the doses and choices of medicines you get might change now and then. Work with your doctor to find the combinations and doses of medicine that work best for you (",
"      <a class=\"graphic graphic_table graphicRef59726 \" href=\"mobipreview.htm?32/6/32875\">",
"       table 1",
"      </a>",
"      ). As your disease progresses and your body gets used to medicines, you might need changes. But if you follow your doctor&rsquo;s suggestions and report back any problems, those changes will pay off.",
"     </p>",
"     <p>",
"      It is a good idea to keep a list of all the medicines you take, and bring it with you each time you visit any doctor. You can find an example of this kind of list at the following Web site:",
"      <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/ucm079489.htm\">",
"       www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm",
"      </a>",
"      .",
"     </p>",
"     <p>",
"      The list below includes just some basic information on the main medicines used in heart failure. If you would like more detailed information, including information on the side effects caused by specific medicines, ask your doctor or nurse for it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8479888\">",
"      <span class=\"h2\">",
"       Medicines to treat heart failure",
"      </span>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         ACE inhibitors and ARBs &ndash;",
"        </strong>",
"        Angiotensin-converting enzyme inhibitors (called &ldquo;ACE inhibitors&rdquo;) and angiotensin receptor blockers (called &ldquo;ARBs&rdquo;) are often grouped together, because they work in similar ways. Doctors usually prescribe ACE inhibitors first. But they sometimes switch patients to ARBs if the patients have side effects with ACE inhibitors.",
"        <br/>",
"        <br/>",
"        ACE inhibitors and ARBs relax blood vessels and can lower blood pressure. This makes it easier for the heart to pump. ACE inhibitors and ARBs also help prevent or undo changes in the shape of the heart that can happen because of heart failure.",
"        <br/>",
"        <br/>",
"        Some examples of ACE inhibitors include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30197?source=see_link\">",
"         enalapril",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/49/25365?source=see_link\">",
"         captopril",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/32/9734?source=see_link\">",
"         lisinopril",
"        </a>",
"        . Some examples of ARBs include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/50/4902?source=see_link\">",
"         candesartan",
"        </a>",
"        (brand name: Atacand&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/15/21749?source=see_link\">",
"         valsartan",
"        </a>",
"        (brand name: Diovan&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         Beta-blockers &ndash;",
"        </strong>",
"        Beta blockers slow the heart down and can lower blood pressure. They help reduce the amount of work the heart has to do.",
"        <br/>",
"        <br/>",
"        When people first start taking beta-blockers, they sometimes feel a little worse than before. That is just while the body gets used to the medicine. But once the body gets used to beta blockers, the medicines can really help. If your doctor prescribes a beta blocker, give it a little time to start working. &nbsp; &nbsp;",
"        <br/>",
"        <br/>",
"        Some examples of beta blockers include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/15/37109?source=see_link\">",
"         carvedilol",
"        </a>",
"        (brand name: Coreg&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/28/25030?source=see_link\">",
"         metoprolol",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/59/22453?source=see_link\">",
"         bisoprolol",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        <strong>",
"         Diuretics (water pills) &ndash;",
"        </strong>",
"        When you have heart failure, your body holds onto extra fluid. Diuretics help the body get rid of extra salt and fluid. They can reduce heart failure symptoms or keep them from getting worse. For example, diuretics can help pull fluid out of the lungs, which makes breathing easier.",
"        <br/>",
"        <br/>",
"        Diuretics make you urinate a lot, especially when you first start taking them. That actually means the medicines are working. But if the need to urinate a lot makes it hard for you to take these medicines, work with your doctor or nurse to find a good time to take them. Take them at the same time every day and do not miss any doses. Skipping just 1 diuretic or taking these medicines at the wrong time or at the wrong dose can land a person in the hospital. It&rsquo;s very important that you take these medicines exactly the way your doctor or nurse tells you to.",
"        <br/>",
"        <br/>",
"        Some examples of diuretics include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/14/12518?source=see_link\">",
"         furosemide",
"        </a>",
"        (brand name: Lasix&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/44/37573?source=see_link\">",
"         torsemide",
"        </a>",
"        (brand name: Demadex&reg;), and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/28/29125?source=see_link\">",
"         bumetanide",
"        </a>",
"        . &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Aldosterone receptor antagonists &ndash;",
"        </strong>",
"        Aldosterone receptor antagonists are similar to diuretics. They help the body get rid of extra salt and fluid. But they also help the body hold onto potassium. That&rsquo;s important because other diuretics sometimes make the body lose too much potassium, which the body needs to work normally.",
"        <br/>",
"        <br/>",
"        When taking this type of medicine, it is very important to have regular blood tests to check your potassium levels and see how your kidneys are working. Your doctor or nurse should follow the results of these tests closely.",
"        <br/>",
"        <br/>",
"        Some examples of aldosterone receptor antagonists include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/27/19893?source=see_link\">",
"         spironolactone",
"        </a>",
"        (brand name: Aldactone&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/49/23316?source=see_link\">",
"         eplerenone",
"        </a>",
"        (brand name: Inspra",
"        <sup>",
"         TM",
"        </sup>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Nitrates with",
"        </strong>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/40/8837?source=see_link\">",
"         hydralazine",
"        </a>",
"        <strong>",
"         &ndash;",
"        </strong>",
"        Nitrates and hydralazine work together to relax and expand blood vessels. This makes it easier for the heart to pump blood throughout the body. This combination of medicines is sometimes used in people who cannot take an ACE inhibitor. Unfortunately, the medicines often cause side effects (such as headaches and nausea), so doctors usually try other options before suggesting them. &nbsp;",
"        <br/>",
"        <br/>",
"        These 2 medicines come in a single pill, but it is possible to get the 2 ingredients separately for much less money. The 2 ingredients come in pills of &ldquo;",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/50/24356?source=see_link\">",
"         isosorbide dinitrate",
"        </a>",
"        &rdquo; and of &ldquo;hydralazine.&rdquo;",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/34/30245?source=see_link\">",
"         Digoxin",
"        </a>",
"        <strong>",
"         &ndash;",
"        </strong>",
"        Digoxin helps the heart pump with more force. This can help reduce some of the symptoms of heart failure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8479914\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1939?source=see_link\">",
"       Patient information: Heart failure and atrial fibrillation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=see_link\">",
"       Patient information: Medicines for atrial fibrillation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=see_link\">",
"       Patient information: Medicines after an ischemic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13956?source=see_link\">",
"       Patient information: Diastolic heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=see_link\">",
"       Patient information: Systolic heart failure (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/41/36499?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16189 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36499=[""].join("\n");
var outline_f35_41_36499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8479858\">",
"      What do heart failure medicines do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8479873\">",
"      Which medicines might I need?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8479888\">",
"      Medicines to treat heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8479914\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"      Tips on taking medicines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13956?source=related_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=related_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36500="Capsaicin: Patient drug information";
var content_f35_41_36500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Capsaicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     see \"Capsaicin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/31/24053?source=see_link\">",
"     see \"Capsaicin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capzasin-HP&reg; [OTC];",
"     </li>",
"     <li>",
"      Capzasin-P&reg; [OTC];",
"     </li>",
"     <li>",
"      DiabetAid&reg; Pain and Tingling Relief [OTC];",
"     </li>",
"     <li>",
"      Qutenza&trade;;",
"     </li>",
"     <li>",
"      Salonpas&reg; Gel-Patch Hot [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Hot [OTC] [DSC];",
"     </li>",
"     <li>",
"      Trixaicin HP [OTC];",
"     </li>",
"     <li>",
"      Trixaicin [OTC];",
"     </li>",
"     <li>",
"      Zostrix&reg; Diabetic Foot Pain [OTC];",
"     </li>",
"     <li>",
"      Zostrix&reg; [OTC];",
"     </li>",
"     <li>",
"      Zostrix&reg;-HP [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zostrix&reg;;",
"     </li>",
"     <li>",
"      Zostrix&reg; H.P.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3437665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help diabetic nerve pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to capsaicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Burning or stinging feeling. This will most often goes away after a few days when using this drug as you have been told.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may wear gloves when putting on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2807389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel, liquid, or lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2807390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Qutenza&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2807391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Other patches:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on the most painful parts of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694470",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry, healthy skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may leave on for up to 8 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2807390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Qutenza&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11474 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36500=[""].join("\n");
var outline_f35_41_36500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145291\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145292\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018208\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018207\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018212\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018213\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018215\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018210\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018211\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018216\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018217\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=related_link\">",
"      Capsaicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/31/24053?source=related_link\">",
"      Capsaicin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36501="Candidal diaper dermatitis A";
var content_f35_41_36501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59361%7EPEDS%2F72165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59361%7EPEDS%2F72165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida diaper dermatitis in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques and pustules are visible with scattered satellite lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Anthony Mancini, Children's Memorial Hospital, Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida diaper dermatitis in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic occlusion by wet diapers predisposes to infection, which initially begins in the perianal area with subsequent extension to the perineum and inguinal creases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Annette Wagner, Children's Memorial Hospital, Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36501=[""].join("\n");
var outline_f35_41_36501=null;
var title_f35_41_36502="Management of posterior urethral valves";
var content_f35_41_36502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of posterior urethral valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Nicholas Holmes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36502/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/41/36502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior urethral valves (PUV) are obstructing membranous folds within the lumen of the posterior urethra (",
"    <a class=\"graphic graphic_figure graphicRef87629 \" href=\"mobipreview.htm?33/30/34274\">",
"     figure 1",
"    </a>",
"    ). PUV is the most common etiology of urinary tract obstruction in the newborn male, occurring in 1 to 5000 to 8000 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/1\">",
"     1",
"    </a>",
"    ]. PUV are also the most common cause of chronic kidney disease (CKD) due to urinary tract obstruction in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of PUV will be reviewed here. The clinical presentation and diagnosis of PUV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=see_link\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRENATAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With prenatal detection of PUV and technological advances in surgical equipment, the management of PUV has evolved to include prenatal surgical intervention. However, this remains investigational, and the vast majority of affected infants should be treated soon after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first case of prenatal surgery to relieve obstructive uropathy was performed in 1981 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Surgical intervention, primarily vesicoamniotic shunt placement, was based upon the rationale that restoring amniotic fluid to normal levels by shunting fetal urine from the obstructed urinary system to the amniotic space would prevent lung hypoplasia and, thus, improve neonatal survival. In addition, relief of the obstruction would also reduce back pressure and reduce injury to the developing nephron, thus improving long-term renal function postnatally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Renal and urologic manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42824?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of antenatal hydronephrosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, over the past three decades since the introduction of fetal intervention for obstructive uropathy, data on outcome of fetal surgery for PUV suggest that it is associated with a risk of fetal and maternal morbidity without proven benefit for long-term renal outcome.",
"   </p>",
"   <p>",
"    This was illustrated in a case series of 40 fetuses cared for at one of the most active tertiary centers for fetal intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/7\">",
"     7",
"    </a>",
"    ]. Criteria for fetal intervention included normal karyotype, favorable fetal urinary electrolytes with beta-microglobulin levels predictive of normal renal function, and a detailed prenatal renal ultrasound that did not show evidence of renal cystic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/7\">",
"     7",
"    </a>",
"    ]. Of the 40 eligible fetuses, 36 underwent surgical intervention, including 14 with PUV at a mean gestational age of 22.5 weeks. In the 14 patients with PUV, procedures included placement of a vesicoamniotic shunt in nine cases, ablation of PUV in two, and in two with fetal bladder marsupialization bladder (ie, bladder was surgically opened and secured to the abdominal wall), plus creation of a ureterostomy in one case. The following findings were noted in the 14 PUV cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five deaths occurred in infants who were born prematurity and had respiratory failure.",
"     </li>",
"     <li>",
"      One pregnancy was terminated because of evidence of shunt failure and findings indicative of poor lung and renal development and function.",
"     </li>",
"     <li>",
"      Eight patients were alive at a mean follow-up of 11.6 years. Five patients had chronic kidney disease (CKD) demonstrated by an elevated serum creatinine, of which two had undergone renal transplantation, and another patient was awaiting organ donation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were seen in a case series from a single fetal treatment center of 20 fetuses with lower urinary tract obstruction, including seven with posterior urethral valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/8\">",
"     8",
"    </a>",
"    ]. The mean gestational age was 34.6 weeks with a mean birth weight of 2.57 kg. There were two neonatal deaths due to pulmonary hypoplasia. Among the survivors, six developed ESRD requiring either dialysis or renal transplantation, and four had minor renal insufficiency at a mean age of 5.83 years.",
"   </p>",
"   <p>",
"    These results demonstrated a significant mortality and morbidity rate due to premature birth and respiratory failure. These case series occurred early in the fetal surgery experience, and medical advances have significantly decreased the mortality rate and ongoing new techniques continue to be developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/9\">",
"     9",
"    </a>",
"    ]. However, it appears that survivors of fetal intervention still had a significant risk of developing CKD and ESRD.",
"   </p>",
"   <p>",
"    Fetal surgery for PUV may be considered in fetuses who have a high risk of in utero or neonatal death due to midtrimester severe oligohydramnios and who have both a normal karyotype and evidence of good renal function based upon fetal urinary evaluation. Fetal urine evaluation is performed by urine sampling from the bladder by catheter placement under ultrasound guidance on more than one occasion. The urine from the initial drainage is discarded and a urine sample obtained after bladder refilling is sent for analysis. A favorable urine sample indicating good renal function has a serum sodium of less than 100",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    chloride less than 90",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    osmolarity less than 210",
"    <span class=\"nowrap\">",
"     mOsm/L,",
"    </span>",
"    and a beta-2 microglobulin less than 6",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If fetal surgery is being considered, it should only be performed in fetal treatment centers with considerable experience and expertise due to the risks to the mother and fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POSTNATAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without fetal intervention, once the diagnosis of PUV is suspected or diagnosed, initial postnatal management includes stabilization of the patient and drainage of the urinary tract.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical management includes correction of electrolyte abnormalities, particularly hyperkalemia, and intervention to treat respiratory distress, and urosepsis. In addition, renal function is monitored before, during temporary bladder drainage, and after PUV ablation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=see_link\">",
"       \"Fluid and electrolyte therapy in newborns\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of neonatal respiratory distress: Disorders of transition\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporary drainage of the urinary tract &mdash; Drainage of the bladder should be done once the patient is stabilized. In most instances, temporary drainage is performed by placement of a catheter in the bladder. In some centers, primary ablation is used without initial drainage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we use a soft feeding tube rather than a Foley catheter with a balloon to drain the bladder. The feeding tube has a larger internal diameter, allowing for better drainage, and the inflated balloon of the Foley catheter may occlude the ureteral orifices. We typically use an 8 French or greater feeding tube depending upon the size of the urethral meatus. Ultrasonography can be used to document the correct placement of the catheter into the bladder. It is common for any type of urethral catheters to coil in the dilated posterior urethra. If urethral catheter drainage cannot be established, then emergent consultation with a pediatric urologist is necessary for cystoscopic evaluation.",
"   </p>",
"   <p>",
"    Once drainage is established, the patient may have large urinary water and solute losses because of tubular dysfunction, resulting in an inability to concentrate the urine or normally absorb solutes (eg, sodium and potassium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, some patients with PUV due to urinary obstruction may have type IV renal tubular acidosis. As a result, careful monitoring of serum electrolyte including serum bicarbonate, and fluid status is required with timely replacement of fluid and electrolytes as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy confirms the diagnosis with direct visualization of the PUV. In addition with advances in surgical technique and instruments, primary ablation during cystoscopy is the preferred initial surgical treatment of PUV because it is a less invasive procedure that may preserve bladder function and decreases the need for subsequent surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3,6,13\">",
"     3,6,13",
"    </a>",
"    ]. The ability to perform this procedure is determined by the size of the male urethra to accommodate the neonatal cystoscope. The timing of this procedure is dependent on the overall health status of the neonate and issues with general anesthesia.",
"   </p>",
"   <p>",
"    Although primary ablation is not generally performed in premature infants, in one small case series of 17 low birth weight infants (median birth weight 2100 g, range 1760 to 2690 g), a Fogarty catheter under direct visual guidance of a neonatal cystoscope was used to disrupt PUV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/14\">",
"     14",
"    </a>",
"    ]. In 14 of the surviving infants (three died of causes unrelated to the procedure), voiding cystourethrography demonstrated effective ablation and adequate bladder drainage. The advantage of this technique is that it avoided long-term catheterization and the need for vesicostomy. However, the use of this technique has been very limited, and it should only be performed by an experienced pediatric urologist for the rare premature infant with obstructive uropathy due to PUV.",
"   </p>",
"   <p>",
"    Valve ablation relieves the urethral obstruction in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3,4,15\">",
"     3,4,15",
"    </a>",
"    ]. With relief of bladder pressure, in those patients with vesicoureteral reflux, resolution of VUR will occur in one-third of the patients after ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Vesicostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If primary valve ablation cannot be done, generally for technical reasons, vesicostomy is the next preferred procedure as it allows good drainage of the urinary tract, which relieves back pressure, and is a reversible procedure. It also allows for the normal cyclical filling and emptying of the bladder at low vesical pressure. Vesicostomy is performed in very preterm infants in whom safe visualization or ablation of the valves is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Higher diversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher diversions with cutaneous ureterostomies and pyelostomies are rarely indicated and do not improve outcomes compared to vesicostomy. It commits a patient to subsequent major upper tract reconstruction. In addition, higher diversions disrupt the filling and emptying of the bladder, which may further impact on bladder function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POST-PROCEDURE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a successful procedure that relieves or bypasses the intervention, management includes detecting and treating bladder dysfunction, and monitoring renal function, and if necessary, managing the consequences of chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286558330\">",
"    <span class=\"h2\">",
"     Bladder function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder function should be evaluated by imaging and urodynamic studies. The use of CIC and anticholinergic medications lowers bladder pressures in patients with severe bladder dysfunction (ie, low capacity, poorly compliant bladders with high filling pressure). It may reduce the rate of vesicoureteral reflux, if present, post-ablation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Bladder dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    After PUV ablation, persistent hydronephrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydroureteronephrosis may reflect abnormal bladder function. In these patients, urodynamic studies are indicated with therapy (ie, CIC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticholinergic therapy) directed towards improved bladder compliance and complete emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/16\">",
"     16",
"    </a>",
"    ]. The use of nocturnal bladder emptying with indwelling Foley catheter may be helpful in those patients who have persistent hydroureteronephrosis. A series of 18 boys who had successful ablation of valves showed marked improvement in hydroureteronephrosis when night-time drainage was implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 119 patients with PUV who were almost all treated with initial early bladder drainage and cystoscopy with primary ablation, one-third of patients had severe bladder dysfunction and required clean intermittent catheterization (CIC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/4\">",
"     4",
"    </a>",
"    ]. In another study, although 27 of 65 patients had symptoms of bladder dysfunction, continence was achieved in 42 of 55 toilet-trained children, and only 3 required CIC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3\">",
"     3",
"    </a>",
"    ]. In both reports, pharmacologic treatment using anticholinergic and alpha-blocker medications was used in children depending upon the results of urodynamic testing. In a small case series of 18 patients with high voiding pressures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small bladder capacity, early administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/11/40117?source=see_link\">",
"     oxybutynin",
"    </a>",
"    (anticholinergic agent) after PUV ablation was associated with improved bladder function on urodynamic testing prior to toilet training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286558340\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is a high risk of CKD in these patients, ongoing monitoring of the renal function of these patients is important. In patients with CKD, management is directed at caring for the associated complications of CKD and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with CKD may have a urinary concentrating defect resulting in excessive urinary losses. This may overwhelm the carrying capacity of the urinary tract, resulting in an enlarged and poorly functioning bladder and persistent hydronephrosis. In these patients, nighttime catheter drainage to completely decompress the urinary tract may be an effective intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H763666\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite prenatal diagnosis and early intervention, a significant number of patients with PUV will develop ESRD as illustrated by the following case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3,4,20\">",
"     3,4,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 65 patients identified prenatally with PUV who were mostly treated with primary ablation as neonates between 1987 and 2004, 11 had ESRD at a median follow-up of 6.8 years (range 1 to 14.3 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3\">",
"       3",
"      </a>",
"      ]. Six patients had undergone renal transplantation. In this report, risk factors associated with poor renal outcome included gestational age before 24 weeks at first diagnosis and the presence of oligohydramnios. The presence of renal parenchymal changes was not predictive of renal failure.",
"     </li>",
"     <li>",
"      In a series of 142 patients, half of whom presented as neonates, ESRD developed in 15 of 119 patients at a mean follow-up of 7.2 years. &nbsp;In a multivariate analysis, a nadir serum creatinine greater than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88.4",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      was most predictive of renal failure (OR 71, 95% CI 10-482) followed by bladder dysfunction (OR 8.9, 95% CI 1.1-73) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 116 patients, at the end of a mean follow-up of 10.3 years, 35 had significant renal impairment with 14 requiring renal replacement therapy (renal transplantation in eight and dialysis therapy in six) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been speculated that patients who presented later in life with PUV would have milder disease and better long-term outcome; however, one retrospective study demonstrated that patients who presented after two years of age had similar risks of developing renal insufficiency as patients who presented at an earlier age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/21\">",
"     21",
"    </a>",
"    ]. In this study, elevated serum creatinine at one year after valve ablation was predictive of renal impairment. In another study of 141 patients who presented at a mean age of 46 months, 12 (9 percent) patients developed chronic kidney disease defined as receiving renal replacement therapy (dialysis or renal transplantation or an estimated glomerular filtration rate of 60",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    at a median follow-up of 2.0 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/22\">",
"     22",
"    </a>",
"    ]. Five of the 12 patients had minimal or no recovery of kidney function after ablation. Of note, in this cohort, 90 cases were reported to have had normal prenatal ultrasounds by parental recall.",
"   </p>",
"   <p>",
"    Another report suggested that patients who presented after five years of age compared to age-matched controls who presented before five years of age had greater impairment of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results demonstrate that a significant number of patients with PUV will have renal impairment, and some will progress to ESRD and require renal replacement therapy. Age at presentation does not appear to impact on the risk of renal impairment. Persistently elevated serum creatinine after relief of the obstruction is a risk factor for ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/4,21,24\">",
"     4,21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing monitoring of renal function is important in this group of patients in order to anticipate associated CKD medical conditions that may require intervention and to provide counseling to patients at risk for ESRD and their families regarding options for renal replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94867309\">",
"    <span class=\"h3\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant survival for patients with PUV is the same as the overall pediatric allograft survival for all children undergoing transplantation. This was illustrated by a study from a single tertiary center of 418 children who underwent renal transplantation at a mean age of 5.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/25\">",
"     25",
"    </a>",
"    ]. There was no difference in the rate of allograft failure between the 59 boys with PUV and 359 children with other underlying primary causes of ESRD at eight-year followup. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H763681\">",
"    <span class=\"h2\">",
"     Lower urinary tract function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower urinary tract (LUT) symptoms are commonly seen in adult patients with PUV. In one study, adult patients (median age 38.5 years) with PUV were more likely than age and sex matched controls to have one or more moderate to severe LUT symptoms (32.4 versus 15.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36502/abstract/26\">",
"     26",
"    </a>",
"    ]. Symptoms included mild hesitancy, weak stream, incomplete emptying, staining, and urgency and stress incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior urethral valves (PUV) are obstructing membranous folds within the lumen of the posterior urethra that are the most common cause of congenital urinary obstruction (",
"      <a class=\"graphic graphic_figure graphicRef87629 \" href=\"mobipreview.htm?33/30/34274\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because of the high morbidity rate associated with fetal intervention and the lack of evidence that intervention reduces the risk of chronic kidney disease (CKD), we suggest that fetal surgery should only be considered in select patients with a high risk of perinatal mortality and be performed in centers with expertise in these procedures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prenatal intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The postnatal management of PUV includes stabilization of the patient and drainage of the urinary tract. Medical management includes correction of electrolyte abnormalities, and treatment for possible complication such as respiratory distress and infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Postnatal management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With advancements in surgical technique and instruments, primary ablation during cystoscopy has become the preferred surgical procedure to relieve the obstruction. It can be performed in most neonates with PUV, including some premature infants. If primary valve ablation cannot be done, vesicostomy is the next preferred procedure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cystoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although all patients with PUV are at risk for developing CKD, patients with a persistently elevated creatinine after relief of their urinary obstruction (eg, PUV ablation) are at increased risk for end-stage renal disease. In addition, a significant number of patients will have persistent bladder dysfunction, vesicoureteral reflux,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hydronephrosis, which in some cases, may require clean intermittent catheterization and anticholinergic medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Renal and urologic manifestations'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-procedure management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/1\">",
"      Brown T, Mandell J, Lebowitz RL. Neonatal hydronephrosis in the era of sonography. AJR Am J Roentgenol 1987; 148:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/2\">",
"      Warshaw BL, Edelbrock HH, Ettenger RB, et al. Renal transplantation in children with obstructive uropathy. J Urol 1980; 123:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/3\">",
"      Sarhan O, Zaccaria I, Macher MA, et al. Long-term outcome of prenatally detected posterior urethral valves: single center study of 65 cases managed by primary valve ablation. J Urol 2008; 179:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/4\">",
"      DeFoor W, Clark C, Jackson E, et al. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol 2008; 180:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/5\">",
"      Harrison MR, Filly RA, Parer JT, et al. Management of the fetus with a urinary tract malformation. JAMA 1981; 246:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/6\">",
"      Harrison MR, Golbus MS, Filly RA. Management of the fetus with a correctable congenital defect. JAMA 1981; 246:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/7\">",
"      Holmes N, Harrison MR, Baskin LS. Fetal surgery for posterior urethral valves: long-term postnatal outcomes. Pediatrics 2001; 108:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/8\">",
"      Biard JM, Johnson MP, Carr MC, et al. Long-term outcomes in children treated by prenatal vesicoamniotic shunting for lower urinary tract obstruction. Obstet Gynecol 2005; 106:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/9\">",
"      Clifton MS, Harrison MR, Ball R, Lee H. Fetoscopic transuterine release of posterior urethral valves: a new technique. Fetal Diagn Ther 2008; 23:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/10\">",
"      Nicolaides KH, Cheng HH, Snijders RJ, Moniz CF. Fetal urine biochemistry in the assessment of obstructive uropathy. Am J Obstet Gynecol 1992; 166:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/11\">",
"      Qureshi F, Jacques SM, Seifman B, et al. In utero fetal urine analysis and renal histology correlate with the outcome in fetal obstructive uropathies. Fetal Diagn Ther 1996; 11:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/12\">",
"      Dinneen MD, Duffy PG, Barratt TM, Ransley PG. Persistent polyuria after posterior urethral valves. Br J Urol 1995; 75:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/13\">",
"      Smith GH, Canning DA, Schulman SL, et al. The long-term outcome of posterior urethral valves treated with primary valve ablation and observation. J Urol 1996; 155:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/14\">",
"      Soliman SM. Primary ablation of posterior urethral valves in low birth weight neonates by a visually guided fogarty embolectomy catheter. J Urol 2009; 181:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/15\">",
"      Macpherson RI, Leithiser RE, Gordon L, Turner WR. Posterior urethral valves: an update and review. Radiographics 1986; 6:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/16\">",
"      Donohoe JM, Weinstein RP, Combs AJ, et al. When can persistent hydroureteronephrosis in posterior urethral valve disease be considered residual stretching? J Urol 2004; 172:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/17\">",
"      Koff SA, Mutabagani KH, Jayanthi VR. The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. J Urol 2002; 167:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/18\">",
"      Casey JT, Hagerty JA, Maizels M, et al. Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol 2012; 188:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/19\">",
"      Koff SA, Gigax MR, Jayanthi VR. Nocturnal bladder emptying: a simple technique for reversing urinary tract deterioration in children with neurogenic bladder. J Urol 2005; 174:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/20\">",
"      Ghanem MA, Wolffenbuttel KP, De Vylder A, Nijman RJ. Long-term bladder dysfunction and renal function in boys with posterior urethral valves based on urodynamic findings. J Urol 2004; 171:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/21\">",
"      Ansari MS, Singh P, Mandhani A, et al. Delayed presentation in posterior urethral valve: long-term implications and outcome. Urology 2008; 71:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/22\">",
"      Engel DL, Pope JC 4th, Adams MC, et al. Risk factors associated with chronic kidney disease in patients with posterior urethral valves without prenatal hydronephrosis. J Urol 2011; 185:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/23\">",
"      Ziylan O, Oktar T, Ander H, et al. The impact of late presentation of posterior urethral valves on bladder and renal function. J Urol 2006; 175:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/24\">",
"      Denes ED, Barthold JS, Gonz&aacute;lez R. Early prognostic value of serum creatinine levels in children with posterior urethral valves. J Urol 1997; 157:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/25\">",
"      Fine MS, Smith KM, Shrivastava D, et al. Posterior urethral valve treatments and outcomes in children receiving kidney transplants. J Urol 2011; 185:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36502/abstract/26\">",
"      Tikkinen KA, Heikkil&auml; J, Rintala RJ, et al. Lower urinary tract symptoms in adults treated for posterior urethral valves in childhood: matched cohort study. J Urol 2011; 186:660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6574 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36502=[""].join("\n");
var outline_f35_41_36502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRENATAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POSTNATAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Vesicostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Higher diversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POST-PROCEDURE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H286558330\">",
"      Bladder function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H286558340\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H763666\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94867309\">",
"      - Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H763681\">",
"      Lower urinary tract function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6574|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/30/34274\" title=\"figure 1\">",
"      Posterior urethral valves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42824?source=related_link\">",
"      Overview of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36503="Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information";
var content_f35_41_36503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15097?source=see_link\">",
"    see \"Sodium chloride preparations (saline and oral salt tablets): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/28/39366?source=see_link\">",
"    see \"Sodium chloride preparations (saline and oral salt tablets): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      4-Way&reg; Saline Moisturizing Mist [OTC];",
"     </li>",
"     <li>",
"      Altachlore [OTC];",
"     </li>",
"     <li>",
"      Altamist [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Baby Saline [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline Nasal Gel [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline No-Drip [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Deep Sea [OTC];",
"     </li>",
"     <li>",
"      Entsol&reg; [OTC];",
"     </li>",
"     <li>",
"      HuMist&reg; [OTC];",
"     </li>",
"     <li>",
"      HyperSal&reg;;",
"     </li>",
"     <li>",
"      Little Noses&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Sterile Saline Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Stuffy Nose Kit [OTC];",
"     </li>",
"     <li>",
"      Muro 128&reg; [OTC];",
"     </li>",
"     <li>",
"      Na-Zone&reg; [OTC];",
"     </li>",
"     <li>",
"      NebuSal&trade;;",
"     </li>",
"     <li>",
"      Ocean&reg; for Kids [OTC];",
"     </li>",
"     <li>",
"      Ocean&reg; [OTC];",
"     </li>",
"     <li>",
"      Pretz&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris&reg; [OTC];",
"     </li>",
"     <li>",
"      Safe Wash&trade; [OTC];",
"     </li>",
"     <li>",
"      Saline Mist [OTC];",
"     </li>",
"     <li>",
"      Saljet&reg; [OTC];",
"     </li>",
"     <li>",
"      Sea Soft Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; [OTC];",
"     </li>",
"     <li>",
"      Sochlor&trade; [OTC];",
"     </li>",
"     <li>",
"      Syrex;",
"     </li>",
"     <li>",
"      Wound Wash Saline&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Lubricant, Ocular",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sodium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage depends upon clinical condition, fluid, electrolyte, and acid-base balance of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Normal daily requirement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: Oral, I.V.: 2-5 mEq/kg/day (Mirtallo, 2004); infants born at &le;32 weeks gestation may require higher dosage (up to 8 mEq/kg/day) for the first 2 weeks of life (Al-Dahhan, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Term neonates: Oral, I.V.: 2-5 mEq/kg/day (Mirtallo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hyponatremia:",
"     </b>",
"     I.V.:",
"     <b>",
"      0.9% isotonic solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose (mEq sodium) = [desired serum sodium (mEq/L) &ndash; actual serum sodium (mEq/L)] x 0.6 x wt (kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For acute correction, use 125 mEq/L as the &ldquo;desired serum sodium&rdquo;; acutely correct serum sodium by 5 mEq/L/dose increments (eg, from a serum concentration of 120 mEq/L to 125 mEq/L) using a serum correction rate of &lt;0.4-0.5 mEq/L/hour; goal serum correction rate: &le;8-10 mEq/L/day. Hypertonic saline should be used with caution and only for severe cases of hyponatremia with a serum sodium &lt;120 mEq/L and patient experiencing symptoms (Marcialis, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nasal dryness/congestion:",
"     </b>",
"     Intranasal: 0.9% intranasal solution:  2-6 drops per nostril as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ocular  dryness:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic, ointment: Apply once daily or more often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic solution: Instill 1-2 drops into affected eye(s) every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Volume expansion, resuscitation:",
"     </b>",
"     AHA, AAP: Neonatal resuscitation recommendation: I.V.: 0.9% isotonic solution: 10 mL/kg; may repeat (Kattwinkel, 2010); in a retrospective analysis of neonates requiring CPR at birth, 21 &plusmn; 14 mL/kg was the effective dose (n=13, GA: &ge;34 weeks) (Wyckoff, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15097?source=see_link\">",
"      see \"Sodium chloride preparations (saline and oral salt tablets): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage depends upon clinical condition, fluid, electrolyte, and acid-base balance of patient; systemic hypertonic solutions (&gt;0.9%) should only be used for the initial treatment of acute serious symptomatic hyponatremia or increased intracranial pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Normal daily requirements:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;50 kg: Oral, I.V: 2-5 mEq/kg/day (Mirtallo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;50 kg, Adolescents, and Adults: Oral, I.V: 1-2 mEq/kg/day (Mirtallo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bronchiolitis, viral (inpatient):",
"     </b>",
"     Infants and Children 1-24 months: Inhalation:",
"     <b>",
"      3% solution",
"     </b>",
"     : 4 mL inhaled every 2 hours for 3 doses followed by every 4 hours for 5 doses and continued every 6 hours until discharge (Kuzik, 2007); pretreatment with a bronchodilator may be necessary to prevent potential bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bronchodilator diluent:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: Inhalation: 1-3 sprays (1-3 mL) to dilute bronchodilator solution in nebulizer before administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults: Inhalation:",
"     <b>",
"      7% solution",
"     </b>",
"     : 4 mL inhaled twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dehydration:",
"     </b>",
"     Infants, Children, and Adolescents: I.V.:",
"     <b>",
"      0.9% isotonic solution:",
"     </b>",
"     Initial:  20 mL/kg/dose; maximum dose: 1000 mL followed by remaining replacement using sodium chloride concentration appropriate for age over 24 hours for dehydration (Meyers, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hyponatremia:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: I.V.: Note: Use",
"     <b>",
"      0.9% isotonic solution or 3% hypertonic solution",
"     </b>",
"     depending on clinical severity and etiology.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose (mEq sodium) = [desired serum sodium (mEq/L) - actual serum sodium (mEq/L)] x 0.6 x wt (kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For acute correction, use 125 mEq/L as the \"desired serum sodium\"; acutely correct serum sodium by 5 mEq/L/dose increments (eg, from a serum concentration of 120 mEq/L to 125 mEq/L) using a serum correction rate of &le;2 mEq/L/hour for the first few hours followed by a serum correction rate of &le;0.5 mEq/L/hour; goal serum correction rate: &le;12 mEq/L/day; more gradual correction in increments of 10 mEq/L/day is indicated in the asymptomatic patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypovolemic shock:",
"     </b>",
"     Infants, Children, and Adolescents: I.V.:",
"     <b>",
"      0.9% isotonic solution:",
"     </b>",
"     20 mL/kg/dose; may repeat up to &ge;60 mL/kg until capillary perfusion improves or signs of fluid overload occur (Ceneviva, 1998; Parker, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Increased intracranial pressure (ICP):",
"     </b>",
"     Infants, Children, and Adolescents: I.V.:",
"     <b>",
"      3% hypertonic solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bolus: Limited data available; optimal dose not established; further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pediatric traumatic brain injury guidelines: 6.5-10 mL/kg/dose (Fisher, 1992; Kochanek, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing: 5 mL/kg/dose administered early in presentation (during critical care transport) was reported in a retrospective trial of 101 pediatric patients (age range: 2 months to 17 years) with suspected increased ICP (Luu, 2011); some centers use 2-5 mL/kg/dose; boluses are typically infused over 30 minutes but are occasionally administered more rapidly depending on the clinical scenario",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Continuous I.V. infusion: 0.1-1 mL/kg/hour titrated to maintain ICP &lt;20 mm Hg (Kochanek, 2012); monitor serum sodium concentration closely; some centers utilize titration protocols with rate adjustments varying with serum sodium concentration; maintain serum osmolarity &lt;360 mOsmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nasal dryness/congestion:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: Intranasal:",
"     <b>",
"      0.9% intranasal solution:",
"     </b>",
"     2-6 drops per nostril as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children, Adolescents, and Adults: Intranasal: Use as often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ocular dryness:",
"     </b>",
"     Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic, ointment: Apply once daily or more often as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic, solution: Instill 1-2 drops into affected eye(s) every 3-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2016668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, intranasal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (100 mL) [chlorofluorocarbon free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Sterile Saline Nasal Mist: 0.9% (50 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Safe Wash&trade;: 0.9% (210 mL) [chlorofluorocarbon free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: &lt;0.5% (14 g) [contains aloe, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (20 g [DSC]) [contains aloe, benzalkonium chloride, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinaris&reg;: 0.2% (28.4 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline No-Drip: &lt;0.5% (22 mL) [contains aloe, benzalkonium chloride, benzyl alcohol, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.45% (50 mL, 100 mL, 250 mL, 500 mL, 1000 mL); 0.9% (25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 3% (500 mL); 5% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.9% (2 mL, 3 mL, 5 mL, 10 mL, 20 mL, 50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [I.V. flush, preservative free]: 0.9% (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 50 mL, 125 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syrex: 0.9% (2.5 mL, 3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [bacteriostatic]: 0.9% (10 mL, 20 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 14.6% (20 mL, 40 mL); 23.4% (100 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 14.6% (20 mL, 40 mL); 23.4% (30 mL, 100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altachlore: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sochlor&trade;: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muro 128&reg;: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, intranasal [concentrate, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 1 teaspoon/dose (360 g) [with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for blood processing [not for injection]: 0.9% (3000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for inhalation [preservative free]: 0.9% (3 mL, 5 mL, 15 mL); 3% (15 mL); 10% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation: 0.9% (250 mL, 500 mL, 1000 mL, 1500 mL, 2000 mL, 3000 mL, 4000 mL, 5000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation [preservative free]: 0.9% (250 mL, 500 mL, 1000 mL, 1500 mL, 2000 mL, 3000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation [slush solution]: 0.9% (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]: 3% (4 mL); 7% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperSal&reg;: 3.5% (4 mL); 7% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NebuSal&trade;: 6% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg;: 3% (44 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [buffered/spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (20 mL) [chlorofluorocarbon free; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: 0.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops/mist/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HuMist&reg;: 0.65% (45 mL) [ethanol free; contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocean&reg;: 0.65% (45 mL, 104 mL, 473 mL) [contains benzalkonium chloride, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocean&reg; for Kids: 0.65% (37.5 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Baby Saline: 0.65% (30 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Saline: 0.65% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Stuffy Nose Kit: 0.65% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [irrigation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (960 mL) [contains benzalkonium chloride, sodium benzoate; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [isotonic, buffered/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (50 mL) [contains benzalkonium chloride, sodium benzoate; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [mist]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-Way&reg; Saline Moisturizing Mist: 0.74% (29.6 mL) [ethanol free; contains benzalkonium chloride, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Allergy &amp; Sinus: 2.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: 0.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (30 mL [DSC]) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinaris&reg;: 0.2% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saline Mist: 0.65% (45 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sea Soft Nasal Mist: 0.65% (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [mist, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg;: 0.9% (44 mL, 90 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg; Baby: 0.9% (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [nasal wash, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (240 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 0.65% (44 mL, 88 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altamist: 0.65% (60 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Deep Sea: 0.65% (44 mL) [contains benzalkonium chloride, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Na-Zone&reg;: 0.65% (60 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altachlore: 5% (15 mL, 30 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muro 128&reg;: 2% (15 mL); 5% (15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sochlor&trade;: 5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saljet&reg;: 0.9% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wound Wash Saline&trade;: 0.9% (90 mL, 210 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline Nasal Gel: 0.65% (20s) [contains aloe, benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, topical: 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol, gel, powder for solution, swab",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Nebulization; studies administering hypertonic saline utilized varying types of nebulizers, including jet and ultrasonic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal: Spray into 1 nostril while gently occluding other",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Apply to affected eye(s); avoid contact of bottle tip with eye or skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with full glass of water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Central-line administration is preferred for hypertonic saline (&gt;0.9%) if available and/or if infusion is to be continued; peripheral administration may be necessary for initiation of treatment in critical patients; use of peripheral administration should be limited; intraosseous administration may be used if unable to obtain intravenous access (Luu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rate of administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bolus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      0.9% isotonic solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Hypotension, shock:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Neonates: Published data not available; consider slower administration to avoid IVH (Kattwinkel, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Administer boluses over 5 minutes (Brierley, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Dehydration: Bolus: Administer over 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      3% hypertonic solution:",
"     </b>",
"     Typically infused over 30 minutes; some trials have described administering at a rate of 10 mEq/kg/hour when treating acute, life-threatening ICP elevation (Kamat, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Maximum rate: 1 mEq/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, mannitol 20%, mannitol 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ciprofloxacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Restoration of sodium ion in hyponatremia [FDA approved in pediatric patients (age not specified) and adults], restores moisture to nasal membranes [FDA approved in pediatric patients (age not specified) and adults], source of electrolytes and water for expansion of the extracellular fluid compartment [FDA approved in pediatric patients (age not specified) and adults], diluent and delivery system of compatible drug additives [FDA approved in pediatric patients (age not specified) and adults]; has also been used for reduction of intracranial pressure (ICP), improvement of mucociliary clearance and airway hydration in CF and acute viral bronchiolitis, reduction of corneal edema, and prevention of muscle cramps and heat prostration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation &gt;0.9% concentration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Per The Joint Commission (TJC) recommendations, concentrated electrolyte solutions (eg, NaCl &gt;0.9%) should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Inappropriate use of low sodium or sodium-free intravenous fluids (eg, D",
"       <sub>",
"        5",
"       </sub>",
"       W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP, 2009).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Congestive heart failure, transient hypotension (especially with adult administration of 23.4% NaCl)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Central pontine myelinolysis (due to rapid correction of hyponatremia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dilution of serum electrolytes, extravasation, hypernatremia, hypervolemia, hypokalemia, overhydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting (oral use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombosis, phlebitis, extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm (inhalation with hypertonic solutions), pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium chloride or any component; hypertonic uterus, hypernatremia (except when used for increased intracranial pressure), fluid retention",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with heart failure, renal insufficiency, cirrhosis, hypertension, and edema",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With systemic therapy, sodium toxicity is almost exclusively related to how fast a sodium deficit is corrected; both rate and magnitude of correction are extremely important; in neonates, maximum serum correction rate should generally not exceed 10 mEq/L/day; in infants, children, adolescents, and adults, do not exceed a maximum serum correction rate of 12 mEq/L/day. Administration of low sodium or sodium free I.V. solutions may result in significant hyponatremia or water intoxication in pediatric patients; monitor serum sodium concentration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bacteriostatic products may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid using products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Chloride may increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: Sodium Chloride may enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations.  Management: This interaction is specific to Hypertonic Saline.  Avoid concurrent use of Hypertonic Saline with Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Sodium requirements do not change during pregnancy (IOM, 2004). Nasal saline rinses may be used for the treatment of pregnancy rhinitis (Wallace, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum sodium, chloride, I &amp; O, weight; ICP, serum osmolarity (when used to treat increased ICP), capillary perfusion, MAP, CVP (fluid resuscitation)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum/plasma sodium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Premature neonates: 132-140 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Full-term neonates: 133-142 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;2 months to Adults: 135-145 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Principal extracellular cation; functions in fluid and electrolyte balance, osmotic pressure control, and water distribution",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.V.: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Mainly in urine but also in sweat, tears, and saliva",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. solutions: NS (0.9%) = 154 mEq/L; 3% NaCl = 513 mEq/L; 5% NaCl = 856 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet 1 g = 17.1 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3% NaCl: Osmolarity: 1027 mOsm/L",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al-Dahhan J, Jannoun L, and Haycock GB, \"Effect of Salt Supplementation of Newborn Premature Infants on Neurodevelopmental Outcome at 10-13 Years of Age,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2002, 86(2):F120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/11882555/pubmed\" id=\"11882555\" target=\"_blank\">",
"        11882555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, \"Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ceneviva G, Paschall JA, Maffei F, et al, \"Hemodynamic Support in Fluid-Refractory Pediatric Septic Shock,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 102(2):e19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/9685464/pubmed\" id=\"9685464\" target=\"_blank\">",
"        9685464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellon EP, Donaldson SH, Johnson R, et al, \"Safety and Tolerability of Inhaled Hypertonic Saline in Young Children With Cystic Fibrosis,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2008, 43(11):1100-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/18828160/pubmed\" id=\"18828160\" target=\"_blank\">",
"        18828160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elkins MR, Robinson M, Rose BR, et al, \"A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients With Cystic Fibrosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(3):229-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/16421364/pubmed\" id=\"16421364\" target=\"_blank\">",
"        16421364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher B, Thomas D, and Peterson B, \"Hypertonic Saline Lowers Raised Intracranial Pressure in Children After Head Trauma,\"",
"      <i>",
"       J Neurosurg Anesthesiol",
"      </i>",
"      , 1992, 4(1):4-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/15815431/pubmed\" id=\"15815431\" target=\"_blank\">",
"        15815431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;Plain D",
"      <sub>",
"       5",
"      </sub>",
"      W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Children,&rdquo; ISMP Medication Safety Alert, August 13, 2009. Available online at file://www.ismp.org/Newsletters/acutecare/articles/20090813.asp.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al, \"Part 15: Neonatal Resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):909-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/20956231/pubmed\" id=\"20956231\" target=\"_blank\">",
"        20956231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khanna S, Davis D, Peterson B, et al, \"Use of Hypertonic Saline in the Treatment of Severe Refractory Posttraumatic Intracranial Hypertension in Pediatric Traumatic Brain Injury,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(4):1144-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/10809296/pubmed\" id=\"10809296\" target=\"_blank\">",
"        10809296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, \"Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents - Second Edition,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 139(Suppl 10):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuzik BA, Al-Qadhi SA, Kent S, et al, \"Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2007, 151(3):266-70, 270.e1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/17719935/pubmed\" id=\"17719935\" target=\"_blank\">",
"        17719935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luu JL, Wendtland CL, Gross MF, et al, \"Three-Percent Saline Administration During Pediatric Critical Care Transport,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2011, 27(12):1113-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/22134236/pubmed\" id=\"22134236\" target=\"_blank\">",
"        22134236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcialis MA, Dessi A, Pintus MC, et al, \"Neonatal Hyponatremia: Differential Diagnosis and Treatment,\"",
"      <i>",
"       J Matern Fetal Neonatal Med",
"      </i>",
"      , 2011, 24(Suppl 1):75-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/21942597/pubmed\" id=\"21942597\" target=\"_blank\">",
"        21942597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyers R, \"Pediatric Fluid and Electrolyte Therapy,&rdquo;",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2009, 14:204&ndash;11",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker MM, Hazelzet JA, and Carcillo JA, \"Pediatric Considerations,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(11 Suppl):S591-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/15542968/pubmed\" id=\"15542968\" target=\"_blank\">",
"        15542968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Subbarao P, Balkovec S, Solomon M, et al, \"Pilot Study of Safety and Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2007, 42(5):471-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/17436328/pubmed\" id=\"17436328\" target=\"_blank\">",
"        17436328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyckoff MH, Perlman JM, and Laptook AR, \"Use of Volume Expansion During Delivery Room Resuscitation in Near-Term and Term Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(4):950-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/41/36503/abstract-text/15805369/pubmed\" id=\"15805369\" target=\"_blank\">",
"        15805369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12796 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36503=[""].join("\n");
var outline_f35_41_36503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221678\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062201\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445045\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062196\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2016668\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221650\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062205\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221694\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062204\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221696\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221693\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062195\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062194\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221659\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221661\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888258\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062200\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062203\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062193\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062207\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062209\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15097?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/28/39366?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36504="Retinal detachment";
var content_f35_41_36504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinal detachment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Jorge G Arroyo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36504/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/41/36504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retina is a multilayer of exquisitely organized neurons that line the back of the eye (",
"    <a class=\"graphic graphic_picture graphicRef68777 \" href=\"mobipreview.htm?7/11/7359\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78102 \" href=\"mobipreview.htm?18/57/19347\">",
"     picture 2",
"    </a>",
"    ). It is designed to convert photons into neural impulses that travel along the visual pathways to the visual cortex. The retinal photoreceptors are some of the most metabolically active cells in the body. They line the outer portion of the neurosensory retina and their outer segments are in contact with the retinal pigment epithelia and underlying choroid. The choroidal circulation has the highest blood flow rate per cubic centimeter of tissue in the human body and provides a critical supply of oxygen to the outer third of the neurosensory retina and, in particular, to the retinal photoreceptors.",
"   </p>",
"   <p>",
"    Retinal detachment occurs when the multilayer neurosensory retina separates from the underlying retinal pigment epithelium and choroid. This separation can occur passively due to accumulation of fluid between these two layers, or it may occur actively due to vitreous traction on the retina, such as with diabetic traction retinal detachment.",
"   </p>",
"   <p>",
"    Separation between the neurosensory retina and the underlying choroidal circulation results in ischemia and rapid and progressive photoreceptor degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/1\">",
"     1",
"    </a>",
"    ]. The amount of photoreceptor degeneration and loss of vision can be minimized by rapid diagnosis and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Without treatment, most symptomatic retinal detachments progress to involve the entire retina and lead to loss of vision.",
"   </p>",
"   <p>",
"    Understanding the basic pathophysiology involved in the process of retinal tear formation and retinal detachment and understanding the symptoms and signs of the early stages of this process are important in identifying high-risk patients, preventing the development of retinal detachments, and preventing loss of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal detachments can be rhegmatogenous (caused by a break in the retina; rhegma is Greek for tear) or nonrhegmatogenous (caused by leakage or exudation from beneath the retina [exudative RD] or vitreous traction pulling on the retina [traction RD]). On occasion the retina appears to be detached but is actually not; this is termed pseudo retinal detachment.",
"   </p>",
"   <p>",
"    A full-thickness retinal break may exist as a round retinal hole or a linear or horseshoe-shaped retinal tear. In both cases, there is a discontinuity in the retina that allows vitreous fluid to pass through the retinal break into the subretinal space, resulting in retinal detachment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rhegmatogenous retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhegmatogenous retinal detachments are the most common type of retinal detachment. By definition they are caused by a full-thickness retinal hole or retinal tear. Although distinct from traction retinal detachments (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Traction retinal detachment'",
"    </a>",
"    below), these full-thickness holes or tears are also usually caused by vitreous traction on the retina. Unlike a traction retinal detachment, however, the traction does not directly pull the retina off the underlying tissue; instead, fluid that leaks through the hole or tear results in retinal detachment.",
"   </p>",
"   <p>",
"    Holes and tears can be asymptomatic or symptomatic; asymptomatic breaks in the retina are much more common than symptomatic breaks, but much less likely to lead to retinal detachment. Thus, most retinal holes or tears found in an asymptomatic patient do not result in retinal detachment, whereas symptomatic retinal breaks often result in retinal detachment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Posterior vitreous detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior vitreous detachment (PVD) is the most common cause of retinal tears which often lead to rhegmatogenous retinal detachment (",
"    <a class=\"graphic graphic_picture graphicRef81192 \" href=\"mobipreview.htm?3/57/3999\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The vitreous is a clear gel-like structure in the back of the eye composed of collagen fibrils and hyaluronic acid that slowly liquefies throughout life. These pockets of liquid can break through the posterior vitreous face and cause PVD from the retina. This event, which occurs typically in patients between the ages of 50 and 75 years, results in a new onset of cobweb-like floaters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased floaters (see below).",
"   </p>",
"   <p>",
"    Vitreous detachment usually occurs over one week, but may take up to three months to completely develop. Any areas in which there might be an abnormally strong vitreoretinal adhesion are areas that, due to vitreous traction, may develop a full-thickness horseshoe retinal tear or operculated retinal tear. The aforementioned lattice degeneration is an example of an area that has an abnormally strong vitreoretinal connection. Anything that tugs on the retina will cause photopsias or flashes of light that last seconds and may be associated with eye movement. In addition, patients who develop a full-thickness retinal tear may also tear a small retinal blood vessel, resulting in a vitreous hemorrhage and an increasing number of floaters or blurred vision.",
"   </p>",
"   <p>",
"    Thus, nontraumatic rhegmatogenous retinal detachments begin with the normal and acute development of PVD. If the patient also has areas of abnormally strong vitreoretinal adhesion, as in areas of lattice degeneration, a full-thickness retinal tear or hole can develop. Liquid vitreous within the eye can percolate through the retinal break creating retinal detachment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Traumatic retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who sustain an ocular injury also can develop a full-thickness retinal break or retinal dialysis. These may lead to subretinal migration of liquid vitreous and the development of a retinal detachment (",
"    <a class=\"graphic graphic_picture graphicRef77996 \" href=\"mobipreview.htm?39/17/40222\">",
"     picture 4",
"    </a>",
"    ). This is much less common than spontaneous rhegmatogenous detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonrhegmatogenous retinal detachment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Traction retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction retinal detachments occur when the vitreous has an abnormally strong attachment to the retina and contracts, thus pulling the retina off the back of the eye. This is typically seen in patients who have proliferative diabetic retinopathy, vitreomacular traction syndrome, retinopathy of prematurity, or sickle cell retinopathy, and who subsequently develop retinal neovascularization. The areas of neovascularization and fibrosis between the retina and the vitreous create a strong adhesion between these two tissues. With vitreous contraction the retina is pulled away from the back of the eye and a traction retinal detachment is created. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Vitrectomy for PDR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traction retinal detachment can also occur in patients who have had perforating trauma and have developed a fibrotic transvitreal retinal band that contracts. In addition, there are rare cases of patients who have an abnormally strong adhesion between the vitreous and the macula (the central part of the retina). Vitreous contraction in these cases can lead to a localized macular traction detachment called vitreo-macula traction syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Exudative retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exudative retinal detachment occurs in patients who do not have a full-thickness retinal break, but rather have an accumulation of fluid beneath the retina. These types of retinal detachments are often associated with inflammatory conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/9\">",
"     9",
"    </a>",
"    ], may occur spontaneously as with central serous chorioretinopathy, or can occur in association with choroidal",
"    <span class=\"nowrap\">",
"     neoplasms/metastases.",
"    </span>",
"    Traditional retinal reattachment surgeries are not effective since exudative retinal detachments are not associated with a full-thickness retinal break. Diagnosing and treating the underlying etiology of the exudative retinal detachment is critical in curing the problem and restoring vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lattice degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lattice degeneration is a relatively common condition found in about 6 to 8 percent of eyes and characterized by focal retinal thinning in the periphery of the retina, associated with overlying vitreous liquefaction, sclerotic lattice-like vessels, and abnormally strong areas of vitreoretinal adhesion. An atrophic retinal hole may occur within a patch of lattice degeneration, which can cause a slowly developing and often asymptomatic peripheral retinal detachment in young patients with myopia.",
"   </p>",
"   <p>",
"    Thus, lattice degeneration can be viewed as an asymptomatic precursor to retinal tears and potential detachment. Significant new tears or detachment occur in only 1 percent of patients with lattice degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/11\">",
"     11",
"    </a>",
"    ]. While prophylactic therapy for these lesions, to prevent retinal detachment has been considered, there are no studies to support this approach and most tears occur in areas of the retina that appear normal. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pseudo retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of cases in which the retina appears to be detached but it is not:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral senile retinoschisis is a splitting of the peripheral retina with an elevated retinal layer; this generally has a very good prognosis",
"     </li>",
"     <li>",
"      White without pressure is a white reflex at the vitreoretinal interface that is normally seen in some patients",
"     </li>",
"     <li>",
"      Choroidal lesion or swelling or infolding due to choroidal neoplasms, swelling, or hypotonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These causes of a pseudo retinal detachment need to be diagnosed by a retina specialist or ophthalmologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY/RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontraumatic rhegmatogenous retinal detachment occurs in approximately 1 in 10,000 people per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Myopia is a major risk factor. In a case-control study of 253 patients with idiopathic retinal detachment and 1138 controls, an eye with a spherical equivalent refractive error of -1 to -3 diopters had a 4-fold increased risk of retinal detachment compared with a nonmyopic eye; the risk was increased 10-fold if the refractive error was greater than -3 diopters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/15\">",
"     15",
"    </a>",
"    ]. These data suggest that almost 55 percent of nontraumatic detachments in eyes without previous surgery are attributable to myopia.",
"   </p>",
"   <p>",
"    Retinal detachment is also a complication of cataract surgery and an association with current use of fluoroquinolones has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H26#H26\">",
"     \"Cataract in adults\", section on 'Complications and outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=see_link&amp;anchor=H142842158#H142842158\">",
"     \"Fluoroquinolones\", section on 'Retinal detachment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PVD typically occurs in patients between the ages of 50 and 75 years. However, it can occur earlier in patients who are myopic, have had a history of ocular trauma, or have had ocular inflammation, all of which lead to a more rapid vitreous liquefaction. Patients with a unilateral PVD are very likely to develop PVD in the other eye; in one series of 51 patients, 90 percent developed PVD in the contralateral eye within three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients diagnosed with an uncomplicated PVD have a 3.4 percent chance of developing a retinal tear within six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lattice degeneration is present in 6 to 8 percent of the general population and in approximately 30 percent of patients with nontraumatic rhegmatogenous retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/19\">",
"     19",
"    </a>",
"    ]. Nevertheless, most patients with lattice degeneration do not develop a retinal detachment. In a prospective study of 276 untreated patients with lattice degeneration (423 eyes) followed for 1 to 25 years (mean 10.8 years), symptomatic retinal detachments occurred in only 3 of 276 patients (1 percent) and 0.7 percent of eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/20\">",
"     20",
"    </a>",
"    ]. Tractional retinal tears were slightly more common, occurring in eight patients (2.9 percent) and 1.9 percent of eyes; one of these led to a clinical retinal detachment. Clinical or progressive subclinical retinal detachment occurred in three eyes (2 percent) with atrophic holes. Asymptomatic retinal detachment was seen in 10 of 150 eyes with atrophic holes (6.7 percent) and had a much less serious prognosis than symptomatic detachment. The risk of retinal detachment in patients with lattice degeneration is much higher if the patient has already had one retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic retinal breaks have been reported in approximately 6 percent of eyes in clinical and autopsy studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/22\">",
"     22",
"    </a>",
"    ]. The natural history of such breaks was investigated in a cohort study of 196 patients (235 involved eyes) who were followed from 1 to 33 years (mean 11 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/23\">",
"     23",
"    </a>",
"    ]. Nineteen eyes (8 percent) originally had or developed 22 areas of subclinical detachment. Ten eyes had acute PVD, which caused symptomatic retinal tears in three eyes, one of which also had a clinical retinal detachment. The chance of retinal detachment due to an asymptomatic retinal break in people in which a retinal detachment had not occurred in either eye was only approximately 0.5 percent. These findings suggest that asymptomatic retinal breaks do not show any significant tendency toward retinal detachment, with the exception of a few cases that progress to subclinical retinal detachment.",
"   </p>",
"   <p>",
"    Other risk factors for retinal detachment include a family history of retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/24\">",
"     24",
"    </a>",
"    ], or a vitreohyaloidopathy (a hereditary abnormality of the vitreous body).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the most common cause of retinal detachment, rhegmatogenous detachment following spontaneous PVD, usually complain of an increasing number of floaters in one eye. The floaters may look like a cobweb, or like one particularly large floater that appears to move in and out of central vision. The large floater represents the fibrous ring around the optic nerve and is sometimes described as \"a large housefly,\" also known as &ldquo;Mosca Volante.&rdquo;",
"   </p>",
"   <p>",
"    These symptoms are usually associated with acute PVD and result from the sudden separation of the vitreous gel from the surface of the retina. This sometimes dramatic presentation of vitreous floaters or debris can range from being an inconvenience or a nuisance to being visually disabling. The floaters usually resolve with time, settle down outside the visual access,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    become less noticeable.",
"   </p>",
"   <p>",
"    As the posterior vitreous face separates from the underlying retinal surface, it may encounter areas of abnormally strong vitreoretinal adhesions. At these sites the separating vitreous will tug on the surface of the retina and create a mechanical depolarization of the axons running through the nerve fiber layer of the retina. This is usually interpreted by the patient as a flash of light or photopsia that lasts less than one second and is sometimes associated with eye movement. These photopsias may be more easily seen in the dark or at night and are usually pinpointed to the affected eye. This appearance contrasts with the fortification spectra often described in patients with ocular migraines; this zigzagging light typically lasts 10 to 20 minutes, is seen in the peripheral visual field of both eyes, and is sometimes associated with blurry central vision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42569?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the patient with visual hallucinations\", section on 'Retinal pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42569?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the patient with visual hallucinations\", section on 'Migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small retinal vessels may avulse or a small horseshoe retinal tear can be created if sufficient vitreoretinal traction is applied to the retina. In this circumstance, patients complain of a shower of black spots consistent with vitreous hemorrhage. Sometimes this shower of spots progresses, leaving the patient with a large vitreous hemorrhage and only count fingers or light perception vision. For patients who present with floaters or flashes, decrease in vision is the most important symptom suggesting a retinal tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who are found to have a dense vitreous hemorrhage on slitlamp biomicroscopy associated with an acute PVD have tenfold increased risk of also having a retinal tear and developing a retinal detachment.",
"   </p>",
"   <p>",
"    Approximately 30 to 50 percent of patients who develop a full-thickness horseshoe retinal tear in the setting of a",
"    <strong>",
"     symptomatic",
"    </strong>",
"    vitreous detachment will go on to develop a rhegmatogenous retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/7\">",
"     7",
"    </a>",
"    ]. Liquefied vitreous fluid has a tendency to percolate through the retinal break causing a neurosensory retinal detachment. Patients who reach this stage often complain of a slowly progressive peripheral visual field defect in the affected eye. Interestingly, they frequently describe a photo stress response in the area of the detached retina. In other words, when they are exposed to a bright light, the retinal photopigments in the area of the detached retina are bleached; the inability of the detached retina to quickly regenerate the retinal photopigments results in darkening of the visual field defect.",
"   </p>",
"   <p>",
"    The rate of progression of retinal detachment varies depending upon the size of the retinal break, location of the break, and movements of the eye. Large horseshoe retinal tears or giant retinal tears that have persistent vitreoretinal traction will usually allow a retinal detachment to progress over the period of hours to days. In contrast, small horseshoe retinal tears or operculated holes often result in more slowly progressive retinal detachment that can take one to four weeks to develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the retinal detachment progresses from the full-thickness retinal breaks posteriorly towards the macula, the size of the visual field defect will enlarge in a corresponding fashion. Patients will lose the ability to read once the retinal detachment involves the macula or the central area of the retina responsible for reading vision. Vision in patients with macula-off rhegmatogenous retinal detachment usually ranges between",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    and count fingers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic vitreous floaters are the most common cause of floaters. In addition to PVD and full-thickness retinal tear, other causes of floaters include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vitreous hemorrhage",
"     </li>",
"     <li>",
"      Vitreous inflammation (eg, Toxoplasma chorioretinitis)",
"     </li>",
"     <li>",
"      Ocular lymphoma",
"     </li>",
"     <li>",
"      Intraocular foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with sudden onset of floaters, or photopsias, who present to primary care, should be initially evaluated by a test of visual acuity and confrontational evaluation of visual fields. Patients with visual loss or who are found to have monocular decreased visual field should be seen urgently by an ophthalmologist or retinal surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/18\">",
"     18",
"    </a>",
"    ]. When possible, all patients should also be evaluated with slitlamp biomicroscopy and a dilated retinal examination. Patients without high risk features (visual field loss, subjective or objective decreased vision, vitreous hemorrhage or vitreous pigment on slitlamp examination) may be referred to an ophthalmologist more electively.",
"   </p>",
"   <p>",
"    Patients who are referred to an ophthalmologist or retina specialist undergo a careful history and ophthalmic examination. Anterior segment examination is performed looking for pigmented vitreous cells behind the lens of the eye. These cells are known as \"tobacco dust\" and represent liberated retinal pigment epithelial cells that have floated into the vitreous from under the retina. Patients who have pigmented cells behind the lens have a very high probability of having a full-thickness retinal break. Fundoscopic examination of these patients will usually reveal vitreous debris and often a white fibrous ring, called a Weiss ring, which corresponds to the area of contact between the posterior vitreous face and the round optic nerve.",
"   </p>",
"   <p>",
"    A careful 360-degree scleral depressed examination using an indirect ophthalmoscope also should be performed. Depressing the peripheral retina allows identification of vitreoretinal abnormalities, vitreoretinal areas of abnormal traction, round atrophic holes, operculated retinal breaks, or full-thickness horseshoe retinal tears. In addition, any retinal detachment that is associated with these breaks can be seen.",
"   </p>",
"   <p>",
"    Patients should also undergo examination of the fellow eye as there is a relatively high rate of bilateral retinal tears or detachments and an asymptomatic tear or detachment could otherwise be missed.",
"   </p>",
"   <p>",
"    No view of the posterior pole or peripheral retina will be obtained in cases where the vitreous cavity is filled with blood due to a severe vitreous hemorrhage. These patients need to have a B scan ultrasound, which usually reveals the dense vitreous hemorrhage floating in the vitreous cavity as well as the presence of any retinal elevation. Patients with dense vitreous hemorrhages are often followed carefully with sequential B scan ultrasounds; a new peripheral retinal detachment requires surgical removal of the vitreous hemorrhage and retinal detachment repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Posterior vitreous detachment management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who present with PVD and do not have any retinal breaks or retinal tears on a 360-degree scleral depressed examination, require only reassurance and education. In a meta-analysis of retrospective studies that included 1600 patients with symptomatic PVD, delayed retinal tears (not seen on initial examination) were found in 1.8 percent; 83 percent of the patients with late tears had vitreous or retinal hemorrhage at initial examination, or developed new symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/26\">",
"     26",
"    </a>",
"    ]. While studies have tried to identify subsets of patients who may not require additional evaluation after the initial examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/27\">",
"     27",
"    </a>",
"    ], we suggest that most patients should be seen in follow-up at about three months. Patients who describe photopsias, or have evidence of retinal bleeding, but no full-thickness or retinal detachment, may require an earlier follow-up in approximately one to two months.",
"   </p>",
"   <p>",
"    The floaters often resolve over a period of 3 to 12 months; they settle down outside the visual axis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    become less noticeable or bothersome. In some cases, however, floaters may be a permanent symptom.",
"   </p>",
"   <p>",
"    In general, patients with a PVD do not require any specific activity limitations. Patients who develop worsening symptoms of flashes, significantly more floaters,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of peripheral or central vision should be reevaluated with a careful scleral depressed peripheral retinal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Retinal hole or tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a full-thickness symptomatic operculated retinal hole or horseshoe retinal tear, but no retinal detachment, clearly benefit from laser retinopexy or cryoretinopexy. These patients are advised that their risk of developing a retinal detachment is around 30 percent and that treatment reduces this risk to less than 1 percent. Since the risks of laser treatments or cryoretinopexy are minimal, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio strongly favors treating symptomatic retinal breaks prophylactically.",
"   </p>",
"   <p>",
"    Patients who undergo laser photocoagulation may be seated in front of a slit lamp after numbing the affected eye with topical drops. A contact lens is then placed on the surface of the eye in order to visualize the retinal break using the slit lamp biomicroscope. Once identified, the retinal break is surrounded by two to three rows of confluent 200-micron size laser burns. The laser intensity necessary for these treatments can vary between 100 and 500 milliwatts depending upon the amount of cataract present and fundus pigmentation.",
"   </p>",
"   <p>",
"    Patients may also be treated with a laser indirect ophthalmoscope that allows the physician to examine, depress, and laser the retina at the same time. This delivery system allows for more peripheral treatment of the retina.",
"   </p>",
"   <p>",
"    Patients who are treated with cryoretinopexy usually have a subconjunctival injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    over the area of the full-thickness retinal break. Using the indirect ophthalmoscope, the cryoretinopexy probe is placed on the surface of the conjunctiva underneath the retinal break. A freezing ball is created at the tip of this probe that freezes through the sclera, choroid, and retina. A number of cryoretinopexy spots are created in order to contiguously surround the retinal break (",
"    <a class=\"graphic graphic_figure graphicRef71437 \" href=\"mobipreview.htm?10/28/10688\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once either treatment is completed it takes approximately two weeks for the body to form its maximal amount of chorioretinal adhesion. Patients are usually advised to minimize eye movement (such as with reading) during this period. Sitting on a couch and watching TV is actually quite effective in minimizing head and eye movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rhegmatogenous retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without treatment, most symptomatic retinal detachments progress to involve the entire retina and lead to loss of vision. Thus, treatment is indicated for nearly all patients with symptomatic detachments.",
"   </p>",
"   <p>",
"    Patients who present with a full-thickness retinal break and a small retinal detachment can be treated with delimiting laser photocoagulation or cryoretinopexy barrier. The chorioretinal scar created with these procedures may hold the retinal detachment in place and prevent it from spreading and threatening the macula. These treatments are most appropriate for small peripheral retinal detachments and for asymptomatic retinal detachments. The process is similar to that discussed for the treatment of a retinal tear. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Retinal hole or tear'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who present with a frank rhegmatogenous retinal detachment will require other techniques in order to reattach the retina. These techniques include a pneumatic retinopexy, a temporary peribulbar balloon, scleral buckle placement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pars plana vitrectomy.",
"   </p>",
"   <p>",
"    Asymptomatic retinal detachments appear to have a better prognosis. A case series of 16 patients with 18 eyes with asymptomatic rhegmatogenous retinal detachments found that none became symptomatic over a mean follow-up of 46 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/28\">",
"     28",
"    </a>",
"    ]. The patients in this cohort were relatively young (mean age 56), none had a superior detachment, all had at least a partial demarcation line on presentation, and only 3 of the 18 detachments had retinal tears (many had atrophic holes). As such, it is uncertain whether these results are generalizable to all patients with asymptomatic retinal detachments.",
"   </p>",
"   <p>",
"    While awaiting further data, we suggest that patients with asymptomatic inferior rhegmatogenous detachments due to atrophic holes be followed with close monitoring or offered laser photocoagulation. For now, we would continue to treat other patients with asymptomatic detachments.",
"   </p>",
"   <p>",
"    Patients with significant rhegmatogenous retinal detachment will require one of three procedures for reattachment: pneumatic retinopexy, scleral buckling, or vitrectomy. Few randomized trials are available to determine the optimal selection of one procedure over another, and the decision is often subjective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/11\">",
"     11",
"    </a>",
"    ]. Pneumatic retinopexy is an office procedure with lower costs and fewer complications, and is appropriate as a first-line procedure for non-complex cases. When not successful, the more invasive procedures can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pneumatic retinopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumatic retinopexy is a procedure performed in the office and includes cryoretinopexy of the retinal break followed by injection of an intravitreal gas bubble (",
"    <a class=\"graphic graphic_picture graphicRef64514 \" href=\"mobipreview.htm?26/55/27504\">",
"     picture 5",
"    </a>",
"    ). With strict head positioning, retinal breaks that are in the superior part of the retina can be tamponaded by the intravitreal gas bubble, closed, and sealed by the chorioretinal adhesion induced by cryoretinopexy. Once the retinal break is closed the retinal epithelial cells quickly reabsorb the subretinal fluid, thereby reattaching the retina. This process of reabsorption usually takes about 12 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may also be possible to use pneumatic retinopexy in patients with retinal breaks that are in the inferior portion of the retina, using an inverted technique that requires patients to maintain a head-down position for six to eight hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumatic retinopexy leads to successful retinal attachment about 70 to 80 percent of the time after one procedure. In cases of failure, most patients are treated with scleral buckle placement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Scleral buckle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleral buckle is performed in the operating room. After a retrobulbar injection or infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , cryoretinopexy to the retinal breaks is performed, followed first by suturing of an explant to the outside of the sclera that indents the wall of the eye and closes the retinal breaks, and then by drainage of subretinal fluid, if needed (",
"    <a class=\"graphic graphic_figure graphicRef57343 \" href=\"mobipreview.htm?3/25/3474\">",
"     figure 2",
"    </a>",
"    ). The scleral indentation created by the sutured exoplant not only helps close the retinal break and allow the chorioretinal retinal adhesion to form, but also helps reduce the vitreoretinal traction present.",
"   </p>",
"   <p>",
"    A modification of the technique involves placing a small balloon catheter underneath a retinal break to temporarily close it and allow sealing of the hole over a period of 12 to 24 hours. Once the retinal hole is sealed closed and the subretinal fluid is reabsorbed, the balloon catheter can be safely removed.",
"   </p>",
"   <p>",
"    A randomized, controlled trial of 198 patients with primary, uncomplicated retinal detachment found no significant differences in outcome in patients assigned to pneumatic retinopexy compared with scleral buckling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scleral buckle placement leads to successful retinal reattachment approximately 80 to 90 percent of the time after one surgery. In cases of failure, most patients are treated with vitrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with more complicated retinal detachments may require an additional vitrectomy (",
"    <a class=\"graphic graphic_figure graphicRef65234 \" href=\"mobipreview.htm?11/36/11840\">",
"     figure 3",
"    </a>",
"    ). With this procedure, three sclerotomies are made on the outside of the eye, one that allows fluid to infuse into the eye, and two others that are used to introduce instruments into the back part of the eye. Using a light pipe and a vitreous cutter all of the central and peripheral vitreous is removed and all of the vitreoretinal traction on any of the breaks excised. The patient's retina can be flattened intraoperatively using an air bubble or heavier than water perfluorocarbon liquid. These patients are usually left with intravitreal air, a long acting gas bubble (SF6 or C3F8), or silicone oil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitrectomy leads to successful retinal reattachment approximately 80 to 90 percent of the time after one surgery. In cases of failures, patients often require more extensive vitreoretinal procedures such as combined cataract extraction and intraocular lens placement, lensectomy, extensive epiretinal membrane peeling, subretinal fibrous band removal, relaxing retinotomies, and silicone oil tamponade. Virtually all patients over age 50 treated with vitrectomy will develop progressive cataract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other causes of retinal detachments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with traction retinal detachments (severe diabetic retinopathy, penetrating ocular injury, or vitreo macular syndrome) may also benefit from surgical retinal reattachment; all of these cases require surgical intervention with a pars plana vitrectomy. During this surgery extensive peeling is often required, utilizing end grabbing forceps and intravitreal scissors. Once the vitreoretinal traction is relieved the retina can be reattached as previously described and left with an intravitreal tamponade.",
"   </p>",
"   <p>",
"    Patients who present with an exudative retinal detachment must have the etiology of this detachment identified and treated. Surgical repair of this type of retinal detachment is not recommended in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is currently impossible to prevent a spontaneous PVD. On the other hand, since vitreoretinal abnormalities such as lattice degeneration with atrophic holes, vitreo retinal tags, or small round retinal holes can lead to retinal detachment, it has been suggested that such patients may benefit from prophylactic laser or cryoretinopexy. However, a major limitation of prophylactic therapy is that most retinal detachments are due to retinal tears that develop in areas of the retina that appear normal prior to vitreous detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus treatment of visible lesions associated with retinal detachment may prevent a tear at those sites, but not a tear in normal appearing retina. A systematic review of studies involving patients with asymptomatic vitreoretinal abnormalities found no trials that met inclusion criteria and thus no conclusions could be made about prophylactic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of definitive data, I feel that the most important aspect of prevention is education of the patient about the symptoms of retinal tear or retinal detachment. Early identification of retinal tears and rapid treatment of this problem usually results in the prevention of a retinal detachment and significant loss of vision. Also, there are some very high risk patients, such as patients who have developed a giant retinal tear in the fellow eye, in whom prophylactic treatment may be reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Photoreceptor neuroprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual prognosis after retinal detachment repair is often limited. Various animal models of retinal detachment have been developed to better understand the cellular and molecular mechanisms underlying this vision loss.",
"   </p>",
"   <p>",
"    Animal models have demonstrated that photoreceptor apoptosis typically occurs in a stereotypic manner in response to retinal detachment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/1,34-37\">",
"     1,34-37",
"    </a>",
"    ]. Separation of the neurosensory retina from the underlying choroidal circulation results in ischemia and retinal degeneration as soon as 12 hours after detachment. Studies of human patients with retinal detachment have also shown a similar pattern of photoreceptor cell loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of potential neuroprotective agents are being tested clinically, which may prevent some of this retinal degeneration and improve final visional outcome in patients with macula off retinal detachments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36504/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/21/44369?source=see_link\">",
"       \"Patient information: Detached retina (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Course, definitions, and pathophysiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Without treatment, most symptomatic retinal detachments progress to involve the entire retina and lead to loss of vision. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retinal detachments are classified as \"rhegmatogenous\" if they are the result of a full-thickness retinal hole or retinal tear and as \"nonrhegmatogenous\" otherwise. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhegmatogenous detachments are most common, and they are most commonly a consequence of posterior vitreous detachment (PVD), a normal event in people between the ages of 50 and 75. In some patients, areas of adhesion during PVD can pull on the retina and cause a tear. Rhegmatogenous detachments can also occur after ocular trauma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rhegmatogenous retinal detachment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonrhegmatogenous detachments can occur in patients with proliferative diabetic retinopathy, retinal neovascularization, trauma, and in other settings. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonrhegmatogenous retinal detachment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Risk factors and clinical presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for rhegmatogenous detachments include myopia and a focal thinning of the periphery of the retinal called lattice degeneration. Asymptomatic retinal breaks do not typically progress to retinal detachment. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology/Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a symptomatic PVD who develop a full-thickness retinal tear are at high risk for retinal detachment. The most common symptom of PVD is an increasing number of floaters in one eye. Flashes of light (photopsias) are also common during PVD; and if a small retinal vessel is torn, the patient may note a shower of black spots or a marked decrease in vision. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with retinal detachment (due to PVD or other etiologies) will typically note a peripheral visual field defect. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptoms of a PVD should be quickly examined by an ophthalmologist to exclude a retinal tear or detachment. Patients with a new and progressive visual field defect suggestive of a retinal detachment require urgent evaluation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of retinal breaks or tears, most patients with PVD require no specific treatment but should be re-examined by an ophthalmologist in three months (or somewhat sooner in patients with photopsias or evidence of retinal bleeding). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Posterior vitreous detachment management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a retinal hole or tear in the presence of a symptomatic PVD should generally be treated by an ophthalmologist with laser photocoagulation or cryoretinopexy to prevent retinal detachment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Retinal hole or tear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a retinal detachment will generally be treated with one or more of the following procedures: pneumatic retinopexy, scleral buckle, or vitrectomy. Patients with small peripheral retinal detachments may be treated with barrier procedures such as laser photocoagulation. Some patients with asymptomatic rhegmatogenous retinal detachments may be closely monitored without therapy or treated with barrier procedures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rhegmatogenous retinal detachment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/1\">",
"      Yang L, Bula D, Arroyo JG, Chen DF. Preventing retinal detachment-associated photoreceptor cell loss in Bax-deficient mice. Invest Ophthalmol Vis Sci 2004; 45:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/2\">",
"      Wilson CA, Khawly JA, Hatchell DL, Machemer R. Experimental traction retinal detachment in the cat. Graefes Arch Clin Exp Ophthalmol 1991; 229:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/3\">",
"      Matthews GP, Das A, Brown S. Visual outcome and ocular survival in patients with retinal detachments secondary to open- or closed-globe injuries. Ophthalmic Surg Lasers 1998; 29:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/4\">",
"      Sarrafizadeh R, Hassan TS, Ruby AJ, et al. Incidence of retinal detachment and visual outcome in eyes presenting with posterior vitreous separation and dense fundus-obscuring vitreous hemorrhage. Ophthalmology 2001; 108:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/5\">",
"      Rumpf J. Jules Gonin. Inventor of the surgical treatment for retinal detachment. Surv Ophthalmol 1976; 21:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/6\">",
"      Hikichi T, Trempe CL, Schepens CL. Posterior vitreous detachment as a risk factor for retinal detachment. Ophthalmology 1995; 102:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/7\">",
"      Byer NE. Natural history of posterior vitreous detachment with early management as the premier line of defense against retinal detachment. Ophthalmology 1994; 101:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/8\">",
"      Margherio RR, Trese MT, Margherio AR, Cartright K. Surgical management of vitreomacular traction syndromes. Ophthalmology 1989; 96:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/9\">",
"      Wolfensberger TJ, Tufail A. Systemic disorders associated with detachment of the neurosensory retina and retinal pigment epithelium. Curr Opin Ophthalmol 2000; 11:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/10\">",
"      Eagle RC Jr. Mechanisms of maculopathy. Ophthalmology 1984; 91:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/11\">",
"      D'Amico DJ. Clinical practice. Primary retinal detachment. N Engl J Med 2008; 359:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/12\">",
"      Char DH. Coats' syndrome: long term follow up. Br J Ophthalmol 2000; 84:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/13\">",
"      Wilkes SR, Beard CM, Kurland LT, et al. The incidence of retinal detachment in Rochester, Minnesota, 1970-1978. Am J Ophthalmol 1982; 94:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/14\">",
"      Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. Arch Ophthalmol 1982; 100:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/15\">",
"      Risk factors for idiopathic rhegmatogenous retinal detachment. The Eye Disease Case-Control Study Group. Am J Epidemiol 1993; 137:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/16\">",
"      Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/17\">",
"      Hikichi T, Yoshida A. Time course of development of posterior vitreous detachment in the fellow eye after development in the first eye. Ophthalmology 2004; 111:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/18\">",
"      Hollands H, Johnson D, Brox AC, et al. Acute-onset floaters and flashes: is this patient at risk for retinal detachment? JAMA 2009; 302:2243.",
"     </a>",
"    </li>",
"    <li>",
"     Byer NE. Rethinking prophylactic therapy of retinal detachment. In: Advances in Vitreoretinal Surgery, Stirpe M (Ed), Ophthalmic Communications Society, New York 1992. p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/20\">",
"      Byer NE. Long-term natural history of lattice degeneration of the retina. Ophthalmology 1989; 96:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/21\">",
"      Folk JC, Arrindell EL, Klugman MR. The fellow eye of patients with phakic lattice retinal detachment. Ophthalmology 1989; 96:72.",
"     </a>",
"    </li>",
"    <li>",
"     Wilkinson CP, Rice TA. Michels Retinal Detachment, Mosby-Year Book, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/23\">",
"      Byer NE. What happens to untreated asymptomatic retinal breaks, and are they affected by posterior vitreous detachment? Ophthalmology 1998; 105:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/24\">",
"      Go SL, Hoyng CB, Klaver CC. Genetic risk of rhegmatogenous retinal detachment: a familial aggregation study. Arch Ophthalmol 2005; 123:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/25\">",
"      Kelley LM, Walker JP, Wing GL, et al. Ultrasound-guided cryotherapy for retinal tears in patients with vitreous hemorrhage. Ophthalmic Surg Lasers 1997; 28:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/26\">",
"      Coffee RE, Westfall AC, Davis GH, et al. Symptomatic posterior vitreous detachment and the incidence of delayed retinal breaks: case series and meta-analysis. Am J Ophthalmol 2007; 144:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/27\">",
"      van Overdam KA, Bettink-Remeijer MW, Klaver CC, et al. Symptoms and findings predictive for the development of new retinal breaks. Arch Ophthalmol 2005; 123:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/28\">",
"      Cohen SM. Natural history of asymptomatic clinical retinal detachments. Am J Ophthalmol 2005; 139:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/29\">",
"      Hilton GF, Tornambe PE. Pneumatic retinopexy. An analysis of intraoperative and postoperative complications. The Retinal Detachment Study Group. Retina 1991; 11:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/30\">",
"      Tornambe PE, Hilton GF. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. The Retinal Detachment Study Group. Ophthalmology 1989; 96:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/31\">",
"      Chang TS, Pelzek CD, Nguyen RL, et al. Inverted pneumatic retinopexy: a method of treating retinal detachments associated with inferior retinal breaks. Ophthalmology 2003; 110:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/32\">",
"      Machemer R. [Development of pars plana vitrectomy. My personal contribution]. Klin Monbl Augenheilkd 1995; 207:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/33\">",
"      Wilkinson C. Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment. Cochrane Database Syst Rev 2001; :CD003170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/34\">",
"      Lewis GP, Charteris DG, Sethi CS, et al. The ability of rapid retinal reattachment to stop or reverse the cellular and molecular events initiated by detachment. Invest Ophthalmol Vis Sci 2002; 43:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/35\">",
"      Hisatomi T, Sakamoto T, Goto Y, et al. Critical role of photoreceptor apoptosis in functional damage after retinal detachment. Curr Eye Res 2002; 24:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/36\">",
"      Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 1995; 36:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/37\">",
"      Berglin L, Algvere PV, Seregard S. Photoreceptor decay over time and apoptosis in experimental retinal detachment. Graefes Arch Clin Exp Ophthalmol 1997; 235:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/38\">",
"      Arroyo JG, Yang L, Bula D, Chen DF. Photoreceptor apoptosis in human retinal detachment. Am J Ophthalmol 2005; 139:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/39\">",
"      Chang CJ, Lai WW, Edward DP, Tso MO. Apoptotic photoreceptor cell death after traumatic retinal detachment in humans. Arch Ophthalmol 1995; 113:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/40\">",
"      Sebag J, Sadun AA. Apoptotic photoreceptor cell death after traumatic retinal detachment in humans. Arch Ophthalmol 1996; 114:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36504/abstract/41\">",
"      Lewis GP, Talaga KC, Linberg KA, et al. The efficacy of delayed oxygen therapy in the treatment of experimental retinal detachment. Am J Ophthalmol 2004; 137:1085.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6910 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36504=[""].join("\n");
var outline_f35_41_36504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rhegmatogenous retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Posterior vitreous detachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Traumatic retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonrhegmatogenous retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Traction retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Exudative retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lattice degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pseudo retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY/RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Posterior vitreous detachment management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Retinal hole or tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rhegmatogenous retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pneumatic retinopexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Scleral buckle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other causes of retinal detachments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Photoreceptor neuroprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Course, definitions, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Risk factors and clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6910|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/28/10688\" title=\"figure 1\">",
"      Cryoretinopexy spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/25/3474\" title=\"figure 2\">",
"      Scleral buckle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/36/11840\" title=\"figure 3\">",
"      Vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6910|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/11/7359\" title=\"picture 1\">",
"      Normal retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/57/19347\" title=\"picture 2\">",
"      Retinal photoreceptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/57/3999\" title=\"picture 3\">",
"      Posterior vitreous detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/17/40222\" title=\"picture 4\">",
"      Traumatic retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/55/27504\" title=\"picture 5\">",
"      Pneumatic retinopexy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/21/44369?source=related_link\">",
"      Patient information: Detached retina (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36505="Principles of interferon therapy in liver disease and the induction of autoimmunity";
var content_f35_41_36505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of interferon therapy in liver disease and the induction of autoimmunity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Ulrich Spengler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/41/36505/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/41/36505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the understanding of autoimmune liver diseases and those of known etiology, such as chronic viral and drug-induced hepatitis, have underscored the importance of autoimmune reactivity in a variety of hepatocellular diseases. The widespread use of interferon (IFN) therapy in chronic viral hepatitis has provided another dimension because of the diverse biologic activities of administered interferons and their propensity to induce",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    modify autoimmunity.",
"   </p>",
"   <p>",
"    Interferons comprise a group of related proteins whose effects include antiviral activity, growth regulatory properties, inhibition of angiogenesis, regulation of cell differentiation, enhancement of major histocompatibility complex antigen expression, and a wide variety of immunomodulatory activities. They were originally classified according to their source and have subsequently been renamed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocyte interferon is interferon alfa (IFNa)",
"     </li>",
"     <li>",
"      Fibroblast interferon is interferon beta (IFNb)",
"     </li>",
"     <li>",
"      Immune interferon is interferon gamma (IFNg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least 18 distinct genes for human IFNa (including 4 pseudogenes) are known; in comparison, there is only one IFNb and one IFNg gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A class of cytokines distantly related to IFNa and the interleukin 10 family comprising three genes designated as interleukins 28A, 28B, and 29 has been discovered and termed interferon lambda [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These cytokines resemble conventional interferon alfa because they are induced by viral infection and double-stranded RNA and render cells resistant to viral infections by activation the same intracellular pathways.",
"   </p>",
"   <p>",
"    Most cells have receptors and respond to interferons. IFNa and IFNb (type 1 interferon) bind to the same cell surface receptor, albeit with different affinities, whereas IFNg binds to a distinct receptor for type 2 interferons. Lambda interferons bind to a shared own receptor consisting of the interleukin 10 receptor beta and an orphan class II receptor chain designated as IL-28Ra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/3\">",
"     3",
"    </a>",
"    ]. On average, type 1 interferons are more than 30 percent homologous and the genes are clustered on the short arm of chromosome 9. None has introns and all have transcripts with 3' instability sequences. In contrast, the IFNg gene is located on the long arm of chromosome 12 and has four exons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Genes of lambda interferons share 15 to 20 percent sequence homology with interferon alpha, but are clustered on chromosome 19 and contain multiple exons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERFERON THERAPY IN LIVER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 interferons were the first therapeutic agents that permitted successful antiviral therapy with acceptable side effects in patients with chronic hepatitis B, D, and C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Among the agents available worldwide for the treatment of chronic viral hepatitis are several recombinant alfa interferons (IFN alfa-2a, alfa-2b, and alfa-2c), a fully synthetic type 1 interferon (consensus interferon), mixtures containing several type 1 interferons from natural sources (lymphoblastoid interferon, human natural leukocyte interferon), and IFNb. Recombinant interferons have also been coupled to polyethylene glycol molecules to modify their pharmacokinetic properties and prolong their half-lives. This modification has significantly improved their therapeutic efficacy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .) In addition, interferons can be combined with antiviral drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and protease inhibitors. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    In contrast to type 1 interferons, IFNg, either alone or in combination with type 1 interferons, has",
"    <strong>",
"     no",
"    </strong>",
"    apparent therapeutic effect on chronic viral liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. By contrast, lambda interferons inhibit replication of hepatitis B and C viruses and are thus undergoing evaluation as treatment options for viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Polymorphisms in the IL28B gene, coding for interferon-lambda-3, have been identified in genome-wide genetic screens to be a prognostic factor for (pegylated) interferon-alfa-induced and spontaneous elimination of hepatitis C virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action in chronic viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is assumed that increased expression of antiviral genes induced by type 1 interferons is an important factor in the elimination of hepatitis viruses. These antiviral genes are only partially understood with respect to function; they comprise 2',5' oligoadenylate synthetase, a 60 kDa protein kinase, and the Mx protein homologue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/9\">",
"     9",
"    </a>",
"    ]. Lambda interferons activate the same set genes as type 1 interferons, but induce steady increases in gene activity and can enhance the antiviral effect of subsaturating doses of interferon alfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since control of chronic hepatitis B is only rarely achieved in patients with an incompetent immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/10\">",
"     10",
"    </a>",
"    ], the immunostimulatory properties of type 1 interferons are probably required to eliminate the hepatitis B virus. A variable reduction of HBV-DNA can be observed in all patients during interferon treatment; however, a transient flare of aminotransferases followed by their normalization, loss of serum HBV-DNA, and loss of HBeAg and HBsAg is only observed in complete IFN responders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This flare is preceded by increased serum levels of beta2-microglobulin, tumor necrosis factor alfa and soluble tumor necrosis factor receptors, and elevations of plasma aminotransferases. It has been attributed to destruction of virus-infected hepatocytes by cytolytic immune effector cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, a transient flare of aminotransferases is not usually observed with interferon therapy in patients with chronic hepatitis C virus infection. Those patients who respond to interferon usually show a gradual decrease in serum aminotransferases shortly after the initiation of interferon therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTERFERON-INDUCED AUTOIMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because type 1 interferons have such marked immunomodulatory effects, they also have the potential to lead to development of autoimmune phenomena during prolonged courses of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. Interferon therapy may aggravate preexisting autoimmunity, unmask silent autoimmune processes, or even induce de novo autoimmune diseases. As an example, enhanced humoral immunity with hypergammaglobulinemia, lymphadenopathy, and increased serum concentrations of interleukin (IL)-6 have been reported in a patient treated with both IFNa and IFNb for chronic hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predisposition to autoimmunity associated with the presence of baseline autoantibodies has been demonstrated in IFN-mediated autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. The association of type 1 interferon-induced autoimmune disease with certain HLA phenotypes has also been proposed. No association of autoantibodies with interferon autoantibodies has been detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of autoantibody formation in IFN-induced autoimmunity is incompletely understood. A number of factors might alter the balance between self-tolerance and activation of autoreactivity. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct effects of type 1 interferons on antibody production, inhibition of T suppressor cell function",
"     </li>",
"     <li>",
"      Enhanced expression of MHC class I antigens",
"     </li>",
"     <li>",
"      Aberrant or enhanced MHC class II antigen expression with subsequent activation of T helper lymphocytes by autoantigens",
"     </li>",
"     <li>",
"      Enhanced conversion of monocytes to (auto-)antigen-presenting dendritic cells",
"     </li>",
"     <li>",
"      Induction of inflammatory cytokines (eg, interleukin 6, tumor necrosis factor, and others)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whatever the mechanism, patients receiving long-term therapy with type 1 interferons must be carefully monitored for the possible development of autoantibodies and autoimmune disease. This issue is further complicated in patients with chronic liver diseases accompanied by a high spontaneous incidence of autoimmune features (eg, autoimmune hepatitis) or in whom frank autoimmune disease such as vasculitis is present. Finally, the presence of non-organ-specific autoantibodies in chronic hepatitis C, although frequently not relevant as a marker of autoimmunity, seems to reduce the response to interferon",
"    <span class=\"nowrap\">",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several diseases and syndromes have been reported in patients with malignant and nonmalignant conditions treated with interferon. These include rheumatoid symptoms, a lupus-like disease, rheumatoid factor-positive monoarthritis, the antiphospholipid syndrome, diabetes mellitus, interstitial pneumonitis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, psoriasis, leukocytoclastic vasculitis, thyroid disease, and autoimmune liver disease (",
"    <a class=\"graphic graphic_table graphicRef80557 \" href=\"mobipreview.htm?29/37/30300\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/27\">",
"     27",
"    </a>",
"    ]. The major autoimmune disorders encountered during interferon treatment of liver disease involve the thyroid gland and the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid autoantibodies and disorders have been reported in patients with chronic hepatitis both before and after interferon treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/20,28-33\">",
"     20,28-33",
"    </a>",
"    ]. The prevalence appears greater in those with chronic hepatitis C virus infection. The reported frequency of thyroid disorders after type 1 interferons varies; this may be due to several factors including different diagnostic criteria and study populations, dose and duration of interferon treatment, and concurrent medications. Whether frequencies in developing thyroid autoantibodies differ between treatment with pegylated interferon-alpha and conventional interferon is uncertain since studies have been mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common interferon-alfa-associated thyroid abnormality is the development of antithyroid antibodies without clinical disease (5 to up to 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/36\">",
"     36",
"    </a>",
"    ]. Approximately 5 to 10 percent of patients develop clinical thyroid disease, including painless thyroiditis, Hashimoto's thyroiditis, or Graves' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/28,29,36,37\">",
"     28,29,36,37",
"    </a>",
"    ]. In rare instances, Graves' ophthalmopathy has been reported following treatment of hepatitis C with interferon alfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/38\">",
"     38",
"    </a>",
"    ]. Interestingly, some studies have suggested that the development of thyroid disorders during interferon treatment of chronic hepatitis C is associated with an increased likelihood of a sustained virological response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The changes in thyroid function usually appear after three months of therapy, but can occur as long as IFN-alfa is given. Rare patients develop thyroid autoantibodies after interferon-alfa treatment has been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/41\">",
"     41",
"    </a>",
"    ]. The risk of any form of thyroid disease is greater in those patients who have increased serum antithyroid antibody concentrations before initiation of IFN-alfa, a finding which suggests that IFN-alfa in some way exacerbates underlying thyroid autoimmune disease. These relationships and the frequency of thyroid disease can be illustrated by the following observations from several large studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/28,29,42,43\">",
"     28,29,42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter survey of 616 patients with chronic hepatitis C treated with IFN-alfa-2a found a 5 percent prevalence of hypothyroidism prior to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/28\">",
"       28",
"      </a>",
"      ]. An additional 5 percent developed thyroid dysfunction during therapy. Patients in both categories were predominantly female. In those patients who developed thyroid disease during interferon therapy, approximately 25 percent were positive for antithyroid peroxidase antibodies at baseline.",
"     </li>",
"     <li>",
"      Another report evaluated 422 patients with chronic viral hepatitis C, B, or D [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/29\">",
"       29",
"      </a>",
"      ]. Increased titers of antithyroid peroxidase antibodies were clustered significantly among women (8.7 versus 3.4 percent), particularly those with chronic hepatitis C (11.2 versus 3.6 percent). Treatment with IFN-alfa significantly increased the prevalence of antithyroid peroxidase antibodies (12.5 to 18.6 percent) and thyroid dysfunction (3.7 to 9.7 percent); euthyroid patients with high baseline antithyroid peroxidase concentration developed thyroid dysfunction during IFN-alfa therapy at an even higher rate (36.4 percent). Hypothyroidism was the most common thyroid abnormality; this occurred early (on treatment) or late (six months after cessation of therapy), and did not necessarily resolve when IFN-alfa was discontinued.",
"     </li>",
"     <li>",
"      A study of 625 HCV infected patients with normal thyroid function at baseline reported the appearance of thyroid abnormalities in 58 patients (9 percent) during interferon treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/43\">",
"       43",
"      </a>",
"      ]. Twenty-six patients had hypothyroidism and nine had hyperthyroidism, with Grave's disease in three patients. Twenty-one patients had biphasic thyroiditis, and in two patients anti-thyroid-peroxidase antibodies appeared without hypothyroidism. Female sex and pre-existing thyroid-peroxidase antibodies were identified as risk factors for developing thyroiditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the presence of antithyroid peroxidase antibodies before treatment appears to be the most significant risk factor for development of clinical thyroid disease during interferon therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/20,29,33,43\">",
"     20,29,33,43",
"    </a>",
"    ]. Additional risk factors for thyroid disease during interferon treatment may include female gender, older age, and the presence of other autoantibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/30\">",
"     30",
"    </a>",
"    ]. At least one report also found that the presence of liver-kidney microsomal antibodies was associated with an increased risk of development of thyroid disorders during IFN therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with chronic hepatitis C and high antithyroid peroxidase antibody titers are at particular risk. The risk of thyroid dysfunction under interferon therapy may also be increased in children with hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/44\">",
"     44",
"    </a>",
"    ]. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    to interferon therapy does not alter the thyroid autoantibody pattern but increases the risk of developing hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with increased thyroid autoantibodies or thyroid dysfunction will recover after completion of antiviral therapy. Thus, interruption of interferon treatment may not always be required but nevertheless should be recommended for patients with severe symptoms. Following interferon withdrawal, spontaneous normalization of thyroid function can be expected in many patients with painless thyroiditis and (biphasic) Hashimoto's thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], while thyroid abnormalities usually persist in those with Graves' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/33,48,49\">",
"     33,48,49",
"    </a>",
"    ]. Persistent thyroglobulin and thyroid peroxidase antibodies after stopping interferon therapy predict the later development of thyroid dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients who develop hyper- or hypothyroidism during interferon therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different forms of hepatotoxicity have been described with interferon therapy. An asymptomatic rise in serum aminotransferases has been noted in up to 25 percent of patients treated by type 1 interferons for malignancies and in as many as 80 percent of patients who were treated with doses greater than 100 million units per week. Abnormalities were usually seen at the onset of interferon therapy and the elevation in serum aminotransferases resolved with continued therapy or after dose reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct interferon-associated liver toxicity is rare during interferon treatment of viral hepatitis and is not considered to be immune-mediated. Furthermore, as noted above, the typical flare of aminotransferases during therapy of chronic hepatitis B, which heralds seroconversion, is not regarded as evidence of autoimmunity. However, fatal hepatic decompensation with ascites, jaundice, and hepatic encephalopathy can occur occasionally during such flares. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoimmune hepatitis can develop during treatment of chronic hepatitis B and C with interferon. Although generally considered to be rare, in one report of 144 patients with hepatitis C, deterioration in liver function and the development of autoantibodies occurred in seven (5 percent) during interferon therapy, all of whom were women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/53\">",
"     53",
"    </a>",
"    ]. Some of these patients had preexisting autoantibodies, suggesting that they may be predisposed to autoimmune hepatitis during interferon therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune hepatitis developed during treatment with standard interferon in most reports. Whether the risk differs between pegylated and standard interferons is unclear. Only a few case reports have been published on autoimmune hepatitis developing during treatment with peginterferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. A plasma-cell rich autoimmune-type hepatitis has also been observed under immunosuppression after liver transplantation, when recurrent hepatitis C was treated with peginterferon in a patient without prior evidence for autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since amino acid sequences of the hepatitis C virus share homologies with the human cytochromes and cellular structures, molecular mimicry may contribute to virus-triggered autoimmunity. There is a striking prevalence of autoimmune phenomena in patients with chronic hepatitis C including circulating cryoglobulins, rheumatoid factor and nonspecific autoantibodies such as antinuclear antibodies, smooth muscle antibodies, liver kidney microsomal (LKM)-1 antibodies, and antithyroid antibodies.",
"   </p>",
"   <p>",
"    At the molecular level, different specificities of anti-LKM-1 antibodies (which, in autoimmune hepatitis type 2, are directed against an epitope of cytochrome P450 2D6 [CYP2D6]) can be demonstrated when comparing patients with hepatitis C and true autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. A study using recombinant CYP2D6 and synthetic peptides from this protein showed that anti-LKM-1 antibodies from patients with autoimmune hepatitis were directed against antigens which differed from those in chronic hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction between autoimmune hepatitis and chronic hepatitis C is particularly important with respect to therapy. Autoimmune hepatitis benefits from immunosuppression by corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , while hepatitis C infection is generally treated with interferon alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inappropriate interferon therapy of autoimmune hepatitis can exacerbate the liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunosuppressive therapy in hepatitis C infection can lower aminotransferase levels; however, it is generally accompanied by a rise of viral load.",
"     </li>",
"     <li>",
"      Symptomatic vasculitis and cryoglobulinemia can be considerably improved by interferon therapy in 60 to 80 percent of patients with HCV viremia, although persistent viral clearance is achieved only infrequently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/62\">",
"       62",
"      </a>",
"      ]. However, some patients with cryoglobulinemia respond to steroid therapy without apparent deterioration of their chronic hepatitis C. Treatment with the anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      appears promising. Rituximab has also been successfully combined with interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"       \"Treatment of the mixed cryoglobulinemia syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with hepatitis C and anti-LKM-1 antibodies, as well as other types of non-organ-specific autoantibodies, appear to benefit from interferon to the same extent as patients with chronic hepatitis C without such antibodies. However, such patients need meticulous monitoring during interferon treatment, since flares of aminotransferases without subsequent clearance of HCV RNA have been observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. This observation suggests that these patients may behave as if they had autoimmune hepatitis. In support of this hypothesis is the finding that when patients with chronic hepatitis C with or without anti-LKM-1 antibodies were compared, the viral load was lower in the patients with anti-LKM-1 antibodies even though both groups had disease of similar severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/65\">",
"       65",
"      </a>",
"      ]. Furthermore, some of these patients have responded to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      directed against presumed autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/66,67\">",
"       66,67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When exacerbation occurs during interferon therapy, interferon must be withdrawn. The benefit of introducing immunosuppression at this point must be balanced against the associated risks of increased viral replication. Interferon-induced autoimmune hepatitis in hepatitis C can occur suddenly and may progress to fulminant hepatic failure, and thus requires rapid recognition and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taking into account the high prevalence of non-organ specific antibodies in chronic hepatitis C, it is important to emphasize that the presence of such antibodies alone has little predictive value for interferon-induced liver-related autoimmunity and that interferon treatment can induce autoimmune hepatitis in individuals without preexisting features of autoimmunity. Furthermore, other autoimmune diseases occur in the same patients, and female gender and specific HLA phenotypes may be genetically predisposing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/54,68\">",
"     54,68",
"    </a>",
"    ]. Similarly, interferon-induced autoimmune hepatitis can occur in patients without preexisting liver disease, as has been reported in a patient with chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immune-mediated skin diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous reactions to interferon therapy, both local and distant from the injection sites, are common. Eczematous and lichenoid reactions are most frequently observed, but the spectrum of skin reactions ranges from self-resolving pruritus and erythematous papules and lupus-like reactions at injection sites to multiple fixed drug eruptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. There are also isolated reports of the development or exacerbation of lichen planus and psoriasis during interferon treatment for chronic HCV; in these cases, skin lesions improve when interferon is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/76,77\">",
"     76,77",
"    </a>",
"    ] pleural effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/78\">",
"     78",
"    </a>",
"    ], bronchiolitis obliterans-organizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/79\">",
"     79",
"    </a>",
"    ] as well as exacerbation of sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/80\">",
"     80",
"    </a>",
"    ] and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/81\">",
"     81",
"    </a>",
"    ] have been observed during interferon therapy. Pulmonary complications of interferon therapy appear to be rare. However, prompt investigation and discontinuation of medication is warranted, if any signs of significant pulmonary involvement develop, because pulmonary dysfunction can become severe, and the outcome is variable. Pneumonitis can present with any combination of fever, dyspnea, and cough, and affects males and females equally and has been described with both standard and peginterferon. In a comprehensive review of the literature and drug toxicity databases, a mortality rate of 7 percent was observed in patients who developed pneumonitis during treatment with peginterferon alfa-2b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/82\">",
"     82",
"    </a>",
"    ]. Pneumonitis has also been reported with peginterferon alfa-2a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus concerning treatment of interstitial pneumonitis induced by interferon. In most reports, pneumonitis improved after interferon withdrawal alone or with corticosteroids. The relatively high mortality rate suggests favoring an aggressive approach, particularly in patients treated with peginterferon who probably should be treated with corticosteroids early after the diagnosis of pneumonitis has been established.",
"   </p>",
"   <p>",
"    In some clinical trials for hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/84-86\">",
"     84-86",
"    </a>",
"    ] the reported incidence of dyspnea and cough were higher in patients on peginterferon combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    than in patients with interferon monotherapy. However, it remains unclear whether this observation reflects increased pulmonary toxicity of peginterferons or immune-modulating effects of ribavirin. De novo induction and exacerbation of sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/78\">",
"     78",
"    </a>",
"    ] have been observed during interferon therapy. Although these complications appear to be rare, they can be severe, and the outcome is variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) develops in &lt;1 percent of patients treated with IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Many more IFNa-treated patients develop a lupus-like syndrome with only some SLE symptoms, which are insufficient to formally fulfill diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/87\">",
"     87",
"    </a>",
"    ]. SLE and lupus-like syndrome have reportedly occurred after a wide range of exposure times, including as early as one month and as late as seven years after drug initiation. Typical manifestations of SLE such as malar rash, oral ulcers, photosensitivity, renal disease and typical autoantibodies (eg, anti-Sm or anti-dsDNA) have been observed, suggesting that these cases were not \"drug-induced\" SLE but instead resembled idiopathic SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/89\">",
"     89",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    As observed in other cases of drug-induced lupus, SLE due to INFa affects males and females equally. Patients typically develop high titers of antinuclear antibodies, including antibodies to dsDNA. Antibody titers diminish and symptoms clear with IFNa discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .) IFN-induced SLE can occasionally be severe; life-threatening multiorgan involvement comprising glomerulonephritis, serositis, discoid rash, myopericarditis, and vasculitis have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon therapy may cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exacerbate glomerular disease, and rarely rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/87,91\">",
"     87,91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon-induced arthritis can mimic rheumatoid arthritis because of the frequent detection of rheumatoid factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/92\">",
"     92",
"    </a>",
"    ]. Antibodies to cyclic citrul-linated peptides are usually not present, potentially helping to differentiate the two conditions. Management of arthritis is mainly empirical.",
"   </p>",
"   <p>",
"    Finally, there is accumulating evidence that interferon treatment of chronic viral hepatitis can induce or exacerbate a variety of immune-mediated neuropathy syndromes, neuromuscular junction disorders and myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/93\">",
"     93",
"    </a>",
"    ]. In isolated case reports of patients with HBV or HCV, interferon therapy and mixed cryoglobulinemia treatment triggered or exacerbated peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/41/36505/abstract/93\">",
"     93",
"    </a>",
"    ]. Patients suffered from sensory or sensorimotor polyneuropathy or mononeuritis multiplex. Furthermore, a variety of demyelinating syndromes, axonal neuropathy, and myasthenia gravis were also encountered in rare instances. Management comprised prompt cessation of interferon treatment in combination with supportive, immunomodulatory, and symptomatic measures as clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604411720\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 interferons have marked immunomodulatory effects and thus have the potential to lead to the development of autoimmune phenomena during prolonged courses of treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Interferon-induced autoimmunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving long-term therapy with type 1 interferons must be carefully monitored for the possible development of autoantibodies and autoimmune disease. A careful history concerning autoimmunity should be taken before the start of therapy, and TSH should be checked at baseline. Organ-independent autoantibodies are optional but should also be determined at baseline if the patient has a history suggesting an enhanced risk of autoimmunity. TSH and relevant autoantibodies should be re-evaluated every three months during treatment or earlier if symptoms arise.",
"     </li>",
"     <li>",
"      Thyroid autoantibodies and disorders have been reported in patients with chronic hepatitis both before and after interferon treatment. The most common interferon-alfa-associated thyroid abnormality is the development of antithyroid antibodies without clinical disease (5 to up to 40 percent). Approximately 5 to 10 percent of patients develop clinical thyroid disease, including painless thyroiditis, Hashimoto's thyroiditis, or Graves' disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thyroid disease'",
"      </a>",
"      above.) Most patients with increased thyroid autoantibodies or thyroid dysfunction will recover after completion of antiviral therapy. The management of patients who develop hyper- or hypothyroidism during interferon therapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several different forms of hepatotoxicity have been described with interferon therapy when given in high doses. Direct interferon-associated liver toxicity is rare during interferon treatment of viral hepatitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous reactions to interferon therapy, both local and distant from the injection sites, are common. Eczematous and lichenoid reactions are most frequently observed, but the spectrum of skin reactions ranges from self-resolving pruritus and erythematous papules and lupus-like reactions at injection sites to multiple fixed drug eruptions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immune-mediated skin diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interstitial pneumonitis, pleural effusion, bronchiolitis obliterans-organizing pneumonia, exacerbation of sarcoidosis, and asthma have been observed during interferon therapy but appear to be rare. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Case reports have described several other autoimmune disorders in association with interferon treatment, including systemic lupus erythematosus, glomerular disease, immune-mediated neuropathy, and myopathy syndromes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Others'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lodish H, Baltimore D, Berk A, et al. Molecular cell biology. Scientific American Books, 3rd ed, Oxford Press, New York 1995. p.916.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/2\">",
"      Kirchner H. Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/3\">",
"      Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/4\">",
"      Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/5\">",
"      Di Bisceglie AM, Rustgi VK, Kassianides C, et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/6\">",
"      S&aacute;ez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/7\">",
"      Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79:3851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/8\">",
"      Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/9\">",
"      Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/10\">",
"      McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/11\">",
"      Scully LJ, Brown D, Lloyd C, et al. Immunological studies before and during interferon therapy in chronic HBV infection: identification of factors predicting response. Hepatology 1990; 12:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/12\">",
"      Itoh Y, Okanoue T, Enjyo F, et al. Elevated interleukin-6 and gamma-globulin during interferon therapy of hepatitis B. Am J Gastroenterol 1992; 87:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/13\">",
"      Yoshie O, Mellman IS, Broeze RJ, et al. Interferon action: effects of mouse alpha and beta interferons on rosette formation, phagocytosis, and surface-antigen expression of cells of the macrophage-type line RAW 309Cr.1. Cell Immunol 1982; 73:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/14\">",
"      Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 1985; 75:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/15\">",
"      Fradelizi D, Gresser I. Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med 1982; 155:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/16\">",
"      Peters M, Ambrus JL, Zheleznyak A, et al. Effect of interferon-alpha on immunoglobulin synthesis by human B cells. J Immunol 1986; 137:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/17\">",
"      Meurs E, Hovanessian AG. Alpha-interferon inhibits the expression of heavy chain mu messenger RNA in Daudi cells. EMBO J 1988; 7:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/18\">",
"      Pascual V, Allantaz F, Patel P, et al. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 2008; 223:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/19\">",
"      Conlon KC, Urba WJ, Smith JW 2nd, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/20\">",
"      Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/21\">",
"      R&ouml;nnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/22\">",
"      Muratori L, Bogdanos DP, Muratori P, et al. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 2005; 3:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/23\">",
"      Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol 1988; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/24\">",
"      Wasmuth HE, Stolte C, Geier A, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/25\">",
"      Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/26\">",
"      Gatselis NK, Georgiadou SP, Koukoulis GK, et al. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/27\">",
"      Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/28\">",
"      Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/29\">",
"      Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/30\">",
"      Marazuela M, Garc&iacute;a-Buey L, Gonz&aacute;lez-Fern&aacute;ndez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/31\">",
"      Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/32\">",
"      Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/33\">",
"      Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/34\">",
"      Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol 2007; 22:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/35\">",
"      Jamil KM, Leedman PJ, Kontorinis N, et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 2009; 24:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/36\">",
"      Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/37\">",
"      Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004; 164:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/38\">",
"      Villanueva RB, Brau N. Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 2002; 12:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/39\">",
"      Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol 2009; 24:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/40\">",
"      Tran HA, Jones TL, Gibson R, Reeves GE. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. BMC Endocr Disord 2011; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/41\">",
"      Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995; 44:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/42\">",
"      Tran HA, Jones TL, Batey RG. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr Disord 2005; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/43\">",
"      Kabbaj N, Guedira MM, El Atmani H, et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006; 67:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/44\">",
"      Gehring S, Kullmer U, Koeppelmann S, et al. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 2006; 12:5787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/45\">",
"      Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/46\">",
"      Tran HA, Reeves GE, Jones TL. The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM 2009; 102:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/47\">",
"      Tran HA, Jones TL, Ianna EA, Reeves GE. The natural history of interferon-&alpha; induced thyroiditis in chronic hepatitis c patients: a long term study. Thyroid Res 2011; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/48\">",
"      Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002; 56:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/49\">",
"      Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/50\">",
"      Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/51\">",
"      Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/52\">",
"      Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/53\">",
"      Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/54\">",
"      Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/55\">",
"      Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003; 38:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/56\">",
"      L&ouml;rke J, Erhardt A, H&auml;ussinger D. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/57\">",
"      Cholongitas E, Samonakis D, Patch D, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/58\">",
"      Kogure T, Ueno Y, Fukushima K, et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 2007; 13:4394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/59\">",
"      Kontorinis N, Agarwal K, Elhajj N, et al. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006; 12:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/60\">",
"      Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/61\">",
"      Muratori L, Lenzi M, Ma Y, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/62\">",
"      Joshi S, Kuczynski M, Heathcote EJ. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci 2007; 52:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/63\">",
"      Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/64\">",
"      Gschwantler M, Schrutka-K&ouml;lbl C, Weiss W. Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by alpha-interferon. Am J Gastroenterol 1995; 90:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/65\">",
"      Giostra F, Manzin A, Lenzi M, et al. Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol 1996; 25:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/66\">",
"      Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/67\">",
"      Bortolotti F, Vajro P, Balli F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/68\">",
"      Garc&iacute;a-Buey L, Garc&iacute;a-Monz&oacute;n C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/69\">",
"      Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother 1992; 4:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/70\">",
"      Basaranoglu M, Celebi S, Karaaslan H, Demir A. Case study on drug-related adverse effects of hepatitis C therapy. Adv Ther 2006; 23:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/71\">",
"      Arrue I, Saiz A, Ortiz-Romero PL, Rodr&iacute;guez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol 2007; 34 Suppl 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/72\">",
"      Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol 2003; 2:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/73\">",
"      Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holterm&uuml;ller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/74\">",
"      Ketikoglou I, Karatapanis S, Elefsiniotis I, et al. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/75\">",
"      Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005; 51:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/76\">",
"      Chin K, Tabata C, Sataka N, et al. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/77\">",
"      Moriya K, Yasuda K, Koike K, et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994; 29:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/78\">",
"      Takeda A, Ikegame K, Kimura Y, et al. Pleural effusion during interferon treatment for chronic hepatitis C. Hepatogastroenterology 2000; 47:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/79\">",
"      Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/80\">",
"      Hoffmann RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998; 28:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/81\">",
"      Bini EJ, Weinshel EH. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc 1999; 74:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/82\">",
"      Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55:579.",
"     </a>",
"    </li>",
"    <li>",
"     Tietz A, Liu J, Schaerer MT, et al. Global review of the rate of interstitial pneumonitis among hepatitis virus C-infected patients treated with pegalyated interferon &plusmn; ribavirin. Hepatology 2009; 50 Suppl 676A: (abstract #794).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/84\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/85\">",
"      Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/86\">",
"      McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/87\">",
"      Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/88\">",
"      Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/89\">",
"      Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/90\">",
"      Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 2008; 14:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/91\">",
"      Ohta S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/92\">",
"      Lormeau C, Falgarone G, Roulot D, Boissier MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/41/36505/abstract/93\">",
"      St&uuml;bgen JP. Interferon alpha and neuromuscular disorders. J Neuroimmunol 2009; 207:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3670 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-DBEF2E8A07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36505=[""].join("\n");
var outline_f35_41_36505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H604411720\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERFERON THERAPY IN LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action in chronic viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTERFERON-INDUCED AUTOIMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immune-mediated skin diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H604411720\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/37/30300\" title=\"table 1\">",
"      Interferon induced diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_41_36506="ECG sinus rhythm WPW";
var content_f35_41_36506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1147px;\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a patient in sinus rhythm with Wolff-Parkinson-White (WPW) pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nearly full preexcitation is manifest in normal sinus rhythm on the 12 lead ECG in this patient with a short accessory pathway refractory period. The ventricular complex in preexcitation is a fusion of the impulse that preexcites the ventricles due to rapid conduction through an accessory pathway and of the impulse that takes the usual route through the AV node; this fusion creates the delta wave that is characteristic of Wolff-Parkinson-White ECG pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 466px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal sinus rhythm at a rate of 71 beats/min, a P wave axis of 45&deg;, and a PR interval of 0.15 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36506=[""].join("\n");
var outline_f35_41_36506=null;
var title_f35_41_36507="Risks benefits genetic testing";
var content_f35_41_36507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benefits and risks of genetic testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Purpose",
"      </td>",
"      <td class=\"subtitle1\">",
"       When used",
"      </td>",
"      <td class=\"subtitle1\">",
"       Examples/benefits and harms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Diagnostic testing",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       To provide definite diagnosis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       In a patient with an existing condition",
"      </td>",
"      <td>",
"       Turner syndrome 45,X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Accurate diagnosis can lead to proper treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Predictive testing",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       To provide risk assessment for presymptomatic states",
"      </td>",
"      <td>",
"       Prenatal for reproductive choice decision",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Presymptomatic intervention may delay onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       For adult risk assessment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Presymptomatic testing",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       To look for the presence of a gene mutation with complete penetrance, that is, having the mutation always leads to having the disease",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       In families with disease, for adults who choose to have testing after counseling",
"      </td>",
"      <td>",
"       Huntington disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Finding of mutation may lead to prognostic information for individual affecting life planning; negative test may provide relief. Harms include worry, stigmatization, labeling; possible \"survivor guilt\" or ostracism if negative in family with others positive.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36507=[""].join("\n");
var outline_f35_41_36507=null;
var title_f35_41_36508="Disorders with genital ambiguit";
var content_f35_41_36508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders with associated genital abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequent in:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Hypospadias/bifid scrotum",
"       </td>",
"       <td>",
"        Aniridia-Wilms tumor association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deletion of 4p, 11q, 13q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder exstrophy sequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fraser syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fryn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smith-Lemli-Opitz syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triploidy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Micropenis",
"       </td>",
"       <td>",
"        Anencephaly sequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carpenter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CHARGE association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deletion of 9p, 18q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4p duplication syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noonan syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"18\">",
"        Cryptorchidism",
"       </td>",
"       <td>",
"        Aarskog syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carpenter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deletion of: 4p, 5p, 9p, 11q, 13q, 18q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duplication of 3q, 4p, 10q, 15q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal arthrogryposis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cloacal exstrophy sequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fraser syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freeman-Sheldon syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miller-Dieker syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noonan syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Robinow syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubinstein-Taybi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smith-Lemli-Opitz syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triploidy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 9 mosaic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weaver syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Hypoplasia of labia majora",
"       </td>",
"       <td>",
"        Deletion of 9p, 18q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Robinow syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 18 syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jones, KL. Smith's recognizable patterns of human malformation, 4th ed, Saunders, Philadelphia 1998. p. 677.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36508=[""].join("\n");
var outline_f35_41_36508=null;
var title_f35_41_36509="Risk of MI with cocaine";
var content_f35_41_36509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative risk of myocardial infarction onset after cocaine use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 341px; background-image: url(data:image/gif;base64,R0lGODlhbAFVAcQAAP////8AAICAgH8AAAAAAEBAQMDAwHBwcDAwMNDQ0BAQEKCgoFBQUGBgYODg4LCwsPDw8CAgIL8AAJCQkD8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABsAVUBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYYBALAgIkCQYOmaONCQoEBREjpgSepK+IEQQJJQgErWoGnbu8uwawwCwJBBGyDCICCge4abq8BQW9v8HUJwYECAa2C8MPAswAzrzTY53V5yrDBQDfnbfvruKd0WXm6Pcmsg+2oQYGDQQaiDphr5wrfAgBJLClYAGJdikKipGYsCIMimAwWtyoQqMXjxxDPjw4kaTIkyPr/5lEiRIkF5csLcLUMjMmwppYcNpEp9NKz53UflIRChQWUSlHi45KCoWp0ktOnUR9SmkqE6tUI2FVsjWro65IwHpdJNZI2bGIzhJRi7YQWyFv2wqKC4Su3D92feS9y2cvD7988wDWMTiwncI4EBueo9hG48VbEkwQsACCCAeTJ1hG8ZhGZ8hY3qESUeAdgogrv3wGbcWhg1siHkCAIItcidUxcLOmYmCZSVkDTeh+MXx3lAWlD5CYQEA559QfoRsPVHrasgYk5AmgR6b4dCbaBCwjIIoBsU7TtHM3+H2QA1vEHogQDe629Jf323/NT5O/frL+5RTgf2kN6JOBBLqF4P9QCyY4V4NIQeggXhI2VeGEfV0olYZEaNeLLxiaxeFVIwqhXjTSZOHhh7aJ5B0LLz4HxokpshRjRyUecSOOTxW24odA7gJNkETWmMSOqPWYY24UDODkk1BGKeUAFDQ55ZVRUrCkC0jKqFRhAgwQwJhklmnmmQE4ieaaZw6wZQtdEvQmJmCKyeadY6qJJ5tuLhGncHNCFSiMdu65pp6Gtjlokio9ssA0D8gXRJ2JHlpopWT2ydWiQ/zpBHcHrDMppxFdimmepmKq6ZGkjtrINfQd4+pVqapaa6KrhtVqXbuakUABCkQADQO0zOrnrbgiu2euOvaql7NmPCpiE2Geaib/otYyO22jjkAQagIMSMortcouW+6d2hbhaUqOmEfAP7KOS6u1ZWJ7arprQfuXvmQQMEEBuogq77H0Znoun/quO4LCSxDwAMAFxPsDpQWnefChCfNLmMZiNKBAsAQ4ZCxXF1taMb6dcpyYypqYpwwMBhQrwiYgUVywvapmbAbDSiRAywQiC/ONwKykwijBJ5esqJ8sO9a0Fwgc8I3DLZQ2mgiyyOwl0jcrfa3O3DbybgEIMCCxCteIOkwxBJzNLtf04lwpynA97ZndXDjc3HYupC3CNdls83cv65FcscUng90d3lu4u4DZfV+tDjvMqKdxtUknzvTOjGvhAAMHQFCA/7jpMJeNZfrws7Xhmd+sOHvVWH3LLwsR0NDRrHet+aacO3rKLQJPfLnX1xKf6eslPXIKNAU4N3DucRufJ/Jh8JzEy+oOf7jcuFKfUedZHIBd9uRuL32a3qsGPhayX/38kecj7vrmYTMSKvPOC19+63GnH52S+9Pd/HhXv0VAwGX509+8+Jct/3XBekgoDdnq86wARm93rOqdI6gGgFDVzYLZOh/dRpY8RyjAEwd0275AeC8ROhA/jxjPLUhXwQUKsH/0Wxwk/hWulLHQVhjUlQaLYrMLDjCDBbRJEUMYxGYNEShLbGETt6XDL2mPgfd64RYgWIQF5M+LH7ShEXFIwP8qkiUCzwheDeHGxCMKMYmHmJpo1NiDKALRjU6EoyEEgEYh0XGFYmwjGZFoRkWAcQSHfF9Y4sc9Q41Qkd8DYCCliEcqwm4RyGEeNBJYxyvesIE5vKQi5PiOP7aAZprBHfzMN0Xy6bEQD1jeo2I2AwjYojQK2AygfsgmCWTJSk+SwNy02J9uLcAWKozcaaqzulVWypdYcpIwuxfKEr4KIAqogS2xEYHxyYmXhxtmNau3vipoAxVBq6XHZIGAzVgOnOF0JDGzwMW10Md9MGCOJ8wTD8J5Mp6gLKMoE5FJTXKyBQvAxjnT+TboATRn44xkRQ5wCjSqcpEPHeQbC7kTO2b/FE+PVCBHlfjPj8ozoup7lS5dyUaTgnSeAhJbbxhKQoy6lJoCtaYi2iasXdAUkC29KcZQ+j/73dOUG4OnUI9H1AeWswoLaYA/aFlTHcUvnCFd40BJqtSloq+pMOwWAn04Sa9+DaxbfGoVJGiLQXnUrNNDazE3KCkPVtUsV90eTK9QzyKcEAApDGNQ4RrXnJIzhqKhYSe7utSsLvaVh+ChYh87WMI6Fqhbjclb4XrZHfCsr2zYrFk7m1TIuqikhGWqYSXaiJVqTavOTO1ZV5vSdtECAg1Aag5E61XS7latKwDtEPhpDME6VLZfpW1RW+uuRfG2sXs90KumygCAvZay/8eVrW9X9sRE3BOfsLUpclVLyMzu8UM/9SxqtRvdKghXCD4DANDIWlnOtpdBj4ja1Cb7AlAEZ5dlTe12b/BZ4E5hbGVLZgtYIZ3nCnXATuvuTh+wN92uAD4NXq+A7zuF9wbBcZCbQTJ8M4J3BtiyHI7QIz4XutHNoBsQGdwzNIxiudLTwGsgJQUXRmP72jimjChAAu63yRk4wB8AEUgzxTve5JZXp941QPssHNwd85ixD05xFDyMBgffFMI1KPAjoGHJ2DYZzHd7wo+KlEY2u7lFcuAbS7O74Rqs2c1DcnOR4MykaPq5Sn7+M45zsAz8GdfM4x2wAIAZ6F82GktaIv+wCBk5aBxM+dBMTrSEMCdIjYp40noNhpddqmjpNfKkjgF1K+nU49Fu2tSUljQWsyjqVvf21Z8MaJhVXclMjNqkpc41rVM9a4jewRsOEMB1MYto5AZ7jJ6WAac7rWs6jMcADPCmSOlcY8/AOtTEFrax66CABmRDzpDEa5PJK+1vr5o4vI52HMb2DypH+MQ+9ra4xRluaFd7DmSLgHkmgGmrrruwn943TnddbH7XgRXYWGl4DX7wZ1N72AxXOKrvQNWCq7viuPY3xvWt8WVV+gYNOMB/76quvL6bUCV/qaxjjq6T28BqCKiMx1t+cCe3m+YIm7nIx12HBxxAFvYOs63/oZvxixM94UAf6rEbgPSdr8XlveaSu7MO74YvnA44TyXLr95zi1OS61r3+sbpkPKVp5vnIG/62eV9kXj/eylLz7Lc74h2ONl95HEQMpGbRwPMCEDs38S3q/c+t1j32+kOl8PY5kgD2Z1myRRft9n5TveuRx1NaM6DbGjzLsx/XPMhh/zXoT70yAPcFQdQsAuAY3q4o57xyQI37nP/8jUku6cCQEDSUcCcgyIj719O/dzvnpu/Px0OsBKNhK6THX9iOfm7N5fuSd761cMBAtqQasdlYJ4+psf6ir919kHq+PWzf/tik37tyR537i8f8D///NLssIDfgRe7zcZe7scn/+1nf/f3fHHANsCibRN3ememfJzHfHWndiZ3B3rTQQwIgJnmbBDYePCXf923dnPwLgggANVldZ2CdZ0HcyFYgY93gK4nBwjQAFNjfKVVX4tngB7YeyzYgjKXBxNAcCgIFyoogX6nf7M1gAT4gW8wVU64bOp1faTWgbzXdz2oeiIIB981fCKGfFOohKBXgKyHhS7IGOg1hJNShPjneWT4g2AYhkwYB+A3h2hYF2qIgGnngzUndG24h/w3O1FThxNzhzHIhjDofc1HgW5IBxGAABEQMIKoF4SIiHnYh0H3ghG4hlooZb3BhdLmhcBGhY4khiBoiVJXB91UgtjzdvR3e/86WIUreIRIWC82VwMUdgsK4HbMtoEC+IqjGIeGeIhZKAcJcHi6uIuZ94BvWDzAWImmCHq1iAMOYIO/JYWhuIz1QoqJOIvsJocSBAGx5Im5AYoftXk7aIXB5XyF6AYJhYu3QI3clX5M54vax4PpqIh+yBinwRwKwF9RKI96R4/vZ48doY6U2AbBZwDM8ShQeIPclm9jmIl4GIwSuY4IeVSRWEeTOIzOWJEH2ZEeyZFtUFCGNnYpWHaiWI/oWJD4eIlGQY4ZZY6waIQgeY6xWBUw+VAy+YsEWSoteYqv8GvlmJIDuZI+yY0IBwnjB2A4qH4CiS7aOIFI6XOlMDQ8ApD/2PeUS9iTnGGQIokIVqNbQhmTRAmVzSiLeuiSj+A3JUY4KCIA50ckcRkkcwkkBSAm0HQl05SXU7KX0eSXFPCW4yBjQXKXAcCXUuKXTwJowTQmiBklexmYdEmYQKILA/CYUKKYUMKYmtmXjukkklkjd1aXLNKE+EQj6EGZpRkOe6aahIOXf/mZWNKZifmZoSmaRWKYmNmYh7mZjEabkOmYt4mbchkmuylNsumbyNmbsymbw5marCmXrjmYbsCW83eS9ReRNkmTaPmM+/cIkqFQEndlWPmFWmkyXEkQXlmGjtA+fMYOOQlQO6mSN3mPUxl652WNQ4mNBnOWVyiM7EkK/2Opk2W5lUbZlT8JjbWmn2TJn6jin/aZlkApoPEZT/NZlPXJkvcZjWnFoATqoPJzoOqZoN8ZlBWKVQWKniIqHOu5iBTqofKZonCYnixKokloojBqoTLaJlFJkdupiYKSoygKoqcWoKUIoC6Kd0IKoQgqoQqKiT86kZYwoDFKpD1akzMJpFN6okw6ok5aotoZpRa5pUtKowuzdRl6lF96oy9antd4njO6orfRovmIo266n3DKo13apGtKiwt6pw2ap8xopg9Bp2rZpk05j2HKk3JaqDbqp8BApTpqpXvqpX3ajUoKqB8qqNlYqTW6oX+aqAG5qPTJnf8Zkkbqa1xKqP/sgKamGqHeyaaZKqpZSaoY+qoaeqlJiagPmYO2apasigyGOqGBQDM6RwLgN1UNKalDyqn9Gayt+qiYCgi3hA0lEH3/R560ap6/aqBpyqexCqmDQGHHYB6kAzj+sKyr2qjRqqtUeaR3gpiMyZsfuQcQEWN/YzsFoGTXSYQoSanQOm14cpz0+pX2igv4qhA0WBqXF51Csq7fOqegCqV1RgjF10H+ggKwoZqFE4AV260qGrGf6oruQQwGQHujYYLbka3HV6bsKrBiWq+n2ouEsACyEAEiMxoPIAttM57a2qtOCbJxKrISm512uq1vKrR6GrAbmaqs5rJEK6wTC6JVGqn/EIurloqkdaq03Hq0QKuo8Lom8spoy2mwM/uxXuux3Sa0BFuwSbqNJJu2vIi2cKtpfGi3Vgu1WDuyeEu1k5q3mlq1XIunftusL6m3WgqrHHi3iwu4SEu4Ybu2zhqohxu4fzu4lDu5m1q5j5u5ddu4heupjcCsoiu1cYu5njurXzuqkQuRmiu4cpuMfdu6vvq6lxu7Dji7n0uztmu4uGt7yti7TPuvjru6tUq7QSu80FogiCulisu7qLu5v9uKwRu9t2u916u6auu6u0u3yJu8vLq9tdu9kou9vhu+c1u+Ulm9ysuuo3S1iZuruvu9YIu+sgu69Hu85lu6ANK8Y/q8/95Lvuqrqv4rs2o6vwLMvdqbvgrsowO8vuxrv7mLvwkMvvmrv0shmHq2wRtcAGT7aCD8ZxrMwdvxwSF8wlkywiRcwijcwlfynCscw9ApB3cmwzZ8wzicwzq8wzzcwz78w9QZIkI8xERcxEZ8xEicxEq8xExsTJThsygAfseoBEuZDp2QXklgeIi3As7gj0tcrQ3LxfwEBcXIsicgGvBYBJbXAtjKocFArgBgri0AD1AQli/gEMNAAFAwerXBAkcGAAkljhhyr1ZGEIWcBNbpAq+hClJAewjFAP3YxLeBsPVRSsJxyEiQyPMBPCcgx1FwsSRgySVwAAhwO5I8Ahe7DP9C+DfpeslNo8nh0MrIWhpYnATUd62ybAIbe8oAsMgnSx5snGTveQTheTp+fEudMMVGUH4zHBEMYILEwMuIdLO1HMqi8QTuyQLYWnpOQB/8sbPA05DSPM7kXM7mfM7onM7qvM7s3M7u/M7wHM/yPM/0XM+T4A+XEQpDYFdQwM/2LAUbm7A/wAlSQND/fGB6TDkoFCoNUCyUgQwOQRnFqLARw1D/0jwOQNDJZnTcAQEXTXAOkFsNXQLTGDHykQC5FTp/I9IJENKbZBkErQsPkFuS4tIjPQLJ9gs5TdEM4BosfdAucAvzgAulHHy5CABXMxq2cwuvUYINIDEAITXZUBr/4QA8p+AQyUFRDqAAqphNIwABHyMAubXVqngagLMdcBkNSQYAVP0NCmA1DkDWyeDV+eoJ1yAATS3WDCDXHwPUc+zNw6AcFEZwSb0O1qoQxHAAW2wez/wLVH3XAEBhyhYQl8EcC8vN8hUylU01ywAuwNzLgJxbo9HWpbcMChkQK0sOkH3Xa6PYHo3azOTXKhDQrbDauFDYSC0wD3MKYYxb8PEwemzbcAkO30CDybwwmP0Nv6DcVD0Cy3AAfkPay/0uxb0LwSHckQ0s2FDdxy3bKUDbnhAs2DYLAHAK4qPUovIPD2AAfT0CDTABveEvj40LkP0xkYIAw4AA630AMpPfpwbwOMPAACebTZbtDKXxAIHM1nqs3JQTM9iw3/1tOysLlw2w3h+T3xDu3d+d0BBROzgrAv2nDOh9GfCB3w9xCi8z33aNC56tsyX+X/sg1IDMTg4tC/1YNKO94KXH4DGODf+1DN3UCu9xCybe4wigzBqe5Eq+5Eze5E7+5FAe5VI+5VRe5VZ+5Vie5Vq+5Vze5V7+5WAe5mI+5mRe5mZ+5mie5mrOByEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk of myocardial infarction onset is plotted on a logarithmic scale for each of the three hours after cocaine use. Relative risks were estimated by comparing the frequency of cocaine use in each of the 3 hours before myocardial infarction onset to its expected frequency based on each patient's reported usual frequency of cocaine use over the prior year. Error bars indicate 95 percent CI. Dotted line represents baseline risk during periods of nonexposure to cocaine. The risk of myocardial infarction was increased 24 times over baseline in the first 60 minutes after cocaine use.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mittleman MA, Mintzer D, Maclure M. Circulation 1999; 99:2737.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36509=[""].join("\n");
var outline_f35_41_36509=null;
var title_f35_41_36510="Modified DCF for advanced gastric cancer";
var content_f35_41_36510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens for advanced esophagogastric cancer: Modified docetaxel, cisplatin, and fluorouracil (modified DCF)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL normal saline (NS)* to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W)* and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV bolus",
"       </td>",
"       <td>",
"        Slow IV push over five minutes. Administer immediately after leucovorin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 to 1000 mL D5W and administer by continuous infusion for 48 hours starting immediately after the FU bolus on day 1. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Day 1 and 2: LOW; Day 3: HIGH. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel and cisplatin are irritants but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not justified (incidence of neutropenic fever approximately 7 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with serum creatinine &gt;1.5 mg/dL were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . Docetaxel should not be given to patients with a serum bilirubin above the ULN or to those with transaminase elevations &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . Lower starting doses of FU may be needed for severe hepatic impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential and platelet count on day 1 prior to each new course of treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel including creatinine and electrolytes, and liver function tests prior to each new treatment course.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity, diarrhea, and fluid retention prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Patients should not be retreated with subsequent cycles of modified DCF until neutrophils recover to &ge;1000 cells/ mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets recover to &gt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Reduce docetaxel dose by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for febrile neutropenia, grade 3 or 4 neutropenia for &ge;7 days, or platelet count &le;75,000/ mm",
"        <sup>",
"         3",
"        </sup>",
"        on the day of treatment",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Withhold cisplatin until serum creatinine is &lt;2 mg/dL",
"        <sup>",
"         [1,3]",
"        </sup>",
"        . Reduce cisplatin dose by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for serum creatinine of 1.8 or 1.9 mg/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Docetaxel can also cause both sensory and motor neuropathy, the incidence of which is related to cumulative dose. Patients with mild neuropathy can continue to receive full cisplatin and docetaxel doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. The protocol recommended a 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        reduction in cisplatin dose for grade 3 or 4 ototoxicity and a 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        reduction in docetaxel dose for grade &ge;2 peripheral neuropathy",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal:",
"        </strong>",
"        After resolution of toxicity, reduce FU and leucovorin doses for grade 3 or 4 diarrhea or stomatitis",
"        <sup>",
"         [4].",
"        </sup>",
"        The protocol suggested initial dose reduction from 400 to 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for the bolus dose of both FU and leucovorin, and a reduction from 1000 to 800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day for the infusional FU",
"        <sup>",
"         [1]",
"        </sup>",
"        . Reduce cisplatin dose by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for grade 4 nausea or vomiting or grade 3 nausea or vomiting for &gt;5 days.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Hold docetaxel for bilirubin one to two times ULN,",
"        <strong>",
"         OR",
"        </strong>",
"        for AST/ALT &gt;5 times ULN,",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;2 but &le;5 times the ULN and alkaline phosphatase &gt;3 times ULN,",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;1 to &le;2 times ULN and alkaline phosphatase &gt;5 times ULN",
"        <sup>",
"         [1]",
"        </sup>",
"        . Reduce docetaxel dose by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        if AST/ALT &gt;2 but &le;5 times ULN and alkaline phosphatase &gt;1 but &le;3 times ULN",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;1 but &le;2 times ULN and alkaline phosphatase &gt;3 but &le;5 times ULN",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; ULN: upper limit of normal; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotranferease.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibilities.",
"     <br/>",
"     &Delta; Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [5]",
"     </sup>",
"     . Use one-half the dose for LEVOleucovorin (l-leucovorin).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Shah M, et al. J Clin Oncol 2011; 29:868.",
"      </li>",
"      <li>",
"       Docetaxel injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"      <li>",
"       Cisplatin injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36510=[""].join("\n");
var outline_f35_41_36510=null;
var title_f35_41_36511="Botulinum toxin injection sites for horizontal neck lines";
var content_f35_41_36511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Examples of botulinum toxin injection sites for horizontal neck lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_41_36511=[""].join("\n");
var outline_f35_41_36511=null;
